|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
increases expression |
ISO |
22(R)-hydroxycholesterol increases expression of NR1H3 mRNA in macrophages |
RGD |
PMID:11546778 |
RGD:401842375 |
NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
increases expression |
ISO |
24-hydroxycholesterol results in increased expression of ABCA1 mRNA; 24-hydroxycholesterol results in increased expression of ABCA1 protein |
CTD |
PMID:15148325 PMID:19126211 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcg1 |
ATP binding cassette subfamily G member 1 |
increases expression |
ISO |
24-hydroxycholesterol results in increased expression of ABCG1 protein |
CTD |
PMID:19126211 |
|
NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions increases metabolic processing |
ISO |
24-hydroxycholesterol affects the metabolism of and results in increased activity of APP protein; 24-hydroxycholesterol results in decreased metabolism of and results in decreased secretion of APP protein 24-hydroxycholesterol results in increased metabolism of APP protein |
CTD |
PMID:15148325 PMID:17532301 PMID:19126211 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases expression multiple interactions |
ISO |
24-hydroxycholesterol results in increased expression of CCL2 mRNA [24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CCL2 mRNA; Quercetin analog inhibits the reaction [24-hydroxycholesterol results in increased expression of CCL2 mRNA]; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CCL2 mRNA] |
CTD |
PMID:24802026 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Cd36 |
CD36 molecule |
increases expression multiple interactions |
ISO |
24-hydroxycholesterol results in increased expression of CD36 mRNA [24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CD36 mRNA; Quercetin analog inhibits the reaction [24-hydroxycholesterol results in increased expression of CD36 mRNA]; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CD36 mRNA]; Quercetin inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CD36 mRNA] |
CTD |
PMID:24802026 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
decreases abundance |
ISO |
CYP27A1 protein results in decreased abundance of 24-hydroxycholesterol |
CTD |
PMID:12119285 |
|
NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551
|
|
G |
Cyp39a1 |
cytochrome P450, family 39, subfamily a, polypeptide 1 |
increases metabolic processing |
ISO |
CYP39A1 protein results in increased metabolism of 24-hydroxycholesterol |
CTD |
PMID:10748047 |
|
NCBI chr 9:17,230,455...17,306,775
Ensembl chr 9:17,230,455...17,306,775
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
[24-hydroxycholesterol co-treated with NR1H3 protein] results in increased expression of CYP3A4 mRNA |
CTD |
PMID:23732298 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp46a1 |
cytochrome P450, family 46, subfamily a, polypeptide 1 |
affects abundance increases chemical synthesis increases metabolic processing |
ISO |
CYP46A1 gene SNP affects the abundance of 24-hydroxycholesterol CYP46A1 protein results in increased chemical synthesis of 24-hydroxycholesterol CYP46A1 protein results in increased metabolism of 24-hydroxycholesterol |
CTD |
PMID:14640697 PMID:19286353 |
|
NCBI chr 6:127,247,543...127,274,765
Ensembl chr 6:127,243,315...127,274,760
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
increases metabolic processing |
ISO |
CYP7A1 protein results in increased metabolism of 24-hydroxycholesterol |
CTD |
PMID:11013305 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
24-hydroxycholesterol binds to and results in decreased activity of ESR1 protein; 24-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of ESR1 protein] |
CTD |
PMID:17873880 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
ISO |
24-hydroxycholesterol binds to and results in decreased activity of ESR2 protein; 24-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of ESR2 protein] |
CTD |
PMID:17873880 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
decreases activity |
ISO |
24-hydroxycholesterol results in decreased activity of HMGCR protein |
CTD |
PMID:7751816 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Itgb1 |
integrin subunit beta 1 |
increases expression multiple interactions |
ISO |
24-hydroxycholesterol results in increased expression of ITGB1 mRNA [24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of ITGB1 mRNA; Quercetin analog inhibits the reaction [24-hydroxycholesterol results in increased expression of ITGB1 mRNA]; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of ITGB1 mRNA]; Quercetin inhibits the reaction [24-hydroxycholesterol results in increased expression of ITGB1 mRNA]; Quercetin inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of ITGB1 mRNA] |
CTD |
PMID:24802026 |
|
NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
increases expression multiple interactions |
ISO |
24-hydroxycholesterol results in increased expression of MMP9 mRNA Quercetin analog inhibits the reaction [24-hydroxycholesterol results in increased expression of MMP9 mRNA] |
CTD |
PMID:24802026 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
multiple interactions |
ISO |
[24-hydroxycholesterol co-treated with NR1H3 protein] results in increased expression of CYP3A4 mRNA |
CTD |
PMID:23732298 |
|
NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722
|
|
G |
Ptges |
prostaglandin E synthase |
multiple interactions increases expression |
ISO |
Quercetin analog inhibits the reaction [24-hydroxycholesterol results in increased expression of PTGES mRNA]; Quercetin inhibits the reaction [24-hydroxycholesterol results in increased expression of PTGES mRNA] |
CTD |
PMID:24802026 |
|
NCBI chr 3:14,177,892...14,189,236
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression multiple interactions |
ISO |
24-hydroxycholesterol results in increased expression of PTGS2 protein [24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of PTGS2 protein |
CTD |
PMID:24802026 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions increases expression |
ISO |
[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of TLR4 mRNA; Quercetin analog inhibits the reaction [24-hydroxycholesterol results in increased expression of TLR4 mRNA]; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of TLR4 mRNA]; Quercetin inhibits the reaction [24-hydroxycholesterol results in increased expression of TLR4 mRNA]; Quercetin inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of TLR4 mRNA] |
CTD |
PMID:24802026 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
multiple interactions increases expression |
ISO EXP |
Docosahexaenoic Acids inhibits the reaction [27-hydroxycholesterol results in increased expression of ABCA1 mRNA]; Linoleic Acid inhibits the reaction [27-hydroxycholesterol results in increased expression of ABCA1 mRNA]; Oleic Acid inhibits the reaction [27-hydroxycholesterol results in increased expression of ABCA1 mRNA] 27-hydroxycholesterol results in increased expression of ABCA1 mRNA; 27-hydroxycholesterol results in increased expression of ABCA1 protein [Fingolimod Hydrochloride results in increased abundance of 27-hydroxycholesterol] which results in increased expression of ABCA1 mRNA |
CTD |
PMID:15148325 PMID:17088262 PMID:18356535 PMID:18841091 PMID:20056921 PMID:28167099 More...
|
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases expression |
ISO |
27-hydroxycholesterol results in increased expression of ABCB1 mRNA |
CTD |
PMID:33880675 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
increases expression |
ISO |
27-hydroxycholesterol results in increased expression of ABCC1 mRNA |
CTD |
PMID:33880675 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcg1 |
ATP binding cassette subfamily G member 1 |
increases expression |
ISO |
27-hydroxycholesterol results in increased expression of ABCG1 protein |
CTD |
PMID:17088262 |
|
NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
increases expression multiple interactions |
ISO |
27-hydroxycholesterol results in increased expression of ACTA2 protein Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased expression of ACTA2 protein]; CTNNB1 protein affects the reaction [27-hydroxycholesterol results in increased expression of ACTA2 protein]; SCIO-469 inhibits the reaction [27-hydroxycholesterol results in increased expression of ACTA2 protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased expression of ACTA2 protein] |
CTD |
PMID:33131013 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases phosphorylation multiple interactions |
ISO |
27-hydroxycholesterol results in increased phosphorylation of AKT1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of AKT1 protein]; HSPA9 protein promotes the reaction [27-hydroxycholesterol results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:33131013 PMID:33880675 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Apoa1 |
apolipoprotein A1 |
multiple interactions |
ISO |
27-hydroxycholesterol promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]; 27-hydroxycholesterol promotes the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]] |
CTD |
PMID:20083572 |
|
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
Apoe |
apolipoprotein E |
increases expression |
EXP |
27-hydroxycholesterol results in increased expression of APOE mRNA; 27-hydroxycholesterol results in increased expression of APOE protein |
CTD |
PMID:28167099 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions increases expression decreases secretion |
ISO |
27-hydroxycholesterol results in decreased metabolism of and results in decreased secretion of APP protein 27-hydroxycholesterol results in increased expression of APP protein alternative form 27-hydroxycholesterol results in decreased secretion of APP protein alternative form |
CTD |
PMID:15148325 PMID:19126211 PMID:19158428 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Arc |
activity-regulated cytoskeleton-associated protein |
decreases expression |
EXP |
27-hydroxycholesterol results in decreased expression of ARC protein |
CTD |
PMID:18503570 |
|
NCBI chr 7:106,555,968...106,559,697
Ensembl chr 7:106,555,785...106,559,378
|
|
G |
Bace1 |
beta-secretase 1 |
increases expression |
ISO |
27-hydroxycholesterol results in increased expression of BACE1 protein |
CTD |
PMID:19126211 |
|
NCBI chr 8:46,142,060...46,166,268
Ensembl chr 8:46,142,116...46,165,876
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
CAT protein inhibits the reaction [27-hydroxycholesterol results in increased expression of HSPA9 protein] |
CTD |
PMID:33880675 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions increases expression |
ISO |
[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CCL2 mRNA; Quercetin analog inhibits the reaction [27-hydroxycholesterol results in increased expression of CCL2 mRNA]; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CCL2 mRNA] |
CTD |
PMID:24802026 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
increases expression increases secretion |
ISO |
27-hydroxycholesterol results in increased expression of CCL3 mRNA 27-hydroxycholesterol results in increased secretion of CCL3 protein |
CTD |
PMID:24370436 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
increases secretion increases expression |
ISO |
27-hydroxycholesterol results in increased secretion of CCL4 protein 27-hydroxycholesterol results in increased expression of CCL4 mRNA |
CTD |
PMID:24370436 |
|
NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231
|
|
G |
Ccn5 |
cellular communication network factor 5 |
multiple interactions increases expression |
ISO |
Fulvestrant inhibits the reaction [27-hydroxycholesterol results in increased expression of CCN5 mRNA] |
CTD |
PMID:17872378 |
|
NCBI chr 3:152,491,247...152,502,639
Ensembl chr 3:152,491,220...152,502,636
|
|
G |
Cd36 |
CD36 molecule |
increases expression multiple interactions |
ISO |
27-hydroxycholesterol results in increased expression of CD36 mRNA [24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CD36 mRNA; Quercetin analog inhibits the reaction [27-hydroxycholesterol results in increased expression of CD36 mRNA]; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CD36 mRNA]; Quercetin inhibits the reaction [27-hydroxycholesterol results in increased expression of CD36 mRNA]; Quercetin inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CD36 mRNA] |
CTD |
PMID:24802026 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Cdh5 |
cadherin 5 |
multiple interactions decreases expression |
ISO |
Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in decreased expression of CDH5 protein]; CTNNB1 protein affects the reaction [27-hydroxycholesterol results in decreased expression of CDH5 protein]; SCIO-469 inhibits the reaction [27-hydroxycholesterol results in decreased expression of CDH5 protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in decreased expression of CDH5 protein] 27-hydroxycholesterol results in decreased expression of CDH5 mRNA; 27-hydroxycholesterol results in decreased expression of CDH5 protein |
CTD |
PMID:33131013 |
|
NCBI chr19:815,415...854,478
Ensembl chr19:815,411...854,368
|
|
G |
Cdh6 |
cadherin 6 |
decreases expression |
ISO |
27-hydroxycholesterol results in decreased expression of CDH6 mRNA |
CTD |
PMID:33131013 |
|
NCBI chr 2:62,079,139...62,225,298
Ensembl chr 2:62,079,137...62,225,228
|
|
G |
Ces1d |
carboxylesterase 1D |
decreases activity multiple interactions |
ISO |
27-hydroxycholesterol results in decreased activity of CES1 protein 27-hydroxycholesterol inhibits the reaction [CES1 protein results in increased metabolism of bioresmethrin] |
CTD |
PMID:19761868 |
|
NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions increases activity |
ISO |
27-hydroxycholesterol inhibits the reaction [CTNNB1 protein binds to GSK3B protein]; 27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to CTNNB1 protein]; 27-hydroxycholesterol results in increased expression of and affects the localization of CTNNB1 protein; Acetylcysteine inhibits the reaction [27-hydroxycholesterol inhibits the reaction [GSK3B protein binds to CTNNB1 protein]]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to CTNNB1 protein]]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased expression of and results in increased activity of CTNNB1 protein]; CTNNB1 protein affects the reaction [27-hydroxycholesterol results in decreased expression of CDH5 protein]; CTNNB1 protein affects the reaction [27-hydroxycholesterol results in increased expression of ACTA2 protein]; CTNNB1 protein affects the reaction [27-hydroxycholesterol results in increased expression of VIM protein]; SCIO-469 inhibits the reaction [27-hydroxycholesterol inhibits the reaction [CTNNB1 protein binds to GSK3B protein]]; SCIO-469 inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to CTNNB1 protein]]; SCIO-469 inhibits the reaction [27-hydroxycholesterol results in increased expression of and results in increased activity of CTNNB1 protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased expression of and results in increased activity of CTNNB1 protein] 27-hydroxycholesterol results in increased activity of CTNNB1 protein |
CTD |
PMID:33131013 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
increases expression multiple interactions |
ISO |
27-hydroxycholesterol results in increased expression of CXCL12 mRNA fulvestrant inhibits the reaction [27-hydroxycholesterol results in increased expression of CXCL12 mRNA] |
CTD |
PMID:17872378 |
|
NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
increases abundance multiple interactions increases chemical synthesis |
ISO EXP |
CYP27A1 protein results in increased abundance of 27-hydroxycholesterol [CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 27-hydroxycholesterol [[CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 27-hydroxycholesterol] which results in increased activity of HMGCR protein; [CYP27A1 protein results in increased hydroxylation of Cholesterol] which results in increased chemical synthesis of 27-hydroxycholesterol; [CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 27-hydroxycholesterol; [CYP27A1 protein results in increased oxidation of 27-hydroxycholesterol] which results in increased chemical synthesis of 3-hydroxy-5-cholestenoic acid; [TGFB1 protein results in increased expression of CYP27A1 protein] which results in increased abundance of 27-hydroxycholesterol CYP27A1 protein results in increased chemical synthesis of 27-hydroxycholesterol |
CTD |
PMID:8496670 PMID:9215552 PMID:9660774 PMID:11408283 PMID:11714861 PMID:12119285 PMID:12531903 PMID:14622972 PMID:15708352 More...
|
|
NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
increases metabolic processing |
ISO EXP |
CYP7A1 protein results in increased metabolism of 27-hydroxycholesterol |
CTD |
PMID:10882719 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Cyp7b1 |
cytochrome P450 family 7 subfamily B member 1 |
increases hydroxylation increases abundance increases metabolic processing |
ISO |
CYP7B1 protein results in increased hydroxylation of 27-hydroxycholesterol CYP7B1 gene mutant form results in increased abundance of 27-hydroxycholesterol CYP7B1 protein results in increased metabolism of 27-hydroxycholesterol |
CTD |
PMID:10588945 PMID:10748047 |
|
NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698
|
|
G |
E2f1 |
E2F transcription factor 1 |
increases expression |
ISO |
27-hydroxycholesterol results in increased expression of E2F1 mRNA |
CTD |
PMID:17872378 |
|
NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361
|
|
G |
Erbb4 |
erb-b2 receptor tyrosine kinase 4 |
decreases expression |
ISO |
27-hydroxycholesterol results in decreased expression of ERBB4 mRNA |
CTD |
PMID:17872378 |
|
NCBI chr 9:69,523,733...70,596,743
Ensembl chr 9:69,531,481...70,596,595
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions increases degradation affects response to substance |
ISO |
27-hydroxycholesterol binds to and affects the folding of and results in increased activity of ESR1 protein; 27-hydroxycholesterol binds to and results in decreased activity of ESR1 protein; 27-hydroxycholesterol inhibits the reaction [Estradiol binds to and results in increased activity of ESR1 protein]; 27-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of ESR1 protein]; 27-hydroxycholesterol promotes the reaction [ESR1 protein binds to TFF1 promoter]; fulvestrant inhibits the reaction [27-hydroxycholesterol results in increased activity of ESR1 protein] 27-hydroxycholesterol results in increased degradation of ESR1 protein ESR1 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS2 mRNA]; ESR1 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS3 mRNA] ESR1 protein affects the susceptibility to 27-hydroxycholesterol |
CTD |
PMID:17872378 PMID:17873880 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions affects response to substance |
ISO |
27-hydroxycholesterol binds to and affects the folding of and results in increased activity of ESR2 protein; 27-hydroxycholesterol binds to and results in decreased activity of ESR2 protein; 27-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of ESR2 protein] ESR2 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS2 mRNA]; ESR2 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS3 mRNA] ESR2 protein affects the susceptibility to 27-hydroxycholesterol |
CTD |
PMID:17872378 PMID:17873880 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Grin1 |
glutamate ionotropic receptor NMDA type subunit 1 |
decreases expression |
EXP |
27-hydroxycholesterol results in decreased expression of GRIN1 protein |
CTD |
PMID:18503570 |
|
NCBI chr 3:8,103,680...8,130,603
Ensembl chr 3:8,103,680...8,130,603
|
|
G |
Grin2a |
glutamate ionotropic receptor NMDA type subunit 2A |
decreases phosphorylation |
EXP |
27-hydroxycholesterol results in decreased phosphorylation of GRIN2A protein |
CTD |
PMID:18503570 |
|
NCBI chr10:5,629,683...6,053,262
Ensembl chr10:5,631,369...6,044,637
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions increases phosphorylation |
ISO |
27-hydroxycholesterol inhibits the reaction [CTNNB1 protein binds to GSK3B protein]; 27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to GSK3B protein]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol inhibits the reaction [GSK3B protein binds to CTNNB1 protein]]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to GSK3B protein]]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of GSK3B protein]; SCIO-469 inhibits the reaction [27-hydroxycholesterol inhibits the reaction [CTNNB1 protein binds to GSK3B protein]]; SCIO-469 inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to GSK3B protein]]; SCIO-469 inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of GSK3B protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased phosphorylation of GSK3B protein] |
CTD |
PMID:33131013 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
increases expression multiple interactions |
ISO |
27-hydroxycholesterol results in increased expression of HIF1A protein HSPA9 protein promotes the reaction [27-hydroxycholesterol results in increased expression of HIF1A protein] |
CTD |
PMID:27856279 PMID:33880675 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
decreases activity decreases expression multiple interactions |
ISO EXP |
27-hydroxycholesterol metabolite results in decreased activity of HMGCR protein; 27-hydroxycholesterol results in decreased activity of HMGCR protein 27-hydroxycholesterol results in decreased expression of HMGCR mRNA; 27-hydroxycholesterol results in decreased expression of HMGCR protein [[CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 27-hydroxycholesterol] which results in increased activity of HMGCR protein; Dehydroepiandrosterone inhibits the reaction [27-hydroxycholesterol results in decreased activity of HMGCR protein]; Pregnenolone inhibits the reaction [27-hydroxycholesterol results in decreased activity of HMGCR protein] |
CTD |
PMID:7749852 PMID:7751816 PMID:7788503 PMID:9059514 PMID:11408283 PMID:18024962 PMID:28167099 More...
|
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
ISO |
27-hydroxycholesterol results in increased expression of HMOX1 mRNA; 27-hydroxycholesterol results in increased expression of HMOX1 protein |
CTD |
PMID:33880675 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hspa9 |
heat shock protein family A (Hsp70) member 9 |
multiple interactions increases expression |
ISO |
CAT protein inhibits the reaction [27-hydroxycholesterol results in increased expression of HSPA9 protein]; HSPA9 protein promotes the reaction [27-hydroxycholesterol results in increased expression of HIF1A protein]; HSPA9 protein promotes the reaction [27-hydroxycholesterol results in increased expression of MYC protein]; HSPA9 protein promotes the reaction [27-hydroxycholesterol results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:33880675 |
|
NCBI chr18:26,536,131...26,554,294
Ensembl chr18:26,535,798...26,554,292
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
increases expression |
ISO |
27-hydroxycholesterol results in increased expression of ICAM1 mRNA |
CTD |
PMID:19426978 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
27-hydroxycholesterol promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein] |
CTD |
PMID:11851725 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
increases secretion increases expression multiple interactions |
ISO |
27-hydroxycholesterol results in increased secretion of IL6 protein 27-hydroxycholesterol results in increased expression of IL6 mRNA Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased expression of IL6 mRNA]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased secretion of IL6 protein]; IL6 protein affects the reaction [27-hydroxycholesterol results in increased phosphorylation of STAT3 protein]; stattic inhibits the reaction [27-hydroxycholesterol results in increased expression of IL6 mRNA]; stattic inhibits the reaction [27-hydroxycholesterol results in increased secretion of IL6 protein] |
CTD |
PMID:11851725 PMID:28739487 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Itgb1 |
integrin subunit beta 1 |
multiple interactions increases expression |
ISO |
[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of ITGB1 mRNA; Quercetin analog inhibits the reaction [27-hydroxycholesterol results in increased expression of ITGB1 mRNA]; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of ITGB1 mRNA]; Quercetin inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of ITGB1 mRNA] |
CTD |
PMID:24802026 |
|
NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195
|
|
G |
Lcat |
lecithin cholesterol acyltransferase |
increases metabolic processing |
ISO |
LCAT protein results in increased metabolism of 27-hydroxycholesterol |
CTD |
PMID:7744831 |
|
NCBI chr19:33,834,748...33,838,214
Ensembl chr19:33,834,403...33,838,231
|
|
G |
Ldlr |
low density lipoprotein receptor |
decreases activity decreases expression |
ISO EXP |
27-hydroxycholesterol results in decreased activity of LDLR protein 27-hydroxycholesterol results in decreased expression of LDLR mRNA; 27-hydroxycholesterol results in decreased expression of LDLR protein |
CTD |
PMID:8820113 PMID:28167099 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Lipe |
lipase E, hormone sensitive type |
multiple interactions |
ISO |
LIPE protein promotes the reaction [27-hydroxycholesterol results in increased expression of STAR mRNA]; LIPE protein promotes the reaction [27-hydroxycholesterol results in increased expression of STAR protein] |
CTD |
PMID:23362264 |
|
NCBI chr 1:80,965,612...80,984,313
Ensembl chr 1:80,965,627...80,984,310
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation multiple interactions |
ISO |
27-hydroxycholesterol results in increased phosphorylation of MAPK1 protein U 0126 inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:33131013 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation multiple interactions |
ISO |
27-hydroxycholesterol results in increased phosphorylation of MAPK3 protein U 0126 inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:33131013 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
increases expression multiple interactions |
ISO |
27-hydroxycholesterol results in increased expression of MMP9 mRNA Quercetin analog inhibits the reaction [27-hydroxycholesterol results in increased expression of MMP9 mRNA] |
CTD |
PMID:24802026 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
increases expression multiple interactions |
ISO |
27-hydroxycholesterol results in increased expression of MYC protein HSPA9 protein promotes the reaction [27-hydroxycholesterol results in increased expression of MYC protein] |
CTD |
PMID:33880675 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions decreases expression |
ISO |
27-hydroxycholesterol inhibits the reaction [Estradiol results in increased expression of NOS2 mRNA]; ESR1 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS2 mRNA]; ESR2 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS2 mRNA] |
CTD |
PMID:17873880 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
decreases expression multiple interactions |
ISO |
27-hydroxycholesterol results in decreased expression of NOS3 mRNA 27-hydroxycholesterol inhibits the reaction [Estradiol results in increased expression of NOS3 mRNA]; ESR1 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS3 mRNA]; ESR2 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS3 mRNA] |
CTD |
PMID:17873880 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Npc1 |
NPC intracellular cholesterol transporter 1 |
affects abundance |
ISO |
NPC1 protein affects the abundance of 27-hydroxycholesterol |
CTD |
PMID:18483620 |
|
NCBI chr18:3,379,482...3,425,100
Ensembl chr18:3,379,482...3,425,049
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression |
ISO |
27-hydroxycholesterol results in increased expression of NQO1 mRNA; 27-hydroxycholesterol results in increased expression of NQO1 protein |
CTD |
PMID:33880675 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
increases expression |
EXP |
27-hydroxycholesterol results in increased expression of NR1H3 mRNA; 27-hydroxycholesterol results in increased expression of NR1H3 protein |
CTD |
PMID:28167099 |
|
NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722
|
|
G |
Nr5a1 |
nuclear receptor subfamily 5, group A, member 1 |
increases activity multiple interactions |
ISO |
27-hydroxycholesterol results in increased activity of NR5A1 protein 27-hydroxycholesterol promotes the reaction [NR5A1 protein results in increased expression of STAR protein] |
CTD |
PMID:9144161 PMID:9804848 |
|
NCBI chr 3:22,464,786...22,486,328
Ensembl chr 3:22,465,502...22,486,328
|
|
G |
Pgr |
progesterone receptor |
increases expression multiple interactions |
ISO |
27-hydroxycholesterol results in increased expression of PGR mRNA; 27-hydroxycholesterol results in increased expression of PGR protein fulvestrant inhibits the reaction [27-hydroxycholesterol results in increased expression of PGR mRNA] |
CTD |
PMID:17872378 |
|
NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression |
EXP |
27-hydroxycholesterol results in increased expression of PPARG mRNA; 27-hydroxycholesterol results in increased expression of PPARG protein |
CTD |
PMID:28167099 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ptges |
prostaglandin E synthase |
increases expression multiple interactions |
ISO |
27-hydroxycholesterol results in increased expression of PTGES mRNA Quercetin analog inhibits the reaction [27-hydroxycholesterol results in increased expression of PTGES mRNA]; Quercetin inhibits the reaction [27-hydroxycholesterol results in increased expression of PTGES mRNA] |
CTD |
PMID:24802026 |
|
NCBI chr 3:14,177,892...14,189,236
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression multiple interactions |
ISO |
27-hydroxycholesterol results in increased expression of PTGS2 protein [24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of PTGS2 protein |
CTD |
PMID:24802026 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Sele |
selectin E |
increases expression |
ISO |
27-hydroxycholesterol results in increased expression of SELE mRNA |
CTD |
PMID:19426978 |
|
NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741
|
|
G |
Smpd2 |
sphingomyelin phosphodiesterase 2 |
decreases activity |
ISO |
27-hydroxycholesterol results in decreased activity of SMPD2 protein |
CTD |
PMID:15261762 |
|
NCBI chr20:44,986,229...44,989,343
Ensembl chr20:44,986,231...44,989,441
|
|
G |
Snca |
synuclein alpha |
increases expression |
ISO |
27-hydroxycholesterol results in increased expression of SNCA mRNA; 27-hydroxycholesterol results in increased expression of SNCA protein |
CTD |
PMID:18841091 |
|
NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
decreases activity |
EXP |
27-hydroxycholesterol results in decreased activity of SRC protein |
CTD |
PMID:18503570 |
|
NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
decreases expression |
EXP |
27-hydroxycholesterol results in decreased expression of SREBF1 mRNA; 27-hydroxycholesterol results in decreased expression of SREBF1 protein |
CTD |
PMID:28167099 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Star |
steroidogenic acute regulatory protein |
multiple interactions increases abundance increases expression |
ISO EXP |
27-hydroxycholesterol promotes the reaction [NR5A1 protein results in increased expression of STAR protein] STAR protein results in increased abundance of 27-hydroxycholesterol 27-hydroxycholesterol promotes the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]; LIPE protein promotes the reaction [27-hydroxycholesterol results in increased expression of STAR mRNA]; LIPE protein promotes the reaction [27-hydroxycholesterol results in increased expression of STAR protein] 27-hydroxycholesterol results in increased expression of STAR mRNA; 27-hydroxycholesterol results in increased expression of STAR protein |
CTD |
PMID:9804848 PMID:12368294 PMID:15863358 PMID:20083572 PMID:23362264 |
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions increases phosphorylation |
ISO |
Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of STAT3 protein]; STAT3 protein promotes the reaction [27-hydroxycholesterol results in increased expression of VEGFA mRNA]; STAT3 protein promotes the reaction [27-hydroxycholesterol results in increased secretion of VEGFA protein] Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of STAT3 protein]; IL6 protein affects the reaction [27-hydroxycholesterol results in increased phosphorylation of STAT3 protein]; stattic inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:27856279 PMID:28739487 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Tff1 |
trefoil factor 1 |
multiple interactions increases expression |
ISO |
27-hydroxycholesterol promotes the reaction [ESR1 protein binds to TFF1 promoter]; fulvestrant inhibits the reaction [27-hydroxycholesterol results in increased expression of TFF1 mRNA] |
CTD |
PMID:17872378 PMID:27856279 |
|
NCBI chr20:9,235,736...9,239,597
Ensembl chr20:9,235,736...9,239,597
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
[TGFB1 protein results in increased expression of CYP27A1 protein] which results in increased abundance of 27-hydroxycholesterol |
CTD |
PMID:15708352 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tlr4 |
toll-like receptor 4 |
increases expression multiple interactions |
ISO |
27-hydroxycholesterol results in increased expression of TLR4 mRNA [24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of TLR4 mRNA; Quercetin analog inhibits the reaction [27-hydroxycholesterol results in increased expression of TLR4 mRNA]; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of TLR4 mRNA]; Quercetin inhibits the reaction [27-hydroxycholesterol results in increased expression of TLR4 mRNA]; Quercetin inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of TLR4 mRNA] |
CTD |
PMID:24802026 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
increases expression |
ISO |
27-hydroxycholesterol results in increased expression of VCAM1 mRNA |
CTD |
PMID:19426978 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions increases secretion increases expression |
ISO |
Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased expression of VEGFA mRNA]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased secretion of VEGFA protein]; STAT3 protein promotes the reaction [27-hydroxycholesterol results in increased expression of VEGFA mRNA]; STAT3 protein promotes the reaction [27-hydroxycholesterol results in increased secretion of VEGFA protein] |
CTD |
PMID:27856279 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vim |
vimentin |
multiple interactions increases expression |
ISO |
Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased expression of VIM protein]; CTNNB1 protein affects the reaction [27-hydroxycholesterol results in increased expression of VIM protein]; SCIO-469 inhibits the reaction [27-hydroxycholesterol results in increased expression of VIM protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased expression of VIM protein] 27-hydroxycholesterol results in increased expression of VIM mRNA; 27-hydroxycholesterol results in increased expression of VIM protein |
CTD |
PMID:33131013 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
G |
Ywhah |
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, eta |
multiple interactions |
ISO |
27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to CTNNB1 protein]; 27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to GSK3B protein]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to CTNNB1 protein]]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to GSK3B protein]]; SCIO-469 inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to CTNNB1 protein]]; SCIO-469 inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to GSK3B protein]]; YWHAH protein affects the reaction [27-hydroxycholesterol results in decreased expression of CDH5 protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased expression of ACTA2 protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased expression of and results in increased activity of CTNNB1 protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased expression of VIM protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased phosphorylation of GSK3B protein] |
CTD |
PMID:33131013 |
|
NCBI chr14:77,696,332...77,705,715
Ensembl chr14:77,696,333...77,705,741
|
|
|
G |
Msmo1 |
methylsterol monooxygenase 1 |
decreases abundance |
ISO |
MSMO1 protein results in decreased abundance of 4,4-dimethyl-5-alpha-cholesta-(8,24)-dien-3-beta-ol |
CTD |
PMID:23125191 |
|
NCBI chr16:24,980,680...24,997,927
Ensembl chr16:24,980,697...24,998,016
|
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
[NR5A1 protein co-treated with 20-hydroxycholesterol co-treated with Tretinoin co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP11A1 mRNA |
CTD |
PMID:21610156 |
|
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
increases metabolic processing |
EXP ISO |
CYP7A1 protein results in increased metabolism of 20-hydroxycholesterol |
CTD |
PMID:10882719 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Hsd17b10 |
hydroxysteroid (17-beta) dehydrogenase 10 |
multiple interactions |
ISO |
[20-hydroxycholesterol co-treated with NAD] binds to HSD17B10 protein |
CTD |
PMID:25526675 |
|
NCBI chr X:21,089,142...21,091,603
Ensembl chr X:21,089,122...21,109,488
|
|
G |
Mc2r |
melanocortin 2 receptor |
multiple interactions |
ISO |
[20-hydroxycholesterol co-treated with Tretinoin co-treated with 8-Bromo Cyclic Adenosine Monophosphate] promotes the reaction [NR5A1 protein binds to MC2R promoter] |
CTD |
PMID:21610156 |
|
NCBI chr18:62,001,980...62,015,567
Ensembl chr18:62,004,948...62,015,488
|
|
G |
Nr5a1 |
nuclear receptor subfamily 5, group A, member 1 |
multiple interactions |
ISO |
[20-hydroxycholesterol co-treated with Tretinoin co-treated with 8-Bromo Cyclic Adenosine Monophosphate] promotes the reaction [NR5A1 protein binds to MC2R promoter]; [NR5A1 protein co-treated with 20-hydroxycholesterol co-treated with Tretinoin co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased abundance of Progesterone; [NR5A1 protein co-treated with 20-hydroxycholesterol co-treated with Tretinoin co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP11A1 mRNA |
CTD |
PMID:21610156 |
|
NCBI chr 3:22,464,786...22,486,328
Ensembl chr 3:22,465,502...22,486,328
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Ecdysterone promotes the reaction [1-Methyl-4-phenylpyridinium results in increased activity of AKT1 protein]]; Ecdysterone promotes the reaction [1-Methyl-4-phenylpyridinium results in increased activity of AKT1 protein] |
CTD |
PMID:26048653 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
Ecdysterone results in increased expression of BAX protein |
CTD |
PMID:33878320 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
affects expression |
ISO |
Ecdysterone affects the expression of BCL2 protein |
CTD |
PMID:33878320 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp3 |
caspase 3 |
increases activity increases cleavage |
ISO |
Ecdysterone results in increased activity of CASP3 protein Ecdysterone results in increased cleavage of CASP3 protein |
CTD |
PMID:29126784 PMID:33878320 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Ecdysterone inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased phosphorylation of and results in decreased activity of GSK3B protein]]; Ecdysterone inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased phosphorylation of and results in decreased activity of GSK3B protein] |
CTD |
PMID:26048653 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Ecdysterone promotes the reaction [1-Methyl-4-phenylpyridinium results in increased expression of HMOX1 protein]]; Ecdysterone promotes the reaction [1-Methyl-4-phenylpyridinium results in increased expression of HMOX1 mRNA]; Ecdysterone promotes the reaction [1-Methyl-4-phenylpyridinium results in increased expression of HMOX1 protein] |
CTD |
PMID:26048653 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
decreases expression increases expression |
ISO |
Ecdysterone results in decreased expression of HSPA5 protein Ecdysterone results in increased expression of HSPA5 mRNA |
CTD |
PMID:29126784 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
affects expression |
ISO |
Ecdysterone affects the expression of MTOR protein |
CTD |
PMID:33878320 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions increases response to substance |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Ecdysterone promotes the reaction [1-Methyl-4-phenylpyridinium affects the localization of NFE2L2 protein]]; Ecdysterone promotes the reaction [1-Methyl-4-phenylpyridinium affects the localization of NFE2L2 protein] NFE2L2 results in increased susceptibility to Ecdysterone |
CTD |
PMID:26048653 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage |
ISO |
Ecdysterone results in increased cleavage of PARP1 protein |
CTD |
PMID:33878320 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Sqstm1 |
sequestosome 1 |
affects expression |
ISO |
Ecdysterone affects the expression of SQSTM1 protein |
CTD |
PMID:33878320 |
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
increases expression |
ISO |
24(S),25-epoxycholesterol increases expression of NR1H3 mRNA in macrophages |
RGD |
PMID:11546778 |
RGD:401842375 |
NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722
|
|
|
G |
Cyp51 |
cytochrome P450, family 51 |
decreases abundance |
ISO |
CYP51A1 mRNA results in decreased abundance of lanostenol |
CTD |
PMID:23125191 |
|
NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
decreases activity |
ISO |
lanostenol results in decreased activity of HMGCR protein |
CTD |
PMID:18024962 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
increases expression multiple interactions |
ISO EXP |
25-hydroxycholesterol results in increased expression of ABCA1 mRNA [25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased expression of ABCA1 mRNA; [25-hydroxycholesterol co-treated with alitretinoin] results in increased expression of ABCA1 protein; [9-deoxy-delta-9-prostaglandin D2 binds to and results in increased activity of PPARG protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased expression of ABCA1 mRNA]; [Bezafibrate binds to and results in increased activity of PPARA protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased expression of ABCA1 mRNA] [Cholesterol co-treated with 25-hydroxycholesterol] results in decreased expression of ABCA1 mRNA |
CTD |
PMID:12595494 PMID:16023994 PMID:17526932 PMID:19260826 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcg1 |
ATP binding cassette subfamily G member 1 |
increases expression |
ISO |
25-hydroxycholesterol results in increased expression of ABCG1 mRNA |
CTD |
PMID:31011801 |
|
NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
increases expression multiple interactions |
EXP |
25-hydroxycholesterol results in increased expression of ACTA2 mRNA 15-deoxyprostaglandin J2 inhibits the reaction [25-hydroxycholesterol results in increased expression of ACTA2 mRNA]; alitretinoin promotes the reaction [25-hydroxycholesterol results in increased expression of ACTA2 mRNA] |
CTD |
PMID:17161435 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Adipor1 |
adiponectin receptor 1 |
multiple interactions decreases expression |
ISO |
[25-hydroxycholesterol co-treated with alitretinoin] results in decreased expression of ADIPOR1 mRNA 25-hydroxycholesterol results in decreased expression of ADIPOR1 mRNA |
CTD |
PMID:16023994 |
|
NCBI chr13:45,859,461...45,879,248
Ensembl chr13:45,859,533...45,879,241
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity |
ISO EXP |
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [25-hydroxycholesterol results in increased activity of CASP3 protein]; Acetylcysteine inhibits the reaction [25-hydroxycholesterol results in increased activity of CASP3 protein]; BAY 11-7085 inhibits the reaction [25-hydroxycholesterol results in increased activity of CASP3 protein]; quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [25-hydroxycholesterol results in increased activity of CASP3 protein] |
CTD |
PMID:25845326 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
increases activity multiple interactions |
EXP |
25-hydroxycholesterol results in increased activity of CASP8 protein 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [25-hydroxycholesterol results in increased activity of CASP8 protein]; Acetylcysteine inhibits the reaction [25-hydroxycholesterol results in increased activity of CASP8 protein]; BAY 11-7085 inhibits the reaction [25-hydroxycholesterol results in increased activity of CASP8 protein]; quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [25-hydroxycholesterol results in increased activity of CASP8 protein] |
CTD |
PMID:25845326 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
increases activity multiple interactions |
EXP |
25-hydroxycholesterol results in increased activity of CASP9 protein 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [25-hydroxycholesterol results in increased activity of CASP9 protein]; Acetylcysteine inhibits the reaction [25-hydroxycholesterol results in increased activity of CASP9 protein]; BAY 11-7085 inhibits the reaction [25-hydroxycholesterol results in increased activity of CASP9 protein]; quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [25-hydroxycholesterol results in increased activity of CASP9 protein] |
CTD |
PMID:25845326 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
increases expression |
EXP |
25-hydroxycholesterol results in increased expression of CDKN1B mRNA |
CTD |
PMID:17161435 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cnn1 |
calponin 1 |
multiple interactions increases expression |
EXP |
15-deoxyprostaglandin J2 inhibits the reaction [25-hydroxycholesterol results in increased expression of CNN1 mRNA]; alitretinoin promotes the reaction [25-hydroxycholesterol results in increased expression of CNN1 mRNA] |
CTD |
PMID:17161435 |
|
NCBI chr 8:20,632,434...20,641,097
Ensembl chr 8:20,632,338...20,641,098
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
multiple interactions increases chemical synthesis |
ISO |
[CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 25-hydroxycholesterol CYP27A1 protein results in increased chemical synthesis of 25-hydroxycholesterol |
CTD |
PMID:8078928 PMID:17890683 |
|
NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
increases metabolic processing |
ISO EXP |
CYP7A1 protein results in increased metabolism of 25-hydroxycholesterol |
CTD |
PMID:10882719 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Cyp7b1 |
cytochrome P450 family 7 subfamily B member 1 |
increases metabolic processing increases abundance |
ISO |
CYP7B1 protein results in increased metabolism of 25-hydroxycholesterol CYP7B1 gene mutant form results in increased abundance of 25-hydroxycholesterol |
CTD |
PMID:10748047 |
|
NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
25-hydroxycholesterol binds to and results in decreased activity of ESR1 protein; 25-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of ESR1 protein] |
CTD |
PMID:17873880 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
ISO |
25-hydroxycholesterol binds to and results in decreased activity of ESR2 protein; 25-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of ESR2 protein] |
CTD |
PMID:17873880 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Fads1 |
fatty acid desaturase 1 |
multiple interactions decreases expression |
ISO |
25-hydroxycholesterol inhibits the reaction [beta-hydroxy simvastatin acid results in increased expression of FADS1 mRNA] 25-hydroxycholesterol results in decreased expression of FADS1 mRNA |
CTD |
PMID:17655842 |
|
NCBI chr 1:206,827,724...206,842,734
Ensembl chr 1:206,827,765...206,842,734
|
|
G |
Fas |
Fas cell surface death receptor |
increases expression |
ISO |
25-hydroxycholesterol results in increased expression of FAS mRNA |
CTD |
PMID:19260826 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Fhl1 |
four and a half LIM domains 1 |
multiple interactions increases expression |
EXP |
15-deoxyprostaglandin J2 inhibits the reaction [25-hydroxycholesterol results in increased expression of FHL1 mRNA]; alitretinoin promotes the reaction [25-hydroxycholesterol results in increased expression of FHL1 mRNA]; Brefeldin A inhibits the reaction [25-hydroxycholesterol results in increased expression of FHL1 mRNA]; Cycloheximide promotes the reaction [25-hydroxycholesterol results in increased expression of FHL1 mRNA]; Dactinomycin promotes the reaction [25-hydroxycholesterol results in increased expression of FHL1 mRNA]; Genistein inhibits the reaction [25-hydroxycholesterol results in increased expression of FHL1 mRNA] |
CTD |
PMID:17161435 |
|
NCBI chr X:134,555,399...134,614,930
Ensembl chr X:134,555,479...134,614,928
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions decreases expression decreases activity |
ISO EXP |
[25-hydroxycholesterol co-treated with Cholesterol] results in decreased activity of HMGCR protein; [25-hydroxycholesterol co-treated with Mevalonic Acid] results in increased ubiquitination of HMGCR protein; Dehydroepiandrosterone inhibits the reaction [25-hydroxycholesterol results in decreased activity of HMGCR protein]; LDLR gene mutant form promotes the reaction [[25-hydroxycholesterol co-treated with Cholesterol] results in decreased activity of HMGCR protein]; Pregnenolone inhibits the reaction [25-hydroxycholesterol results in decreased activity of HMGCR protein] 25-hydroxycholesterol results in decreased expression of HMGCR protein 25-hydroxycholesterol metabolite results in decreased activity of HMGCR protein; 25-hydroxycholesterol results in decreased activity of HMGCR protein 25-hydroxycholesterol results in decreased expression of HMGCR mRNA; 25-hydroxycholesterol results in decreased expression of HMGCR protein |
CTD |
PMID:7749852 PMID:7751816 PMID:9059514 PMID:12477733 PMID:18024962 PMID:19260826 PMID:21944868 PMID:27447558 More...
|
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases secretion increases expression |
ISO |
25-hydroxycholesterol promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein] 25-hydroxycholesterol results in increased secretion of IL1B protein 25-hydroxycholesterol results in increased expression of IL1B mRNA |
CTD |
PMID:11851725 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
increases secretion multiple interactions |
ISO EXP |
25-hydroxycholesterol results in increased secretion of IL6 protein 25-hydroxycholesterol inhibits the reaction [IL6 protein results in increased phosphorylation of STAT3 protein] 25-hydroxycholesterol inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] |
CTD |
PMID:11851725 PMID:27052460 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Inha |
inhibin subunit alpha |
increases expression |
EXP |
25-hydroxycholesterol results in increased expression of INHA mRNA; 25-hydroxycholesterol results in increased expression of INHA protein |
CTD |
PMID:19464342 |
|
NCBI chr 9:76,994,465...76,997,366
Ensembl chr 9:76,993,589...76,997,248
|
|
G |
Inhba |
inhibin subunit beta A |
increases expression decreases expression |
EXP |
25-hydroxycholesterol results in increased expression of INHBA mRNA 25-hydroxycholesterol results in decreased expression of INHBA protein |
CTD |
PMID:19464342 |
|
NCBI chr17:49,091,635...49,111,573
Ensembl chr17:49,095,920...49,108,982
|
|
G |
Inhbb |
inhibin subunit beta B |
increases expression |
EXP |
25-hydroxycholesterol results in increased expression of INHBB mRNA; 25-hydroxycholesterol results in increased expression of INHBB protein |
CTD |
PMID:19464342 |
|
NCBI chr13:30,530,860...30,536,566
Ensembl chr13:30,530,860...30,537,832
|
|
G |
Insig1 |
insulin induced gene 1 |
decreases expression |
ISO |
25-hydroxycholesterol results in decreased expression of INSIG1 mRNA |
CTD |
PMID:19260826 |
|
NCBI chr 4:7,315,494...7,323,972
Ensembl chr 4:7,315,495...7,323,952
|
|
G |
Ldlr |
low density lipoprotein receptor |
decreases expression multiple interactions |
ISO |
25-hydroxycholesterol results in decreased expression of LDLR mRNA; 25-hydroxycholesterol results in decreased expression of LDLR protein 25-hydroxycholesterol inhibits the reaction [[Resveratrol results in increased activity of and results in increased cleavage of SREBF2 protein] which results in increased expression of LDLR mRNA]; 25-hydroxycholesterol inhibits the reaction [Resveratrol results in increased expression of LDLR mRNA]; LDLR gene mutant form promotes the reaction [[25-hydroxycholesterol co-treated with Cholesterol] results in decreased activity of HMGCR protein]; LDLR gene mutant form results in increased susceptibility to [25-hydroxycholesterol co-treated with Cholesterol] |
CTD |
PMID:12477733 PMID:19260826 PMID:22153697 PMID:27447558 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Lpl |
lipoprotein lipase |
decreases expression decreases activity |
ISO |
25-hydroxycholesterol results in decreased expression of LPL mRNA 25-hydroxycholesterol results in decreased activity of LPL protein |
CTD |
PMID:8567968 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Marchf6 |
membrane associated ring-CH-type finger 6 |
increases stability |
ISO |
25-hydroxycholesterol results in increased stability of MARCHF6 protein |
CTD |
PMID:30545937 |
|
NCBI chr 2:82,455,686...82,532,917
Ensembl chr 2:82,455,689...82,532,910
|
|
G |
Nos2 |
nitric oxide synthase 2 |
increases expression |
ISO |
25-hydroxycholesterol results in increased expression of NOS2 mRNA |
CTD |
PMID:12085989 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
decreases expression |
ISO |
25-hydroxycholesterol results in decreased expression of NOS3 mRNA |
CTD |
PMID:19426978 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
increases activity multiple interactions |
ISO |
25-hydroxycholesterol results in increased activity of NR1H3 protein [25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased expression of ABCA1 mRNA; [25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased transport of Cholesterol; [9-deoxy-delta-9-prostaglandin D2 binds to and results in increased activity of PPARG protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased expression of ABCA1 mRNA]; [9-deoxy-delta-9-prostaglandin D2 binds to and results in increased activity of PPARG protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased transport of Cholesterol]; [Bezafibrate binds to and results in increased activity of PPARA protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased expression of ABCA1 mRNA]; [Bezafibrate binds to and results in increased activity of PPARA protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased transport of Cholesterol]; SULT2B1 protein inhibits the reaction [25-hydroxycholesterol results in increased activity of NR1H3 protein] |
CTD |
PMID:9603267 PMID:12595494 PMID:27052460 |
|
NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722
|
|
G |
Nr5a1 |
nuclear receptor subfamily 5, group A, member 1 |
increases activity multiple interactions |
ISO |
25-hydroxycholesterol results in increased activity of NR5A1 protein 25-hydroxycholesterol promotes the reaction [NR5A1 protein results in increased expression of STAR protein] |
CTD |
PMID:9144161 PMID:9804848 |
|
NCBI chr 3:22,464,786...22,486,328
Ensembl chr 3:22,465,502...22,486,328
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
[Bezafibrate binds to and results in increased activity of PPARA protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased expression of ABCA1 mRNA]; [Bezafibrate binds to and results in increased activity of PPARA protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased transport of Cholesterol] |
CTD |
PMID:12595494 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
[9-deoxy-delta-9-prostaglandin D2 binds to and results in increased activity of PPARG protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased expression of ABCA1 mRNA]; [9-deoxy-delta-9-prostaglandin D2 binds to and results in increased activity of PPARG protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased transport of Cholesterol] |
CTD |
PMID:12595494 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Rora |
RAR-related orphan receptor A |
affects binding |
ISO |
25-hydroxycholesterol binds to RORA protein |
CTD |
PMID:31195007 |
|
NCBI chr 8:69,301,635...70,034,741
Ensembl chr 8:69,301,733...70,025,931
|
|
G |
Rorc |
RAR-related orphan receptor C |
affects binding multiple interactions |
ISO |
25-hydroxycholesterol binds to RORC protein bisphenol A analog inhibits the reaction [25-hydroxycholesterol binds to RORC protein]; T0901317 inhibits the reaction [25-hydroxycholesterol binds to RORC protein] |
CTD |
PMID:22659100 PMID:31195007 |
|
NCBI chr 2:182,009,707...182,034,910
Ensembl chr 2:182,009,286...182,034,907
|
|
G |
Scd |
stearoyl-CoA desaturase |
decreases expression |
ISO |
25-hydroxycholesterol results in decreased expression of SCD protein |
CTD |
PMID:27447558 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
increases expression multiple interactions |
ISO |
25-hydroxycholesterol results in increased expression of SREBF1 protein [25-hydroxycholesterol co-treated with Cholesterol] results in decreased cleavage of SREBF1 protein |
CTD |
PMID:19260826 PMID:27324795 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Srebf2 |
sterol regulatory element binding transcription factor 2 |
decreases activity multiple interactions |
ISO |
25-hydroxycholesterol results in decreased activity of SREBF2 protein 25-hydroxycholesterol inhibits the reaction [[Resveratrol results in increased activity of and results in increased cleavage of SREBF2 protein] which results in increased expression of LDLR mRNA]; 25-hydroxycholesterol inhibits the reaction [Resveratrol results in increased activity of and results in increased cleavage of SREBF2 protein]; 25-hydroxycholesterol inhibits the reaction [Resveratrol results in increased expression of SREBF2 protein modified form]; [25-hydroxycholesterol co-treated with Cholesterol] results in decreased cleavage of SREBF2 protein; Clozapine inhibits the reaction [25-hydroxycholesterol results in decreased activity of SREBF2 protein] |
CTD |
PMID:17052361 PMID:22153697 PMID:27324795 |
|
NCBI chr 7:113,663,202...113,720,850
Ensembl chr 7:113,663,202...113,720,848
|
|
G |
Star |
steroidogenic acute regulatory protein |
multiple interactions |
ISO |
25-hydroxycholesterol promotes the reaction [NR5A1 protein results in increased expression of STAR protein] |
CTD |
PMID:9804848 |
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
EXP |
25-hydroxycholesterol inhibits the reaction [IL6 protein results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:27052460 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Sult2b1 |
sulfotransferase family 2B member 1 |
multiple interactions |
ISO |
SULT2B1 protein inhibits the reaction [25-hydroxycholesterol results in increased activity of NR1H3 protein] SULT2B1 protein inhibits the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased abundance of 25-hydroxycholesterol] |
CTD |
PMID:27052460 |
|
NCBI chr 1:96,200,155...96,261,295
Ensembl chr 1:96,200,156...96,261,295
|
|
G |
Tnfsf15 |
TNF superfamily member 15 |
increases expression |
ISO |
25-hydroxycholesterol results in increased expression of TNFSF15 mRNA |
CTD |
PMID:19426978 |
|
NCBI chr 5:77,134,885...77,156,171
Ensembl chr 5:77,139,878...77,156,228
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
increases expression |
ISO |
25-hydroxycholesterol results in increased expression of VCAM1 mRNA |
CTD |
PMID:19426978 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
increases expression multiple interactions |
ISO EXP |
27-hydroxycholesterol results in increased expression of ABCA1 mRNA; 27-hydroxycholesterol results in increased expression of ABCA1 protein Docosahexaenoic Acids inhibits the reaction [27-hydroxycholesterol results in increased expression of ABCA1 mRNA]; Linoleic Acid inhibits the reaction [27-hydroxycholesterol results in increased expression of ABCA1 mRNA]; Oleic Acid inhibits the reaction [27-hydroxycholesterol results in increased expression of ABCA1 mRNA] [Fingolimod Hydrochloride results in increased abundance of 27-hydroxycholesterol] which results in increased expression of ABCA1 mRNA |
CTD |
PMID:15148325 PMID:17088262 PMID:18356535 PMID:18841091 PMID:20056921 PMID:28167099 More...
|
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases expression |
ISO |
27-hydroxycholesterol results in increased expression of ABCB1 mRNA |
CTD |
PMID:33880675 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
increases expression |
ISO |
27-hydroxycholesterol results in increased expression of ABCC1 mRNA |
CTD |
PMID:33880675 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcg1 |
ATP binding cassette subfamily G member 1 |
increases expression |
ISO |
27-hydroxycholesterol results in increased expression of ABCG1 protein |
CTD |
PMID:17088262 |
|
NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions increases expression |
ISO |
Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased expression of ACTA2 protein]; CTNNB1 protein affects the reaction [27-hydroxycholesterol results in increased expression of ACTA2 protein]; SCIO-469 inhibits the reaction [27-hydroxycholesterol results in increased expression of ACTA2 protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased expression of ACTA2 protein] |
CTD |
PMID:33131013 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions increases phosphorylation |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of AKT1 protein]; HSPA9 protein promotes the reaction [27-hydroxycholesterol results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:33131013 PMID:33880675 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Apoa1 |
apolipoprotein A1 |
multiple interactions |
ISO |
27-hydroxycholesterol promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]; 27-hydroxycholesterol promotes the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]] |
CTD |
PMID:20083572 |
|
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
Apoe |
apolipoprotein E |
increases expression |
EXP |
27-hydroxycholesterol results in increased expression of APOE mRNA; 27-hydroxycholesterol results in increased expression of APOE protein |
CTD |
PMID:28167099 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions increases expression decreases secretion |
ISO |
27-hydroxycholesterol results in decreased metabolism of and results in decreased secretion of APP protein 27-hydroxycholesterol results in increased expression of APP protein alternative form 27-hydroxycholesterol results in decreased secretion of APP protein alternative form |
CTD |
PMID:15148325 PMID:19126211 PMID:19158428 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Arc |
activity-regulated cytoskeleton-associated protein |
decreases expression |
EXP |
27-hydroxycholesterol results in decreased expression of ARC protein |
CTD |
PMID:18503570 |
|
NCBI chr 7:106,555,968...106,559,697
Ensembl chr 7:106,555,785...106,559,378
|
|
G |
Bace1 |
beta-secretase 1 |
increases expression |
ISO |
27-hydroxycholesterol results in increased expression of BACE1 protein |
CTD |
PMID:19126211 |
|
NCBI chr 8:46,142,060...46,166,268
Ensembl chr 8:46,142,116...46,165,876
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
CAT protein inhibits the reaction [27-hydroxycholesterol results in increased expression of HSPA9 protein] |
CTD |
PMID:33880675 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases expression multiple interactions |
ISO |
27-hydroxycholesterol results in increased expression of CCL2 mRNA [24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CCL2 mRNA; Quercetin analog inhibits the reaction [27-hydroxycholesterol results in increased expression of CCL2 mRNA]; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CCL2 mRNA] |
CTD |
PMID:24802026 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
increases expression increases secretion |
ISO |
27-hydroxycholesterol results in increased expression of CCL3 mRNA 27-hydroxycholesterol results in increased secretion of CCL3 protein |
CTD |
PMID:24370436 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
increases secretion increases expression |
ISO |
27-hydroxycholesterol results in increased secretion of CCL4 protein 27-hydroxycholesterol results in increased expression of CCL4 mRNA |
CTD |
PMID:24370436 |
|
NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231
|
|
G |
Ccn5 |
cellular communication network factor 5 |
increases expression multiple interactions |
ISO |
27-hydroxycholesterol results in increased expression of CCN5 mRNA Fulvestrant inhibits the reaction [27-hydroxycholesterol results in increased expression of CCN5 mRNA] |
CTD |
PMID:17872378 |
|
NCBI chr 3:152,491,247...152,502,639
Ensembl chr 3:152,491,220...152,502,636
|
|
G |
Cd36 |
CD36 molecule |
multiple interactions increases expression |
ISO |
[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CD36 mRNA; Quercetin analog inhibits the reaction [27-hydroxycholesterol results in increased expression of CD36 mRNA]; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CD36 mRNA]; Quercetin inhibits the reaction [27-hydroxycholesterol results in increased expression of CD36 mRNA]; Quercetin inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CD36 mRNA] |
CTD |
PMID:24802026 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Cdh5 |
cadherin 5 |
decreases expression multiple interactions |
ISO |
27-hydroxycholesterol results in decreased expression of CDH5 mRNA; 27-hydroxycholesterol results in decreased expression of CDH5 protein Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in decreased expression of CDH5 protein]; CTNNB1 protein affects the reaction [27-hydroxycholesterol results in decreased expression of CDH5 protein]; SCIO-469 inhibits the reaction [27-hydroxycholesterol results in decreased expression of CDH5 protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in decreased expression of CDH5 protein] |
CTD |
PMID:33131013 |
|
NCBI chr19:815,415...854,478
Ensembl chr19:815,411...854,368
|
|
G |
Cdh6 |
cadherin 6 |
decreases expression |
ISO |
27-hydroxycholesterol results in decreased expression of CDH6 mRNA |
CTD |
PMID:33131013 |
|
NCBI chr 2:62,079,139...62,225,298
Ensembl chr 2:62,079,137...62,225,228
|
|
G |
Ces1d |
carboxylesterase 1D |
multiple interactions decreases activity |
ISO |
27-hydroxycholesterol inhibits the reaction [CES1 protein results in increased metabolism of bioresmethrin] 27-hydroxycholesterol results in decreased activity of CES1 protein |
CTD |
PMID:19761868 |
|
NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions increases activity |
ISO |
27-hydroxycholesterol inhibits the reaction [CTNNB1 protein binds to GSK3B protein]; 27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to CTNNB1 protein]; 27-hydroxycholesterol results in increased expression of and affects the localization of CTNNB1 protein; Acetylcysteine inhibits the reaction [27-hydroxycholesterol inhibits the reaction [GSK3B protein binds to CTNNB1 protein]]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to CTNNB1 protein]]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased expression of and results in increased activity of CTNNB1 protein]; CTNNB1 protein affects the reaction [27-hydroxycholesterol results in decreased expression of CDH5 protein]; CTNNB1 protein affects the reaction [27-hydroxycholesterol results in increased expression of ACTA2 protein]; CTNNB1 protein affects the reaction [27-hydroxycholesterol results in increased expression of VIM protein]; SCIO-469 inhibits the reaction [27-hydroxycholesterol inhibits the reaction [CTNNB1 protein binds to GSK3B protein]]; SCIO-469 inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to CTNNB1 protein]]; SCIO-469 inhibits the reaction [27-hydroxycholesterol results in increased expression of and results in increased activity of CTNNB1 protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased expression of and results in increased activity of CTNNB1 protein] 27-hydroxycholesterol results in increased activity of CTNNB1 protein |
CTD |
PMID:33131013 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
increases expression multiple interactions |
ISO |
27-hydroxycholesterol results in increased expression of CXCL12 mRNA fulvestrant inhibits the reaction [27-hydroxycholesterol results in increased expression of CXCL12 mRNA] |
CTD |
PMID:17872378 |
|
NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
increases abundance increases chemical synthesis multiple interactions |
ISO EXP |
CYP27A1 protein results in increased abundance of 27-hydroxycholesterol CYP27A1 protein results in increased chemical synthesis of 27-hydroxycholesterol [CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 27-hydroxycholesterol [[CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 27-hydroxycholesterol] which results in increased activity of HMGCR protein; [CYP27A1 protein results in increased hydroxylation of Cholesterol] which results in increased chemical synthesis of 27-hydroxycholesterol; [CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 27-hydroxycholesterol; [CYP27A1 protein results in increased oxidation of 27-hydroxycholesterol] which results in increased chemical synthesis of 3-hydroxy-5-cholestenoic acid; [TGFB1 protein results in increased expression of CYP27A1 protein] which results in increased abundance of 27-hydroxycholesterol |
CTD |
PMID:8496670 PMID:9215552 PMID:9660774 PMID:11408283 PMID:11714861 PMID:12119285 PMID:12531903 PMID:14622972 PMID:15708352 More...
|
|
NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
increases metabolic processing |
ISO EXP |
CYP7A1 protein results in increased metabolism of 27-hydroxycholesterol |
CTD |
PMID:10882719 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Cyp7b1 |
cytochrome P450 family 7 subfamily B member 1 |
increases abundance increases metabolic processing increases hydroxylation |
ISO |
CYP7B1 gene mutant form results in increased abundance of 27-hydroxycholesterol CYP7B1 protein results in increased metabolism of 27-hydroxycholesterol CYP7B1 protein results in increased hydroxylation of 27-hydroxycholesterol |
CTD |
PMID:10588945 PMID:10748047 |
|
NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698
|
|
G |
E2f1 |
E2F transcription factor 1 |
increases expression |
ISO |
27-hydroxycholesterol results in increased expression of E2F1 mRNA |
CTD |
PMID:17872378 |
|
NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361
|
|
G |
Erbb4 |
erb-b2 receptor tyrosine kinase 4 |
decreases expression |
ISO |
27-hydroxycholesterol results in decreased expression of ERBB4 mRNA |
CTD |
PMID:17872378 |
|
NCBI chr 9:69,523,733...70,596,743
Ensembl chr 9:69,531,481...70,596,595
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions affects response to substance increases degradation |
ISO |
27-hydroxycholesterol binds to and affects the folding of and results in increased activity of ESR1 protein; 27-hydroxycholesterol binds to and results in decreased activity of ESR1 protein; 27-hydroxycholesterol inhibits the reaction [Estradiol binds to and results in increased activity of ESR1 protein]; 27-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of ESR1 protein]; 27-hydroxycholesterol promotes the reaction [ESR1 protein binds to TFF1 promoter]; fulvestrant inhibits the reaction [27-hydroxycholesterol results in increased activity of ESR1 protein] ESR1 protein affects the susceptibility to 27-hydroxycholesterol ESR1 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS2 mRNA]; ESR1 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS3 mRNA] 27-hydroxycholesterol results in increased degradation of ESR1 protein |
CTD |
PMID:17872378 PMID:17873880 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions affects response to substance |
ISO |
27-hydroxycholesterol binds to and affects the folding of and results in increased activity of ESR2 protein; 27-hydroxycholesterol binds to and results in decreased activity of ESR2 protein; 27-hydroxycholesterol inhibits the reaction [Estradiol results in increased activity of ESR2 protein] ESR2 protein affects the susceptibility to 27-hydroxycholesterol ESR2 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS2 mRNA]; ESR2 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS3 mRNA] |
CTD |
PMID:17872378 PMID:17873880 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Grin1 |
glutamate ionotropic receptor NMDA type subunit 1 |
decreases expression |
EXP |
27-hydroxycholesterol results in decreased expression of GRIN1 protein |
CTD |
PMID:18503570 |
|
NCBI chr 3:8,103,680...8,130,603
Ensembl chr 3:8,103,680...8,130,603
|
|
G |
Grin2a |
glutamate ionotropic receptor NMDA type subunit 2A |
decreases phosphorylation |
EXP |
27-hydroxycholesterol results in decreased phosphorylation of GRIN2A protein |
CTD |
PMID:18503570 |
|
NCBI chr10:5,629,683...6,053,262
Ensembl chr10:5,631,369...6,044,637
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
increases phosphorylation multiple interactions |
ISO |
27-hydroxycholesterol results in increased phosphorylation of GSK3B protein 27-hydroxycholesterol inhibits the reaction [CTNNB1 protein binds to GSK3B protein]; 27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to GSK3B protein]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol inhibits the reaction [GSK3B protein binds to CTNNB1 protein]]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to GSK3B protein]]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of GSK3B protein]; SCIO-469 inhibits the reaction [27-hydroxycholesterol inhibits the reaction [CTNNB1 protein binds to GSK3B protein]]; SCIO-469 inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to GSK3B protein]]; SCIO-469 inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of GSK3B protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased phosphorylation of GSK3B protein] |
CTD |
PMID:33131013 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
increases expression multiple interactions |
ISO |
27-hydroxycholesterol results in increased expression of HIF1A protein HSPA9 protein promotes the reaction [27-hydroxycholesterol results in increased expression of HIF1A protein] |
CTD |
PMID:27856279 PMID:33880675 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions decreases expression decreases activity |
ISO EXP |
[[CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 27-hydroxycholesterol] which results in increased activity of HMGCR protein; Dehydroepiandrosterone inhibits the reaction [27-hydroxycholesterol results in decreased activity of HMGCR protein]; Pregnenolone inhibits the reaction [27-hydroxycholesterol results in decreased activity of HMGCR protein] 27-hydroxycholesterol results in decreased expression of HMGCR mRNA; 27-hydroxycholesterol results in decreased expression of HMGCR protein 27-hydroxycholesterol metabolite results in decreased activity of HMGCR protein; 27-hydroxycholesterol results in decreased activity of HMGCR protein |
CTD |
PMID:7749852 PMID:7751816 PMID:7788503 PMID:9059514 PMID:11408283 PMID:18024962 PMID:28167099 More...
|
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
ISO |
27-hydroxycholesterol results in increased expression of HMOX1 mRNA; 27-hydroxycholesterol results in increased expression of HMOX1 protein |
CTD |
PMID:33880675 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hspa9 |
heat shock protein family A (Hsp70) member 9 |
multiple interactions increases expression |
ISO |
CAT protein inhibits the reaction [27-hydroxycholesterol results in increased expression of HSPA9 protein]; HSPA9 protein promotes the reaction [27-hydroxycholesterol results in increased expression of HIF1A protein]; HSPA9 protein promotes the reaction [27-hydroxycholesterol results in increased expression of MYC protein]; HSPA9 protein promotes the reaction [27-hydroxycholesterol results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:33880675 |
|
NCBI chr18:26,536,131...26,554,294
Ensembl chr18:26,535,798...26,554,292
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
increases expression |
ISO |
27-hydroxycholesterol results in increased expression of ICAM1 mRNA |
CTD |
PMID:19426978 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
27-hydroxycholesterol promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein] |
CTD |
PMID:11851725 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
increases secretion multiple interactions increases expression |
ISO |
27-hydroxycholesterol results in increased secretion of IL6 protein Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased expression of IL6 mRNA]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased secretion of IL6 protein]; IL6 protein affects the reaction [27-hydroxycholesterol results in increased phosphorylation of STAT3 protein]; stattic inhibits the reaction [27-hydroxycholesterol results in increased expression of IL6 mRNA]; stattic inhibits the reaction [27-hydroxycholesterol results in increased secretion of IL6 protein] |
CTD |
PMID:11851725 PMID:28739487 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Itgb1 |
integrin subunit beta 1 |
multiple interactions increases expression |
ISO |
[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of ITGB1 mRNA; Quercetin analog inhibits the reaction [27-hydroxycholesterol results in increased expression of ITGB1 mRNA]; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of ITGB1 mRNA]; Quercetin inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of ITGB1 mRNA] |
CTD |
PMID:24802026 |
|
NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195
|
|
G |
Lcat |
lecithin cholesterol acyltransferase |
increases metabolic processing |
ISO |
LCAT protein results in increased metabolism of 27-hydroxycholesterol |
CTD |
PMID:7744831 |
|
NCBI chr19:33,834,748...33,838,214
Ensembl chr19:33,834,403...33,838,231
|
|
G |
Ldlr |
low density lipoprotein receptor |
decreases activity decreases expression |
ISO EXP |
27-hydroxycholesterol results in decreased activity of LDLR protein 27-hydroxycholesterol results in decreased expression of LDLR mRNA; 27-hydroxycholesterol results in decreased expression of LDLR protein |
CTD |
PMID:8820113 PMID:28167099 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Lipe |
lipase E, hormone sensitive type |
multiple interactions |
ISO |
LIPE protein promotes the reaction [27-hydroxycholesterol results in increased expression of STAR mRNA]; LIPE protein promotes the reaction [27-hydroxycholesterol results in increased expression of STAR protein] |
CTD |
PMID:23362264 |
|
NCBI chr 1:80,965,612...80,984,313
Ensembl chr 1:80,965,627...80,984,310
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO |
U 0126 inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:33131013 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation multiple interactions |
ISO |
27-hydroxycholesterol results in increased phosphorylation of MAPK3 protein U 0126 inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:33131013 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions increases expression |
ISO |
Quercetin analog inhibits the reaction [27-hydroxycholesterol results in increased expression of MMP9 mRNA] |
CTD |
PMID:24802026 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
increases expression multiple interactions |
ISO |
27-hydroxycholesterol results in increased expression of MYC protein HSPA9 protein promotes the reaction [27-hydroxycholesterol results in increased expression of MYC protein] |
CTD |
PMID:33880675 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions decreases expression |
ISO |
27-hydroxycholesterol inhibits the reaction [Estradiol results in increased expression of NOS2 mRNA]; ESR1 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS2 mRNA]; ESR2 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS2 mRNA] |
CTD |
PMID:17873880 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions decreases expression |
ISO |
27-hydroxycholesterol inhibits the reaction [Estradiol results in increased expression of NOS3 mRNA]; ESR1 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS3 mRNA]; ESR2 protein affects the reaction [27-hydroxycholesterol results in decreased expression of NOS3 mRNA] |
CTD |
PMID:17873880 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Npc1 |
NPC intracellular cholesterol transporter 1 |
affects abundance |
ISO |
NPC1 protein affects the abundance of 27-hydroxycholesterol |
CTD |
PMID:18483620 |
|
NCBI chr18:3,379,482...3,425,100
Ensembl chr18:3,379,482...3,425,049
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression |
ISO |
27-hydroxycholesterol results in increased expression of NQO1 mRNA; 27-hydroxycholesterol results in increased expression of NQO1 protein |
CTD |
PMID:33880675 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
increases expression |
EXP |
27-hydroxycholesterol results in increased expression of NR1H3 mRNA; 27-hydroxycholesterol results in increased expression of NR1H3 protein |
CTD |
PMID:28167099 |
|
NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722
|
|
G |
Nr5a1 |
nuclear receptor subfamily 5, group A, member 1 |
increases activity multiple interactions |
ISO |
27-hydroxycholesterol results in increased activity of NR5A1 protein 27-hydroxycholesterol promotes the reaction [NR5A1 protein results in increased expression of STAR protein] |
CTD |
PMID:9144161 PMID:9804848 |
|
NCBI chr 3:22,464,786...22,486,328
Ensembl chr 3:22,465,502...22,486,328
|
|
G |
Pgr |
progesterone receptor |
increases expression multiple interactions |
ISO |
27-hydroxycholesterol results in increased expression of PGR mRNA; 27-hydroxycholesterol results in increased expression of PGR protein fulvestrant inhibits the reaction [27-hydroxycholesterol results in increased expression of PGR mRNA] |
CTD |
PMID:17872378 |
|
NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression |
EXP |
27-hydroxycholesterol results in increased expression of PPARG mRNA; 27-hydroxycholesterol results in increased expression of PPARG protein |
CTD |
PMID:28167099 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ptges |
prostaglandin E synthase |
increases expression multiple interactions |
ISO |
27-hydroxycholesterol results in increased expression of PTGES mRNA Quercetin analog inhibits the reaction [27-hydroxycholesterol results in increased expression of PTGES mRNA]; Quercetin inhibits the reaction [27-hydroxycholesterol results in increased expression of PTGES mRNA] |
CTD |
PMID:24802026 |
|
NCBI chr 3:14,177,892...14,189,236
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression multiple interactions |
ISO |
27-hydroxycholesterol results in increased expression of PTGS2 protein [24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of PTGS2 protein |
CTD |
PMID:24802026 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Sele |
selectin E |
increases expression |
ISO |
27-hydroxycholesterol results in increased expression of SELE mRNA |
CTD |
PMID:19426978 |
|
NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741
|
|
G |
Smpd2 |
sphingomyelin phosphodiesterase 2 |
decreases activity |
ISO |
27-hydroxycholesterol results in decreased activity of SMPD2 protein |
CTD |
PMID:15261762 |
|
NCBI chr20:44,986,229...44,989,343
Ensembl chr20:44,986,231...44,989,441
|
|
G |
Snca |
synuclein alpha |
increases expression |
ISO |
27-hydroxycholesterol results in increased expression of SNCA mRNA; 27-hydroxycholesterol results in increased expression of SNCA protein |
CTD |
PMID:18841091 |
|
NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
decreases activity |
EXP |
27-hydroxycholesterol results in decreased activity of SRC protein |
CTD |
PMID:18503570 |
|
NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
decreases expression |
EXP |
27-hydroxycholesterol results in decreased expression of SREBF1 mRNA; 27-hydroxycholesterol results in decreased expression of SREBF1 protein |
CTD |
PMID:28167099 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Star |
steroidogenic acute regulatory protein |
multiple interactions increases expression increases abundance |
ISO EXP |
27-hydroxycholesterol promotes the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]; LIPE protein promotes the reaction [27-hydroxycholesterol results in increased expression of STAR mRNA]; LIPE protein promotes the reaction [27-hydroxycholesterol results in increased expression of STAR protein] 27-hydroxycholesterol results in increased expression of STAR mRNA; 27-hydroxycholesterol results in increased expression of STAR protein STAR protein results in increased abundance of 27-hydroxycholesterol 27-hydroxycholesterol promotes the reaction [NR5A1 protein results in increased expression of STAR protein] |
CTD |
PMID:9804848 PMID:12368294 PMID:15863358 PMID:20083572 PMID:23362264 |
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
increases phosphorylation multiple interactions |
ISO |
27-hydroxycholesterol results in increased phosphorylation of STAT3 protein Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of STAT3 protein]; IL6 protein affects the reaction [27-hydroxycholesterol results in increased phosphorylation of STAT3 protein]; stattic inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of STAT3 protein] Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of STAT3 protein]; STAT3 protein promotes the reaction [27-hydroxycholesterol results in increased expression of VEGFA mRNA]; STAT3 protein promotes the reaction [27-hydroxycholesterol results in increased secretion of VEGFA protein] |
CTD |
PMID:27856279 PMID:28739487 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Tff1 |
trefoil factor 1 |
increases expression multiple interactions |
ISO |
27-hydroxycholesterol results in increased expression of TFF1 mRNA 27-hydroxycholesterol promotes the reaction [ESR1 protein binds to TFF1 promoter]; fulvestrant inhibits the reaction [27-hydroxycholesterol results in increased expression of TFF1 mRNA] |
CTD |
PMID:17872378 PMID:27856279 |
|
NCBI chr20:9,235,736...9,239,597
Ensembl chr20:9,235,736...9,239,597
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
[TGFB1 protein results in increased expression of CYP27A1 protein] which results in increased abundance of 27-hydroxycholesterol |
CTD |
PMID:15708352 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions increases expression |
ISO |
[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of TLR4 mRNA; Quercetin analog inhibits the reaction [27-hydroxycholesterol results in increased expression of TLR4 mRNA]; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of TLR4 mRNA]; Quercetin inhibits the reaction [27-hydroxycholesterol results in increased expression of TLR4 mRNA]; Quercetin inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of TLR4 mRNA] |
CTD |
PMID:24802026 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
increases expression |
ISO |
27-hydroxycholesterol results in increased expression of VCAM1 mRNA |
CTD |
PMID:19426978 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
G |
Vegfa |
vascular endothelial growth factor A |
increases secretion multiple interactions increases expression |
ISO |
27-hydroxycholesterol results in increased secretion of VEGFA protein Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased expression of VEGFA mRNA]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased secretion of VEGFA protein]; STAT3 protein promotes the reaction [27-hydroxycholesterol results in increased expression of VEGFA mRNA]; STAT3 protein promotes the reaction [27-hydroxycholesterol results in increased secretion of VEGFA protein] |
CTD |
PMID:27856279 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vim |
vimentin |
increases expression multiple interactions |
ISO |
27-hydroxycholesterol results in increased expression of VIM mRNA; 27-hydroxycholesterol results in increased expression of VIM protein Acetylcysteine inhibits the reaction [27-hydroxycholesterol results in increased expression of VIM protein]; CTNNB1 protein affects the reaction [27-hydroxycholesterol results in increased expression of VIM protein]; SCIO-469 inhibits the reaction [27-hydroxycholesterol results in increased expression of VIM protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased expression of VIM protein] |
CTD |
PMID:33131013 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
G |
Ywhah |
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, eta |
multiple interactions |
ISO |
27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to CTNNB1 protein]; 27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to GSK3B protein]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to CTNNB1 protein]]; Acetylcysteine inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to GSK3B protein]]; SCIO-469 inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to CTNNB1 protein]]; SCIO-469 inhibits the reaction [27-hydroxycholesterol inhibits the reaction [YWHAH protein binds to GSK3B protein]]; YWHAH protein affects the reaction [27-hydroxycholesterol results in decreased expression of CDH5 protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased expression of ACTA2 protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased expression of and results in increased activity of CTNNB1 protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased expression of VIM protein]; YWHAH protein affects the reaction [27-hydroxycholesterol results in increased phosphorylation of GSK3B protein] |
CTD |
PMID:33131013 |
|
NCBI chr14:77,696,332...77,705,715
Ensembl chr14:77,696,333...77,705,741
|
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
increases chemical synthesis multiple interactions |
ISO |
CYP27A1 protein results in increased chemical synthesis of 3-hydroxy-5-cholestenoic acid [CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 3-hydroxy-5-cholestenoic acid; [CYP27A1 protein results in increased oxidation of 27-hydroxycholesterol] which results in increased chemical synthesis of 3-hydroxy-5-cholestenoic acid |
CTD |
PMID:8078928 PMID:9215552 PMID:9660774 PMID:14622972 |
|
NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551
|
|
G |
Ncoa2 |
nuclear receptor coactivator 2 |
multiple interactions |
ISO |
3-hydroxy-5-cholestenoic acid affects the reaction [NR1H3 protein binds to NCOA2 protein] |
CTD |
PMID:11089551 |
|
NCBI chr 5:5,835,642...6,069,693
Ensembl chr 5:5,835,706...6,067,451
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
multiple interactions |
ISO |
3-hydroxy-5-cholestenoic acid affects the reaction [NR1H3 protein binds to NCOA2 protein]; 3-hydroxy-5-cholestenoic acid binds to and results in increased activity of NR1H3 protein |
CTD |
PMID:11089551 |
|
NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722
|
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
decreases activity |
ISO |
lanosten-3-ol-32-al results in decreased activity of HMGCR protein |
CTD |
PMID:12617470 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
increases activity |
ISO |
4,4-dimethylcholesta-8,14,24-trienol results in increased activity of NR1H3 protein |
CTD |
PMID:9603267 |
|
NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722
|
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions increases chemical synthesis |
ISO |
[CYP3A4 protein results in increased oxidation of Cholesterol] which results in increased chemical synthesis of cholest-5-ene-3,4-diol CYP3A4 protein results in increased chemical synthesis of cholest-5-ene-3,4-diol |
CTD |
PMID:11514559 PMID:19954708 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
|
G |
Egfr |
epidermal growth factor receptor |
increases phosphorylation |
EXP |
cholesterol alpha-oxide results in increased phosphorylation of EGFR protein |
CTD |
PMID:20466046 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Ephx1 |
epoxide hydrolase 1 |
increases metabolic processing multiple interactions |
ISO |
EPHX1 protein results in increased metabolism of cholesterol alpha-oxide disparlure promotes the reaction [EPHX1 protein results in increased metabolism of cholesterol alpha-oxide]; Lanosterol analog inhibits the reaction [EPHX1 protein results in increased metabolism of cholesterol alpha-oxide] |
CTD |
PMID:2043152 |
|
NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235
|
|
G |
Ephx2 |
epoxide hydrolase 2 |
multiple interactions |
ISO |
cholesterol alpha-oxide inhibits the reaction [EPHX2 protein results in increased metabolism of stilbene oxide analog] |
CTD |
PMID:2043152 |
|
NCBI chr15:40,289,901...40,327,632
Ensembl chr15:40,289,902...40,327,615
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
EXP |
RTKI cpd inhibits the reaction [cholesterol alpha-oxide results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:20466046 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation multiple interactions |
EXP |
cholesterol alpha-oxide results in increased phosphorylation of MAPK3 protein RTKI cpd inhibits the reaction [cholesterol alpha-oxide results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:20466046 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
increases expression |
EXP |
cholesterol alpha-oxide results in increased expression of MMP2 mRNA |
CTD |
PMID:20466046 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
increases expression |
EXP |
cholesterol alpha-oxide results in increased expression of MMP9 mRNA |
CTD |
PMID:20466046 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
increases phosphorylation multiple interactions |
EXP |
cholesterol alpha-oxide results in increased phosphorylation of MTOR protein RTKI cpd inhibits the reaction [cholesterol alpha-oxide results in increased phosphorylation of MTOR protein] |
CTD |
PMID:20466046 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
multiple interactions |
ISO |
[1,4-bis(2-(3,5-dichloropyridyloxy))benzene inhibits the reaction [androst-16-en-3-ol results in decreased activity of NR1I3 protein]] which results in increased expression of CYP2B6 mRNA; [Endosulfan inhibits the reaction [androst-16-en-3-ol results in decreased activity of NR1I3 protein]] which results in increased expression of CYP2B6 mRNA |
CTD |
PMID:20361990 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
decreases activity multiple interactions |
ISO |
androst-16-en-3-ol results in decreased activity of NR1I3 protein 1,4-bis(2-(3,5-dichloropyridyloxy))benzene inhibits the reaction [androst-16-en-3-ol results in decreased activity of NR1I3 protein]; [1,4-bis(2-(3,5-dichloropyridyloxy))benzene inhibits the reaction [androst-16-en-3-ol results in decreased activity of NR1I3 protein]] which results in increased expression of CYP2B6 mRNA; [Endosulfan inhibits the reaction [androst-16-en-3-ol results in decreased activity of NR1I3 protein]] which results in increased expression of CYP2B6 mRNA |
CTD |
PMID:20361990 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
|
G |
Msmo1 |
methylsterol monooxygenase 1 |
increases abundance |
ISO |
MSMO1 protein results in increased abundance of lathosterol |
CTD |
PMID:23125191 |
|
NCBI chr16:24,980,680...24,997,927
Ensembl chr16:24,980,697...24,998,016
|
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
6-oxocampestanol results in decreased expression of BCL2 protein |
CTD |
PMID:32001316 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
affects expression |
ISO |
6-oxocampestanol affects the expression of BCL2L1 protein |
CTD |
PMID:32001316 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bid |
BH3 interacting domain death agonist |
affects expression |
ISO |
6-oxocampestanol affects the expression of BID protein |
CTD |
PMID:32001316 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Ccnb1 |
cyclin B1 |
decreases expression |
ISO |
6-oxocampestanol results in decreased expression of CCNB1 protein |
CTD |
PMID:32001316 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
6-oxocampestanol results in increased expression of CDKN1A protein |
CTD |
PMID:32001316 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Esr1 |
estrogen receptor 1 |
increases expression |
ISO |
6-oxocampestanol results in increased expression of ESR1 protein |
CTD |
PMID:32001316 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
affects localization |
ISO |
6-oxocampestanol affects the localization of ESR2 protein |
CTD |
PMID:32001316 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Pgr |
progesterone receptor |
affects localization |
ISO |
6-oxocampestanol affects the localization of PGR protein |
CTD |
PMID:32001316 |
|
NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
multiple interactions |
ISO |
6-oxocampestanol results in increased expression of and results in increased phosphorylation of RB1 protein |
CTD |
PMID:32001316 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Tp53 |
tumor protein p53 |
increases expression |
ISO |
6-oxocampestanol results in increased expression of TP53 protein |
CTD |
PMID:32001316 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
|
G |
Abcd1 |
ATP binding cassette subfamily D member 1 |
decreases expression multiple interactions |
ISO |
7-ketocholesterol results in decreased expression of ABCD1 mRNA alpha-Tocopherol inhibits the reaction [7-ketocholesterol results in decreased expression of ABCD1 mRNA]; argan oil inhibits the reaction [7-ketocholesterol results in decreased expression of ABCD1 mRNA] |
CTD |
PMID:29065513 |
|
NCBI chr X:151,428,334...151,450,115
Ensembl chr X:151,428,578...151,450,115
|
|
G |
Abcd3 |
ATP binding cassette subfamily D member 3 |
decreases expression multiple interactions |
ISO |
7-ketocholesterol results in decreased expression of ABCD3 mRNA alpha-Tocopherol inhibits the reaction [7-ketocholesterol results in decreased expression of ABCD3 mRNA]; argan oil inhibits the reaction [7-ketocholesterol results in decreased expression of ABCD3 mRNA] |
CTD |
PMID:29065513 |
|
NCBI chr 2:209,852,087...209,905,763
Ensembl chr 2:209,852,087...209,906,020
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
multiple interactions decreases expression |
ISO |
[7-ketocholesterol co-treated with KNG1 protein modified form] results in decreased expression of ABCG5 mRNA; [7-ketocholesterol co-treated with Oligomycins] results in decreased expression of ABCG5 mRNA; [7-ketocholesterol co-treated with Rotenone] results in decreased expression of ABCG5 mRNA 7-ketocholesterol results in decreased expression of ABCG5 mRNA |
CTD |
PMID:23454145 |
|
NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563
|
|
G |
Abcg8 |
ATP binding cassette subfamily G member 8 |
multiple interactions |
ISO |
[7-ketocholesterol co-treated with Oligomycins] results in decreased expression of ABCG8 mRNA; [7-ketocholesterol co-treated with Rotenone] results in decreased expression of ABCG8 mRNA |
CTD |
PMID:23454145 |
|
NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912
|
|
G |
Acat1 |
acetyl-CoA acetyltransferase 1 |
multiple interactions |
ISO |
[7-ketocholesterol co-treated with KNG1 protein modified form] results in decreased expression of ACAT1 mRNA; [7-ketocholesterol co-treated with Rotenone] results in decreased expression of ACAT1 mRNA |
CTD |
PMID:23454145 |
|
NCBI chr 8:53,979,813...54,008,861
Ensembl chr 8:53,979,813...54,008,855
|
|
G |
Acox1 |
acyl-CoA oxidase 1 |
decreases expression |
ISO |
7-ketocholesterol results in decreased expression of ACOX1 mRNA |
CTD |
PMID:29065513 |
|
NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions affects binding |
ISO EXP |
7-ketocholesterol inhibits the reaction [AHR protein binds to CYP1A1 enhancer]; 7-ketocholesterol inhibits the reaction [Tetrachlorodibenzodioxin binds to AHR protein]; 7-ketocholesterol inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to CYP1A1 enhancer]]; 7-ketocholesterol inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of AHR mRNA] 7-ketocholesterol binds to AHR protein |
CTD |
PMID:11042205 PMID:16480812 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
7-ketocholesterol results in decreased phosphorylation of and results in decreased activity of AKT1 protein; alpha-Tocopherol inhibits the reaction [7-ketocholesterol results in decreased phosphorylation of and results in decreased activity of AKT1 protein] |
CTD |
PMID:19351882 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions |
EXP |
7-ketocholesterol results in increased expression of BAX protein Acetylcysteine inhibits the reaction [7-ketocholesterol results in increased expression of BAX protein]; BAY 11-7085 inhibits the reaction [7-ketocholesterol results in increased expression of BAX protein]; quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [7-ketocholesterol results in increased expression of BAX protein] |
CTD |
PMID:25845326 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression |
EXP |
Acetylcysteine inhibits the reaction [7-ketocholesterol results in decreased expression of BCL2 protein]; BAY 11-7085 inhibits the reaction [7-ketocholesterol results in decreased expression of BCL2 protein]; quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [7-ketocholesterol results in decreased expression of BCL2 protein] |
CTD |
PMID:25845326 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l11 |
Bcl2-like 11 |
affects localization |
ISO |
7-ketocholesterol affects the localization of BCL2L11 protein |
CTD |
PMID:15955068 |
|
NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
|
|
G |
Bid |
BH3 interacting domain death agonist |
decreases expression multiple interactions |
EXP |
7-ketocholesterol results in decreased expression of BID protein Acetylcysteine inhibits the reaction [7-ketocholesterol results in decreased expression of BID protein]; BAY 11-7085 inhibits the reaction [7-ketocholesterol results in decreased expression of BID protein]; quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [7-ketocholesterol results in decreased expression of BID protein] |
CTD |
PMID:25845326 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Casp1 |
caspase 1 |
multiple interactions affects localization increases activity |
ISO |
Amitriptyline inhibits the reaction [7-ketocholesterol affects the localization of CASP1 protein]; Amitriptyline inhibits the reaction [7-ketocholesterol results in increased activity of CASP1 protein]; methyl-beta-cyclodextrin inhibits the reaction [7-ketocholesterol results in increased activity of CASP1 protein]; SMPD1 protein affects the reaction [7-ketocholesterol affects the localization of CASP1 protein]; SMPD1 protein affects the reaction [7-ketocholesterol results in increased activity of CASP1 protein]; tempol inhibits the reaction [7-ketocholesterol results in increased activity of CASP1 protein]; Verapamil inhibits the reaction [7-ketocholesterol results in increased activity of CASP1 protein] |
CTD |
PMID:28633109 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp3 |
caspase 3 |
increases activity increases cleavage multiple interactions |
ISO EXP |
7-ketocholesterol results in increased activity of CASP3 protein 7-ketocholesterol results in increased cleavage of CASP3 protein alpha-Tocopherol inhibits the reaction [7-ketocholesterol results in increased cleavage of CASP3 protein]; argan oil inhibits the reaction [7-ketocholesterol results in increased cleavage of CASP3 protein] 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [7-ketocholesterol results in increased activity of CASP3 protein]; Acetylcysteine inhibits the reaction [7-ketocholesterol results in increased activity of CASP3 protein]; BAY 11-7085 inhibits the reaction [7-ketocholesterol results in increased activity of CASP3 protein]; quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [7-ketocholesterol results in increased activity of CASP3 protein] 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [7-ketocholesterol results in increased activity of CASP3 protein]; Acetylcysteine inhibits the reaction [7-ketocholesterol results in increased activity of CASP3 protein]; alpha-Tocopherol inhibits the reaction [7-ketocholesterol results in increased activity of CASP3 protein]; BAY 11-7085 inhibits the reaction [7-ketocholesterol results in increased activity of CASP3 protein]; beta-Tocopherol affects the reaction [7-ketocholesterol results in increased activity of CASP3 protein]; quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [7-ketocholesterol results in increased activity of CASP3 protein]; Serotonin inhibits the reaction [7-ketocholesterol results in increased activity of CASP3 protein] |
CTD |
PMID:12450566 PMID:16934673 PMID:24650663 PMID:25845326 PMID:29065513 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
increases activity multiple interactions |
ISO |
7-ketocholesterol results in increased activity of CASP7 protein Serotonin inhibits the reaction [7-ketocholesterol results in increased activity of CASP7 protein] |
CTD |
PMID:24650663 |
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp8 |
caspase 8 |
multiple interactions increases activity |
EXP |
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [7-ketocholesterol results in increased activity of CASP8 protein]; Acetylcysteine inhibits the reaction [7-ketocholesterol results in increased activity of CASP8 protein]; BAY 11-7085 inhibits the reaction [7-ketocholesterol results in increased activity of CASP8 protein]; quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [7-ketocholesterol results in increased activity of CASP8 protein] |
CTD |
PMID:25845326 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases activity |
EXP |
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [7-ketocholesterol results in increased activity of CASP9 protein]; Acetylcysteine inhibits the reaction [7-ketocholesterol results in increased activity of CASP9 protein]; BAY 11-7085 inhibits the reaction [7-ketocholesterol results in increased activity of CASP9 protein]; quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [7-ketocholesterol results in increased activity of CASP9 protein] |
CTD |
PMID:25845326 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases expression multiple interactions |
ISO |
7-ketocholesterol results in increased expression of CCL2 protein resveratrol inhibits the reaction [7-ketocholesterol results in increased expression of CCL2 protein] |
CTD |
PMID:24895526 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions increases expression |
ISO |
resveratrol inhibits the reaction [7-ketocholesterol results in increased expression of CCL3 protein] |
CTD |
PMID:24895526 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
increases expression multiple interactions |
ISO |
7-ketocholesterol results in increased expression of CCL4 protein resveratrol inhibits the reaction [7-ketocholesterol results in increased expression of CCL4 protein] |
CTD |
PMID:24895526 |
|
NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions increases expression |
ISO |
resveratrol inhibits the reaction [7-ketocholesterol results in increased expression of CCL5 protein] |
CTD |
PMID:24895526 |
|
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Cd38 |
CD38 molecule |
multiple interactions |
ISO |
CD38 gene mutant form promotes the reaction [7-ketocholesterol results in increased expression of MAP1LC3B protein] |
CTD |
PMID:24445604 |
|
NCBI chr14:67,172,062...67,212,328
Ensembl chr14:67,172,063...67,211,986
|
|
G |
Csf2 |
colony stimulating factor 2 |
increases expression multiple interactions |
ISO |
7-ketocholesterol results in increased expression of CSF2 protein resveratrol inhibits the reaction [7-ketocholesterol results in increased expression of CSF2 protein] |
CTD |
PMID:24895526 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Csf3 |
colony stimulating factor 3 |
increases expression multiple interactions |
ISO |
7-ketocholesterol results in increased expression of CSF3 protein resveratrol inhibits the reaction [7-ketocholesterol results in increased expression of CSF3 protein] |
CTD |
PMID:24895526 |
|
NCBI chr10:83,660,787...83,664,569
Ensembl chr10:83,661,207...83,663,603
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
increases expression |
ISO |
7-ketocholesterol results in increased expression of CXCL10 protein |
CTD |
PMID:24895526 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cybb |
cytochrome b-245 beta chain |
affects localization multiple interactions |
ISO |
7-ketocholesterol affects the localization of CYBB protein Amitriptyline inhibits the reaction [7-ketocholesterol affects the localization of CYBB protein]; Amitriptyline inhibits the reaction [7-ketocholesterol analog affects the localization of CYBB protein] |
CTD |
PMID:28633109 |
|
NCBI chr X:13,358,101...13,392,570
Ensembl chr X:13,359,430...13,392,586
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions decreases expression |
ISO EXP |
7-ketocholesterol inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1A1 protein]; 7-ketocholesterol inhibits the reaction [AHR protein binds to CYP1A1 enhancer]; 7-ketocholesterol inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to CYP1A1 enhancer]]; 7-ketocholesterol inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein] 7-ketocholesterol inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CYP1A1 protein]; 7-ketocholesterol inhibits the reaction [[Benzo(a)pyrene co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of CYP1A1 mRNA]; 7-ketocholesterol inhibits the reaction [[Benzo(a)pyrene co-treated with 9,10-Dimethyl-1,2-benzanthracene] results in increased expression of CYP1A1 protein]; 7-ketocholesterol inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] 7-ketocholesterol results in decreased expression of CYP1A1 protein |
CTD |
PMID:11042205 PMID:18708364 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
increases metabolic processing |
ISO |
CYP27A1 protein results in increased metabolism of 7-ketocholesterol |
CTD |
PMID:10869358 |
|
NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
decreases activity |
EXP |
7-ketocholesterol results in decreased activity of CYP7A1 protein |
CTD |
PMID:1175606 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Egfr |
epidermal growth factor receptor |
increases phosphorylation |
EXP |
7-ketocholesterol results in increased phosphorylation of EGFR protein |
CTD |
PMID:20466046 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
decreases activity increases expression multiple interactions |
ISO |
7-ketocholesterol results in decreased activity of HMGCR protein 7-ketocholesterol results in increased expression of HMGCR mRNA [7-ketocholesterol co-treated with KNG1 protein modified form] results in decreased expression of HMGCR mRNA; [7-ketocholesterol co-treated with Oligomycins] results in decreased expression of HMGCR mRNA; [7-ketocholesterol co-treated with Rotenone] results in decreased expression of HMGCR mRNA |
CTD |
PMID:7751816 PMID:23454145 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hsd17b4 |
hydroxysteroid (17-beta) dehydrogenase 4 |
decreases expression |
ISO |
7-ketocholesterol results in decreased expression of HSD17B4 mRNA |
CTD |
PMID:29065513 |
|
NCBI chr18:43,328,903...43,417,950
Ensembl chr18:43,328,824...43,417,952
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
increases expression |
ISO |
7-ketocholesterol results in increased expression of ICAM1 mRNA; 7-ketocholesterol results in increased expression of ICAM1 protein |
CTD |
PMID:15720832 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Il10 |
interleukin 10 |
decreases expression multiple interactions increases expression |
ISO |
7-ketocholesterol results in decreased expression of IL10 mRNA resveratrol promotes the reaction [7-ketocholesterol results in increased expression of IL10 protein] |
CTD |
PMID:24727230 PMID:24895526 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1b |
interleukin 1 beta |
increases expression multiple interactions |
ISO |
7-ketocholesterol results in increased expression of IL1B protein Amitriptyline inhibits the reaction [7-ketocholesterol results in increased expression of IL1B protein]; SMPD1 protein affects the reaction [7-ketocholesterol results in increased expression of IL1B protein] |
CTD |
PMID:28633109 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il1rn |
interleukin 1 receptor antagonist |
multiple interactions |
ISO |
[resveratrol co-treated with 7-ketocholesterol] results in increased expression of IL1RN protein |
CTD |
PMID:24895526 |
|
NCBI chr 3:7,111,567...7,127,451
Ensembl chr 3:7,111,550...7,127,445
|
|
G |
Il6 |
interleukin 6 |
increases expression multiple interactions |
ISO |
7-ketocholesterol results in increased expression of IL6 protein 7-ketocholesterol results in decreased degradation of and results in increased expression of IL6 mRNA; pyrazolanthrone inhibits the reaction [7-ketocholesterol results in increased expression of IL6 mRNA]; resveratrol inhibits the reaction [7-ketocholesterol results in increased expression of IL6 protein]; SB 203580 inhibits the reaction [7-ketocholesterol results in increased expression of IL6 mRNA] |
CTD |
PMID:18515973 PMID:24895526 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Kng1 |
kininogen 1 |
multiple interactions |
ISO |
[7-ketocholesterol co-treated with KNG1 protein modified form] results in decreased expression of ABCG5 mRNA; [7-ketocholesterol co-treated with KNG1 protein modified form] results in decreased expression of ACAT1 mRNA; [7-ketocholesterol co-treated with KNG1 protein modified form] results in decreased expression of HMGCR mRNA |
CTD |
PMID:23454145 |
|
NCBI chr11:77,812,757...77,835,555
Ensembl chr11:77,812,752...77,835,555
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
increases expression multiple interactions |
ISO |
7-ketocholesterol results in increased expression of MAP1LC3B protein CD38 gene mutant form promotes the reaction [7-ketocholesterol results in increased expression of MAP1LC3B protein] |
CTD |
PMID:24445604 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO EXP |
U 0126 inhibits the reaction [7-ketocholesterol results in increased phosphorylation of MAPK1 protein] RTKI cpd inhibits the reaction [7-ketocholesterol results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:15955068 PMID:20466046 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation multiple interactions |
ISO EXP |
7-ketocholesterol results in increased phosphorylation of MAPK3 protein RTKI cpd inhibits the reaction [7-ketocholesterol results in increased phosphorylation of MAPK3 protein] U 0126 inhibits the reaction [7-ketocholesterol results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:15955068 PMID:20466046 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
increases expression multiple interactions |
EXP ISO |
7-ketocholesterol results in increased expression of MMP2 mRNA 7-ketocholesterol results in increased expression of MMP2 protein resveratrol inhibits the reaction [7-ketocholesterol results in increased expression of MMP2 protein] |
CTD |
PMID:20466046 PMID:24895526 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
increases expression multiple interactions |
EXP ISO |
7-ketocholesterol results in increased expression of MMP9 mRNA 7-ketocholesterol results in increased expression of MMP9 protein resveratrol inhibits the reaction [7-ketocholesterol results in increased expression of MMP9 protein] |
CTD |
PMID:20466046 PMID:24895526 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
increases phosphorylation multiple interactions |
EXP |
7-ketocholesterol results in increased phosphorylation of MTOR protein RTKI cpd inhibits the reaction [7-ketocholesterol results in increased phosphorylation of MTOR protein] |
CTD |
PMID:20466046 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
increases expression multiple interactions |
ISO EXP |
7-ketocholesterol results in increased expression of NFKB1 protein Acetylcysteine inhibits the reaction [7-ketocholesterol results in increased expression of NFKB1 protein]; BAY 11-7085 inhibits the reaction [7-ketocholesterol results in increased expression of NFKB1 protein]; quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [7-ketocholesterol results in increased expression of NFKB1 protein] resveratrol inhibits the reaction [7-ketocholesterol results in increased expression of NFKB1 protein] |
CTD |
PMID:24895526 PMID:25845326 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
increases phosphorylation multiple interactions |
EXP |
7-ketocholesterol results in increased phosphorylation of NFKBIA protein Acetylcysteine inhibits the reaction [7-ketocholesterol results in increased expression of NFKBIA protein]; BAY 11-7085 inhibits the reaction [7-ketocholesterol results in increased phosphorylation of NFKBIA protein]; quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [7-ketocholesterol results in increased expression of NFKBIA protein] |
CTD |
PMID:25845326 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions affects localization |
ISO |
Amitriptyline inhibits the reaction [7-ketocholesterol affects the localization of NLRP3 protein] |
CTD |
PMID:28633109 |
|
NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Nos2 |
nitric oxide synthase 2 |
increases expression |
ISO |
7-ketocholesterol results in increased expression of NOS2 mRNA |
CTD |
PMID:12085989 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Npc1l1 |
NPC1 like intracellular cholesterol transporter 1 |
decreases expression |
ISO |
7-ketocholesterol results in decreased expression of NPC1L1 |
CTD |
PMID:23454145 |
|
NCBI chr14:81,071,448...81,091,113
Ensembl chr14:81,071,451...81,091,113
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage multiple interactions |
EXP |
7-ketocholesterol results in increased cleavage of PARP1 protein Acetylcysteine inhibits the reaction [7-ketocholesterol results in increased cleavage of PARP1 protein]; BAY 11-7085 inhibits the reaction [7-ketocholesterol results in increased cleavage of PARP1 protein]; quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [7-ketocholesterol results in increased cleavage of PARP1 protein] |
CTD |
PMID:25845326 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pon1 |
paraoxonase 1 |
multiple interactions |
ISO |
7-ketocholesterol inhibits the reaction [Methylcholanthrene results in increased expression of PON1 mRNA]; 7-ketocholesterol inhibits the reaction [Quercetin results in increased expression of PON1 mRNA]; 7-ketocholesterol inhibits the reaction [resveratrol results in increased expression of PON1 mRNA] |
CTD |
PMID:15169886 PMID:15458977 |
|
NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360
|
|
G |
Pon2 |
paraoxonase 2 |
increases activity increases expression |
ISO |
7-ketocholesterol results in increased activity of PON2 protein 7-ketocholesterol results in increased expression of PON2 mRNA |
CTD |
PMID:12615656 |
|
NCBI chr 4:33,389,702...33,425,186
Ensembl chr 4:33,389,714...33,425,248
|
|
G |
Pon3 |
paraoxonase 3 |
multiple interactions |
ISO |
7-ketocholesterol inhibits the reaction [PON3 protein results in increased metabolism of Lovastatin] |
CTD |
PMID:12615656 |
|
NCBI chr 4:33,356,983...33,383,681
Ensembl chr 4:33,349,168...33,383,855
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
decreases expression multiple interactions |
ISO |
7-ketocholesterol results in decreased expression of PPARA mRNA alpha-Tocopherol inhibits the reaction [7-ketocholesterol results in decreased expression of PPARA mRNA]; argan oil inhibits the reaction [7-ketocholesterol results in decreased expression of PPARA mRNA] |
CTD |
PMID:29065513 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ptk2b |
protein tyrosine kinase 2 beta |
multiple interactions |
ISO |
7-ketocholesterol results in increased phosphorylation of and results in increased activity of PTK2B protein |
CTD |
PMID:15955068 |
|
NCBI chr15:40,360,722...40,481,235
Ensembl chr15:40,360,723...40,481,282
|
|
G |
Pycard |
PYD and CARD domain containing |
affects localization multiple interactions |
ISO |
7-ketocholesterol affects the localization of PYCARD protein Amitriptyline inhibits the reaction [7-ketocholesterol affects the localization of PYCARD protein]; SMPD1 protein affects the reaction [7-ketocholesterol affects the localization of PYCARD protein] |
CTD |
PMID:28633109 |
|
NCBI chr 1:182,601,657...182,603,013
Ensembl chr 1:182,601,174...182,602,955
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
increases expression multiple interactions |
ISO EXP |
7-ketocholesterol results in increased expression of RELA protein 7-ketocholesterol results in increased expression of and results in increased phosphorylation of RELA protein; Acetylcysteine inhibits the reaction [7-ketocholesterol results in increased expression of and results in increased phosphorylation of RELA protein]; BAY 11-7085 inhibits the reaction [7-ketocholesterol results in increased expression of and results in increased phosphorylation of RELA protein]; quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [7-ketocholesterol results in increased expression of and results in increased phosphorylation of RELA protein] resveratrol inhibits the reaction [7-ketocholesterol results in increased expression of RELA protein] |
CTD |
PMID:24895526 PMID:25845326 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Smpd1 |
sphingomyelin phosphodiesterase 1 |
multiple interactions |
ISO |
SMPD1 protein affects the reaction [7-ketocholesterol affects the localization of CASP1 protein]; SMPD1 protein affects the reaction [7-ketocholesterol affects the localization of PYCARD protein]; SMPD1 protein affects the reaction [7-ketocholesterol results in increased activity of CASP1 protein]; SMPD1 protein affects the reaction [7-ketocholesterol results in increased expression of IL1B protein] |
CTD |
PMID:28633109 |
|
NCBI chr 1:159,892,946...159,896,789
Ensembl chr 1:159,892,859...159,896,794
|
|
G |
Tgm2 |
transglutaminase 2 |
multiple interactions |
ISO |
7-ketocholesterol inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of TGM2 mRNA] |
CTD |
PMID:16480812 |
|
NCBI chr 3:146,772,684...146,801,924
Ensembl chr 3:146,772,687...146,801,981
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases expression |
ISO |
resveratrol inhibits the reaction [7-ketocholesterol results in increased expression of TNF protein] |
CTD |
PMID:24895526 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
increases expression multiple interactions |
EXP |
7-ketocholesterol results in increased expression of TP53 protein Acetylcysteine inhibits the reaction [7-ketocholesterol results in increased expression of TP53 protein]; BAY 11-7085 inhibits the reaction [7-ketocholesterol results in increased expression of TP53 protein]; quercetin 3-O-beta-(2''-galloyl)-rhamnopyranoside inhibits the reaction [7-ketocholesterol results in increased expression of TP53 protein] |
CTD |
PMID:25845326 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
increases expression |
ISO |
7-ketocholesterol results in increased expression of VCAM1 mRNA; 7-ketocholesterol results in increased expression of VCAM1 protein |
CTD |
PMID:15720832 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
G |
Vegfa |
vascular endothelial growth factor A |
increases expression multiple interactions |
ISO |
7-ketocholesterol results in increased expression of VEGFA protein resveratrol inhibits the reaction [7-ketocholesterol results in increased expression of VEGFA protein] |
CTD |
PMID:24895526 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
|
G |
Adam17 |
ADAM metallopeptidase domain 17 |
decreases activity |
EXP |
cholest-5-en-3 beta,7 alpha-diol results in decreased activity of ADAM17 protein |
CTD |
PMID:15591071 |
|
NCBI chr 6:40,872,936...40,920,700
Ensembl chr 6:40,872,856...40,920,639
|
|
G |
App |
amyloid beta precursor protein |
increases chemical synthesis decreases secretion |
EXP |
APP protein results in increased chemical synthesis of cholest-5-en-3 beta,7 alpha-diol cholest-5-en-3 beta,7 alpha-diol results in decreased secretion of APP protein |
CTD |
PMID:15591071 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity |
ISO |
alpha-Tocopherol inhibits the reaction [cholest-5-en-3 beta,7 alpha-diol results in increased activity of CASP3 protein]; beta-Tocopherol affects the reaction [cholest-5-en-3 beta,7 alpha-diol results in increased activity of CASP3 protein] |
CTD |
PMID:12450566 PMID:16934673 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions increases expression |
ISO |
[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CCL2 mRNA; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CCL2 mRNA]; Quercetin analog inhibits the reaction [cholest-5-en-3 beta,7 alpha-diol results in increased expression of CCL2 mRNA] |
CTD |
PMID:24802026 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
increases secretion increases expression |
ISO |
cholest-5-en-3 beta,7 alpha-diol results in increased secretion of CCL3 protein cholest-5-en-3 beta,7 alpha-diol results in increased expression of CCL3 mRNA |
CTD |
PMID:24370436 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
increases expression increases secretion |
ISO |
cholest-5-en-3 beta,7 alpha-diol results in increased expression of CCL4 mRNA cholest-5-en-3 beta,7 alpha-diol results in increased secretion of CCL4 protein |
CTD |
PMID:24370436 |
|
NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231
|
|
G |
Cd36 |
CD36 molecule |
increases expression multiple interactions |
ISO |
cholest-5-en-3 beta,7 alpha-diol results in increased expression of CD36 mRNA [24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CD36 mRNA; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CD36 mRNA]; Quercetin analog inhibits the reaction [cholest-5-en-3 beta,7 alpha-diol results in increased expression of CD36 mRNA]; Quercetin inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of CD36 mRNA] |
CTD |
PMID:24802026 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Cyp46a1 |
cytochrome P450, family 46, subfamily a, polypeptide 1 |
increases hydroxylation |
ISO |
CYP46A1 protein results in increased hydroxylation of cholest-5-en-3 beta,7 alpha-diol |
CTD |
PMID:14640697 |
|
NCBI chr 6:127,247,543...127,274,765
Ensembl chr 6:127,243,315...127,274,760
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
multiple interactions |
EXP |
[Uranyl Nitrate results in decreased activity of CYP7A1 protein] which results in decreased chemical synthesis of cholest-5-en-3 beta,7 alpha-diol |
CTD |
PMID:20362056 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
decreases activity |
EXP |
cholest-5-en-3 beta,7 alpha-diol results in decreased activity of HMGCR protein |
CTD |
PMID:9199277 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hsd17b10 |
hydroxysteroid (17-beta) dehydrogenase 10 |
multiple interactions |
ISO |
[cholest-5-en-3 beta,7 alpha-diol co-treated with NAD] binds to HSD17B10 protein |
CTD |
PMID:25526675 |
|
NCBI chr X:21,089,142...21,091,603
Ensembl chr X:21,089,122...21,109,488
|
|
G |
Itgb1 |
integrin subunit beta 1 |
increases expression multiple interactions |
ISO |
cholest-5-en-3 beta,7 alpha-diol results in increased expression of ITGB1 mRNA [24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of ITGB1 mRNA; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of ITGB1 mRNA]; Quercetin analog inhibits the reaction [cholest-5-en-3 beta,7 alpha-diol results in increased expression of ITGB1 mRNA]; Quercetin inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of ITGB1 mRNA] |
CTD |
PMID:24802026 |
|
NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195
|
|
G |
Lpl |
lipoprotein lipase |
decreases activity decreases expression |
ISO |
cholest-5-en-3 beta,7 alpha-diol results in decreased activity of LPL protein cholest-5-en-3 beta,7 alpha-diol results in decreased expression of LPL mRNA |
CTD |
PMID:8567968 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases activity |
ISO |
cholest-5-en-3 beta,7 alpha-diol results in increased activity of MAPK1 protein |
CTD |
PMID:11058697 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases activity |
ISO |
cholest-5-en-3 beta,7 alpha-diol results in increased activity of MAPK3 protein |
CTD |
PMID:11058697 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions increases expression |
ISO |
Quercetin analog inhibits the reaction [cholest-5-en-3 beta,7 alpha-diol results in increased expression of MMP9 mRNA] |
CTD |
PMID:24802026 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Ptges |
prostaglandin E synthase |
increases expression multiple interactions |
ISO |
cholest-5-en-3 beta,7 alpha-diol results in increased expression of PTGES mRNA Quercetin analog inhibits the reaction [cholest-5-en-3 beta,7 alpha-diol results in increased expression of PTGES mRNA] |
CTD |
PMID:24802026 |
|
NCBI chr 3:14,177,892...14,189,236
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions increases expression |
ISO |
[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of PTGS2 protein cholest-5-en-3 beta,7 alpha-diol results in increased expression of PTGS2 protein |
CTD |
PMID:24802026 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Tlr4 |
toll-like receptor 4 |
increases expression multiple interactions |
ISO |
cholest-5-en-3 beta,7 alpha-diol results in increased expression of TLR4 mRNA [24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of TLR4 mRNA; Quercetin analog inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of TLR4 mRNA]; Quercetin inhibits the reaction [[24-hydroxycholesterol co-treated with 27-hydroxycholesterol co-treated with cholest-5-en-3 beta,7 alpha-diol] results in increased expression of TLR4 mRNA] |
CTD |
PMID:24802026 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
|
G |
Ar |
androgen receptor |
decreases response to substance |
ISO |
AR alternative form results in decreased susceptibility to abiraterone |
CTD |
PMID:25908785 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Cd46 |
CD46 molecule |
increases expression decreases response to substance |
ISO |
abiraterone results in increased expression of CD46 protein CD46 protein results in decreased susceptibility to abiraterone |
CTD |
PMID:30185663 |
|
NCBI chr13:106,575,586...106,606,325
Ensembl chr13:106,574,858...106,660,445
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
decreases activity multiple interactions |
EXP ISO |
abiraterone results in decreased activity of CYP17A1 protein [[abiraterone results in decreased activity of CYP17A1 protein] which results in decreased hydroxylation of Pregnenolone] which results in increased chemical synthesis of 17-alpha-Hydroxypregnenolone; [[abiraterone results in decreased activity of CYP17A1 protein] which results in decreased hydroxylation of Progesterone] which results in increased chemical synthesis of 17-alpha-Hydroxyprogesterone; [abiraterone results in decreased activity of CYP17A1 protein] which results in decreased hydroxylation of Pregnenolone; [abiraterone results in decreased activity of CYP17A1 protein] which results in decreased hydroxylation of Progesterone abiraterone analog results in decreased activity of CYP17A1 protein; abiraterone results in decreased activity of CYP17A1 protein |
CTD |
PMID:17194026 PMID:25993309 PMID:29100959 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Eef1a1 |
eukaryotic translation elongation factor 1 alpha 1 |
decreases expression |
ISO |
abiraterone results in decreased expression of EEF1A1 mRNA |
CTD |
PMID:27015953 |
|
NCBI chr 8:79,341,554...79,344,784
Ensembl chr 8:79,341,557...79,344,839
|
|
G |
F3 |
coagulation factor III, tissue factor |
increases expression |
ISO |
abiraterone results in increased expression of F3 protein |
CTD |
PMID:25569083 |
|
NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
|
|
G |
Tuba1a |
tubulin, alpha 1A |
decreases expression |
ISO |
abiraterone results in decreased expression of TUBA1A mRNA |
CTD |
PMID:27015953 |
|
NCBI chr 7:130,113,214...130,116,880
Ensembl chr 7:130,081,032...130,196,186
|
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
decreases activity |
EXP |
7-dehydrocholesterol results in decreased activity of CYP7A1 protein |
CTD |
PMID:1175606 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Dhcr7 |
7-dehydrocholesterol reductase |
increases abundance multiple interactions increases reduction |
ISO |
DHCR7 mutant form results in increased abundance of 7-dehydrocholesterol [BM 15766 results in decreased activity of DHCR7 protein] which results in increased abundance of 7-dehydrocholesterol DHCR7 results in increased reduction of 7-dehydrocholesterol Simvastatin inhibits the reaction [DHCR7 mutant form results in increased abundance of 7-dehydrocholesterol] |
CTD |
PMID:15896653 PMID:16365879 PMID:16446309 PMID:16824767 |
|
NCBI chr 1:199,015,081...199,031,055
Ensembl chr 1:199,015,081...199,031,055
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
increases export affects expression multiple interactions affects export increases transport |
ISO EXP |
ABCA1 protein results in increased export of Cholesterol cholesterol cotreated with 25-hydroxycholesterol decreases expression of abca1 mrna and protein in rat hepatoma cells; and increases expression of abca1 mRNA in rat fibroblasts 1-Butanol inhibits the reaction [Linoleic Acid inhibits the reaction [ABCA1 protein results in increased export of Cholesterol]]; 1-oleoyl-2-acetylglycerol inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; [HCAR2 protein results in decreased expression of ABCA1 protein] which results in decreased export of Cholesterol; [Resveratrol results in increased expression of ABCA1 protein] which results in increased secretion of Cholesterol; APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]; APOA1 protein promotes the reaction [ABCA1 protein results in increased export of Cholesterol]; Arachidonic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; glycolaldehyde inhibits the reaction [ABCA1 protein results in increased export of Cholesterol]; Glyoxal inhibits the reaction [ABCA1 protein results in increased export of Cholesterol]; Linoleic Acid inhibits the reaction [ABCA1 protein results in increased export of Cholesterol]; Linoleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; mastoparan inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased export of Cholesterol]]; Oleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; palmitoleic acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; PLD2 protein affects the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased export of Cholesterol]]; PLD2 protein inhibits the reaction [Linoleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased export of Cholesterol]]]; triacsin C inhibits the reaction [Linoleic Acid inhibits the reaction [ABCA1 protein results in increased transport of Cholesterol]] [[colestimide co-treated with Pravastatin] results in increased expression of ABCA1 protein] which results in decreased abundance of Cholesterol; [Cholesterol co-treated with 25-hydroxycholesterol] results in decreased expression of ABCA1 mRNA; Cholesterol inhibits the reaction [bisphenol A results in decreased expression of ABCA1 mRNA] ABCA1 protein affects the export of Cholesterol [[Niacin binds to and results in increased activity of HCAR2 protein] which results in decreased expression of ABCA1 protein] which results in decreased export of Cholesterol; [[Plant Preparations co-treated with Cholesterol, Dietary] results in increased expression of ABCA1 mRNA] which results in increased secretion of Cholesterol; [Capsaicin results in increased expression of ABCA1 protein] which results in decreased uptake of Cholesterol; [Capsaicin results in increased expression of ABCA1 protein] which results in increased secretion of Cholesterol; [Cholesterol co-treated with Dietary Fats] results in increased expression of ABCA1 mRNA; [Cholesterol deficiency co-treated with Dietary Fats] results in decreased expression of ABCA1 mRNA |
CTD RGD |
PMID:14993927 PMID:15694933 PMID:15983222 PMID:16118212 PMID:17526932 PMID:18356535 PMID:20372816 PMID:20655299 PMID:21908651 PMID:22022523 PMID:23900008 PMID:28859904 PMID:17526932 More...
|
RGD:2308820 |
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
increases secretion |
ISO |
ABCB11 protein results in increased secretion of Cholesterol |
CTD |
PMID:14570929 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
affects export |
ISO |
ABCB4 protein affects the export of Cholesterol |
CTD |
PMID:15019087 |
|
NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202
|
|
G |
Abcg1 |
ATP binding cassette subfamily G member 1 |
multiple interactions |
ISO |
[Niacin results in increased expression of ABCG1 protein] which results in increased export of Cholesterol; HCAR2 protein inhibits the reaction [[Niacin results in increased expression of ABCG1 protein] which results in increased export of Cholesterol] [resveratrol results in increased expression of ABCG1 protein] which results in increased secretion of Cholesterol |
CTD |
PMID:20372816 PMID:21317532 |
|
NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
increases activity multiple interactions |
ISO |
Cholesterol results in increased activity of ABCG2 protein Sulfasalazine promotes the reaction [Cholesterol results in increased activity of ABCG2 protein] |
CTD |
PMID:27475308 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
affects export multiple interactions increases expression decreases expression increases secretion |
ISO EXP |
ABCG5 protein affects the export of Cholesterol [Diosgenin results in increased expression of ABCG5 mRNA] which results in increased secretion of Cholesterol; [Ethinyl Estradiol results in decreased expression of ABCG5 mRNA] which results in decreased secretion of Cholesterol Cholesterol results in increased expression of ABCG5 mRNA Cholesterol results in decreased expression of ABCG5 mRNA [Cholesterol deficiency co-treated with Dietary Fats] results in decreased expression of ABCG5 mRNA; Cholates promotes the reaction [ABCG5 protein results in increased secretion of Cholesterol]; Diosgenin promotes the reaction [ABCG5 protein results in increased secretion of Cholesterol] |
CTD |
PMID:12963437 PMID:15611112 PMID:15683829 PMID:15696852 PMID:18356535 |
|
NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563
|
|
G |
Abcg8 |
ATP binding cassette subfamily G member 8 |
increases secretion multiple interactions increases expression decreases expression affects export |
ISO EXP |
ABCG8 protein results in increased secretion of Cholesterol [Diosgenin results in increased expression of ABCG8 mRNA] which results in increased secretion of Cholesterol; [Ethinyl Estradiol results in decreased expression of ABCG8 mRNA] which results in decreased secretion of Cholesterol Cholesterol results in increased expression of ABCG8 mRNA Cholesterol results in decreased expression of ABCG8 mRNA [Cholesterol deficiency co-treated with Dietary Fats] results in decreased expression of ABCG8 mRNA; Cholates promotes the reaction [ABCG8 protein results in increased secretion of Cholesterol]; Diosgenin promotes the reaction [ABCG8 protein results in increased secretion of Cholesterol] ABCG8 protein affects the export of Cholesterol |
CTD |
PMID:12963437 PMID:15611112 PMID:15683829 PMID:15696852 PMID:18356535 |
|
NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
multiple interactions |
ISO |
[lard co-treated with Cholesterol co-treated with Sucrose co-treated with Atrazine] results in increased expression of ACACA mRNA; [lard co-treated with Cholesterol co-treated with Sucrose co-treated with Ethinyl Estradiol] results in increased expression of ACACA mRNA |
CTD |
PMID:24440342 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Acadm |
acyl-CoA dehydrogenase medium chain |
multiple interactions |
ISO |
[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of ACADM mRNA; Atrazine promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of ACADM mRNA] |
CTD |
PMID:24440342 |
|
NCBI chr 2:242,858,865...242,883,036
Ensembl chr 2:242,858,865...242,883,147
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions |
ISO |
[Copper co-treated with Cholesterol] results in increased activity of ACHE protein; Clioquinol inhibits the reaction [[Copper co-treated with Cholesterol] results in increased activity of ACHE protein] |
CTD |
PMID:25856695 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Acly |
ATP citrate lyase |
multiple interactions |
ISO |
[lard co-treated with Cholesterol co-treated with Sucrose co-treated with Atrazine] results in increased expression of ACLY mRNA; [lard co-treated with Cholesterol co-treated with Sucrose co-treated with Ethinyl Estradiol] results in increased expression of ACLY mRNA |
CTD |
PMID:24440342 |
|
NCBI chr10:85,412,045...85,464,253
Ensembl chr10:85,412,049...85,463,320
|
|
G |
Acox1 |
acyl-CoA oxidase 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of ACOX1 mRNA; Atrazine promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of ACOX1 mRNA]; cypermethrin promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of ACOX1 mRNA]; Ethinyl Estradiol promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of ACOX1 mRNA] |
CTD |
PMID:24440342 |
|
NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO |
[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased expression of ACTA2 protein; Acetylcysteine inhibits the reaction [[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased expression of ACTA2 protein] |
CTD |
PMID:35622622 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Ager |
advanced glycosylation end product-specific receptor |
affects abundance |
ISO |
AGER protein affects the abundance of Cholesterol |
CTD |
PMID:20372816 |
|
NCBI chr20:4,148,150...4,151,361
Ensembl chr20:4,147,890...4,151,078
|
|
G |
Agt |
angiotensinogen |
multiple interactions affects abundance increases expression |
ISO EXP |
Cholesterol inhibits the reaction [irbesartan results in increased expression of AGT protein] [Puromycin Aminonucleoside co-treated with Cholesterol] results in increased expression of AGT mRNA; Hydralazine inhibits the reaction [AGT protein affects the abundance of Cholesterol]; Losartan inhibits the reaction [AGT protein affects the abundance of Cholesterol] Cholesterol results in increased expression of AGT protein |
CTD |
PMID:12495295 PMID:19028402 PMID:19109942 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
increases expression multiple interactions |
ISO |
Cholesterol results in increased expression of AGTR1 mRNA Cholesterol inhibits the reaction [irbesartan results in increased expression of AGTR1 mRNA] |
CTD |
PMID:19028402 |
|
NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946
|
|
G |
Agtr2 |
angiotensin II receptor, type 2 |
multiple interactions |
EXP |
[Cholesterol co-treated with Methylthiouracil] results in increased expression of AGTR2 mRNA; [Cholesterol co-treated with Methylthiouracil] results in increased expression of AGTR2 protein; [Puromycin Aminonucleoside co-treated with Cholesterol] results in increased expression of AGTR2 mRNA; Rosiglitazone promotes the reaction [[Cholesterol co-treated with Methylthiouracil] results in increased expression of AGTR2 mRNA]; Rosiglitazone promotes the reaction [[Cholesterol co-treated with Methylthiouracil] results in increased expression of AGTR2 protein] |
CTD |
PMID:12495295 PMID:21269478 |
|
NCBI chr X:112,119,876...112,124,060
Ensembl chr X:112,120,228...112,124,057
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
ISO |
[beta-Naphthoflavone results in increased activity of AHR protein] which results in decreased chemical synthesis of and results in decreased secretion of Cholesterol |
CTD |
PMID:22234961 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO EXP |
Cholesterol inhibits the reaction [irbesartan results in increased expression of AKT1 protein] [Streptozocin co-treated with Coconut Oil co-treated with Cholesterol] results in decreased phosphorylation of AKT1 protein; Metformin inhibits the reaction [[Streptozocin co-treated with Coconut Oil co-treated with Cholesterol] results in decreased phosphorylation of AKT1 protein]; Plant Extracts inhibits the reaction [[Streptozocin co-treated with Coconut Oil co-treated with Cholesterol] results in decreased phosphorylation of AKT1 protein] Cholesterol results in increased expression of and results in increased phosphorylation of AKT1 protein |
CTD |
PMID:19028402 PMID:19672739 PMID:31877369 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alb |
albumin |
multiple interactions |
EXP |
[cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of ALB protein; [lard co-treated with Cholesterol] results in increased expression of ALB protein |
CTD |
PMID:26606054 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Anxa2 |
annexin A2 |
multiple interactions |
ISO |
[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of ANXA2 mRNA |
CTD |
PMID:22129739 |
|
NCBI chr 8:70,105,268...70,141,663
Ensembl chr 8:70,105,253...70,141,658
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
multiple interactions increases expression |
EXP |
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Cholesterol analog results in increased expression of APAF1 mRNA]; Acetylcysteine inhibits the reaction [Cholesterol analog results in increased expression of APAF1 mRNA] |
CTD |
PMID:19477266 |
|
NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540
|
|
G |
Apoa1 |
apolipoprotein A1 |
multiple interactions increases export affects transport decreases expression increases secretion |
ISO EXP |
1-oleoyl-2-acetylglycerol inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; [9-deoxy-delta-9-prostaglandin D2 binds to and results in increased activity of PPARG protein] promotes the reaction [APOA1 protein results in increased transport of Cholesterol]; [Acrolein affects the metabolism of APOA1 protein] which results in decreased secretion of Cholesterol; [Bezafibrate binds to and results in increased activity of PPARA protein] promotes the reaction [APOA1 protein results in increased transport of Cholesterol]; [pirinixic acid binds to and results in increased activity of PPARA protein] promotes the reaction [APOA1 protein results in increased transport of Cholesterol]; Acrolein inhibits the reaction [APOA1 protein affects the transport of Cholesterol]; APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]; APOA1 protein promotes the reaction [ABCA1 protein results in increased export of Cholesterol]; Arachidonic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; CYP27A1 protein promotes the reaction [APOA1 protein results in increased secretion of Cholesterol]; Fingolimod Hydrochloride promotes the reaction [APOA1 protein results in increased secretion of Cholesterol]; isosilybin A promotes the reaction [APOA1 protein results in increased secretion of Cholesterol]; Linoleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; mastoparan inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased export of Cholesterol]]; Oleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; palmitoleic acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; PLD2 protein affects the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased export of Cholesterol]]; PLD2 protein inhibits the reaction [Linoleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased export of Cholesterol]]]; Resveratrol inhibits the reaction [APOA1 protein results in increased export of Cholesterol] [Ethanol co-treated with APOA1 protein] results in decreased abundance of Cholesterol APOA1 affects the transport of Cholesterol Cholesterol results in decreased expression of APOA1 protein 2-chloro-5-nitrobenzanilide inhibits the reaction [Niacin promotes the reaction [APOA1 protein results in increased export of Cholesterol]]; 27-hydroxycholesterol promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]; 27-hydroxycholesterol promotes the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]; [Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol; [Glutathione co-treated with Quercetin] promotes the reaction [APOA1 protein results in increased export of Cholesterol]; [T0901317 co-treated with APOA1 protein] results in increased secretion of Cholesterol; Aspirin promotes the reaction [APOA1 affects the transport of Cholesterol]; Niacin promotes the reaction [APOA1 protein results in increased export of Cholesterol]; PPARA affects the reaction [Aspirin promotes the reaction [APOA1 affects the transport of Cholesterol]]; PPARG protein promotes the reaction [Niacin promotes the reaction [APOA1 protein results in increased export of Cholesterol]]; Probucol inhibits the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]; Probucol inhibits the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]; Quercetin promotes the reaction [APOA1 protein results in increased export of Cholesterol]; STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]; T0901317 promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol] |
CTD |
PMID:12531903 PMID:12595494 PMID:15983222 PMID:16037261 PMID:16115471 PMID:16118212 PMID:16126721 PMID:17478430 PMID:19797938 PMID:20056921 PMID:20083572 PMID:21088444 PMID:23041272 PMID:25204422 PMID:26729088 More...
|
|
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
Apob |
apolipoprotein B |
increases expression multiple interactions |
EXP |
Cholesterol results in increased expression of APOB protein Selenium inhibits the reaction [Cholesterol results in increased expression of APOB protein] |
CTD |
PMID:16271152 PMID:16581047 |
|
NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497
|
|
G |
Apoe |
apolipoprotein E |
affects response to substance affects localization multiple interactions increases abundance increases export |
ISO EXP |
APOE protein affects the susceptibility to Cholesterol Cholesterol affects the localization of APOE protein Cholesterol promotes the reaction [APOE protein binds to CAV1 protein] APOE gene mutant form results in increased abundance of Cholesterol APOE protein results in increased export of Cholesterol 24-diamino-5-phenylthiazole inhibits the reaction [T0901317 promotes the reaction [[APOE gene mutant form results in increased susceptibility to Dietary Fats] which results in increased abundance of Cholesterol]]; [[Air Pollutants results in increased abundance of Particulate Matter] promotes the reaction [APOE protein affects the susceptibility to Dietary Fats]] which affects the abundance of Cholesterol; [APOE affects the susceptibility to Dietary Fats] which affects the abundance of Cholesterol; APOE gene mutant form promotes the reaction [Dietary Fats results in increased abundance of Cholesterol]; APOE inhibits the reaction [Cholesterol, Dietary results in increased abundance of Cholesterol]; Capsaicin inhibits the reaction [[APOE affects the susceptibility to Dietary Fats] which affects the abundance of Cholesterol]; CAV1 protein affects the reaction [Cholesterol affects the localization of APOE protein]; Enalapril inhibits the reaction [APOE gene mutant form results in increased abundance of Cholesterol]; methyl-beta-cyclodextrin inhibits the reaction [Cholesterol affects the localization of APOE protein]; N-butyloxycarbonyl-methionyl-aspartyl-glycyl-cysteinyl-glutamyl-leucine inhibits the reaction [[[Air Pollutants results in increased abundance of Particulate Matter] promotes the reaction [APOE protein affects the susceptibility to Dietary Fats]] which affects the abundance of Cholesterol]; notoginsenoside R1 inhibits the reaction [APOE gene mutant form results in increased abundance of Cholesterol]; paricalcitol inhibits the reaction [APOE gene mutant form results in increased abundance of Cholesterol]; T0901317 promotes the reaction [[APOE gene mutant form results in increased susceptibility to Dietary Fats] which results in increased abundance of Cholesterol] |
CTD |
PMID:11397713 PMID:12472773 PMID:16179587 PMID:21169230 PMID:21908651 PMID:22022523 PMID:24933211 PMID:25037058 PMID:32853627 PMID:34673409 More...
|
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions increases oxidation |
ISO EXP |
[Copper co-treated with Cholesterol] results in increased expression of APP mRNA APP protein results in increased oxidation of Cholesterol |
CTD |
PMID:15591071 PMID:17134702 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Aqp9 |
aquaporin 9 |
increases expression |
ISO |
Cholesterol results in increased expression of AQP9 mRNA |
CTD |
PMID:26296894 |
|
NCBI chr 8:71,797,231...71,837,485
Ensembl chr 8:71,797,234...71,837,395
|
|
G |
Areg |
amphiregulin |
increases expression multiple interactions |
ISO |
Cholesterol results in increased expression of AREG mRNA CLEC4E protein promotes the reaction [Cholesterol results in increased expression of AREG mRNA] |
CTD |
PMID:26296894 |
|
NCBI chr14:16,972,185...16,981,443
Ensembl chr14:16,972,187...16,981,535
|
|
G |
Atp7b |
ATPase copper transporting beta |
increases abundance |
EXP |
ATP7B gene mutant form results in increased abundance of Cholesterol |
CTD |
PMID:17303181 |
|
NCBI chr16:69,952,286...70,024,404
Ensembl chr16:69,951,778...70,023,636
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
decreases expression multiple interactions |
EXP ISO |
Cholesterol analog results in decreased expression of BAX mRNA Cholesterol inhibits the reaction [Cadmium Chloride results in increased expression of BAX protein] |
CTD |
PMID:19477266 PMID:29486218 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression multiple interactions |
EXP ISO |
Cholesterol analog results in decreased expression of BCL2 mRNA Cholesterol inhibits the reaction [Cadmium Chloride results in decreased expression of BCL2 protein] |
CTD |
PMID:19477266 PMID:29486218 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2a1 |
BCL2-related protein A1 |
increases expression |
EXP |
Cholesterol analog results in increased expression of BCL2A1 mRNA |
CTD |
PMID:19477266 |
|
NCBI chr 8:89,716,914...89,724,998
Ensembl chr 8:89,716,914...89,724,998
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions |
ISO |
Cholesterol inhibits the reaction [arachidonyl dopamine results in decreased expression of BCL2L1 mRNA] |
CTD |
PMID:33393692 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions |
EXP |
[Dietary Fats co-treated with Cholesterol] results in decreased expression of BDNF protein; Selenium inhibits the reaction [[Dietary Fats co-treated with Cholesterol] results in decreased expression of BDNF protein] |
CTD |
PMID:30695686 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Bik |
BCL2-interacting killer |
increases expression |
EXP |
Cholesterol analog results in increased expression of BIK mRNA |
CTD |
PMID:19477266 |
|
NCBI chr 7:114,672,277...114,691,296
Ensembl chr 7:114,672,277...114,691,296
|
|
G |
C3h15orf48 |
similar to human chromosome 15 open reading frame 48 |
increases expression |
ISO |
Cholesterol results in increased expression of C15ORF48 mRNA |
CTD |
PMID:26296894 |
|
NCBI chr 3:109,719,952...109,723,505
Ensembl chr 3:109,719,897...109,724,006 Ensembl chr 3:109,719,897...109,724,006
|
|
G |
Casp1 |
caspase 1 |
increases expression increases cleavage multiple interactions increases activity affects localization |
EXP ISO |
Cholesterol analog results in increased expression of CASP1 mRNA Cholesterol results in increased cleavage of CASP1 protein Amitriptyline inhibits the reaction [Cholesterol analog affects the localization of CASP1 protein]; Amitriptyline inhibits the reaction [Cholesterol analog results in increased activity of CASP1 protein]; bisphenol A promotes the reaction [Cholesterol results in increased cleavage of CASP1 protein]; methyl-beta-cyclodextrin inhibits the reaction [Cholesterol analog results in increased activity of CASP1 protein]; NBN protein inhibits the reaction [bisphenol A promotes the reaction [Cholesterol results in increased cleavage of CASP1 protein]]; SMPD1 protein affects the reaction [Cholesterol analog affects the localization of CASP1 protein]; SMPD1 protein affects the reaction [Cholesterol analog results in increased activity of CASP1 protein]; tempol inhibits the reaction [Cholesterol analog results in increased activity of CASP1 protein]; Verapamil inhibits the reaction [Cholesterol analog results in increased activity of CASP1 protein] [Cholesterol co-treated with Ergosterol] results in increased expression of CASP1 mRNA; [Cholesterol co-treated with Ergosterol] results in increased expression of CASP1 protein; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of CASP1 mRNA]; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of CASP1 protein] |
CTD |
PMID:19477266 PMID:25833014 PMID:28633109 PMID:33239236 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases cleavage increases activity increases expression |
ISO EXP |
[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased cleavage of CASP3 protein; [Copper co-treated with Cholesterol] results in increased activity of CASP3 protein; Acetylcysteine inhibits the reaction [[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased cleavage of CASP3 protein]; Cholesterol inhibits the reaction [Cadmium Chloride results in increased expression of CASP3 protein modified form]; methyl-beta-cyclodextrin inhibits the reaction [Cholesterol results in increased activity of CASP3 protein] [[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in increased activity of CASP3 protein; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] inhibits the reaction [Silver Compounds results in increased activity of CASP3 protein]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] promotes the reaction [Silver Compounds results in increased activity of CASP3 protein]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] results in decreased activity of CASP3 protein Cholesterol results in increased cleavage of CASP3 protein Cholesterol analog results in increased expression of CASP3 mRNA Cholesterol analog results in increased cleavage of CASP3 protein 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Cholesterol analog results in increased expression of CASP3 mRNA]; Acetylcysteine inhibits the reaction [Cholesterol analog results in increased expression of CASP3 mRNA] |
CTD |
PMID:17134702 PMID:19477266 PMID:21872649 PMID:28275691 PMID:29486218 PMID:35385781 PMID:35622622 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp4 |
caspase 4 |
multiple interactions increases expression |
EXP |
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Cholesterol analog results in increased expression of CASP4 mRNA]; Acetylcysteine inhibits the reaction [Cholesterol analog results in increased expression of CASP4 mRNA] |
CTD |
PMID:19477266 |
|
NCBI chr 8:2,599,017...2,635,097
Ensembl chr 8:2,598,876...2,635,092
|
|
G |
Casp8 |
caspase 8 |
multiple interactions increases expression increases activity |
EXP |
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Cholesterol analog results in increased activity of CASP8 protein]; 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Cholesterol analog results in increased expression of CASP8 mRNA]; Acetylcysteine inhibits the reaction [Cholesterol analog results in increased activity of CASP8 protein]; Acetylcysteine inhibits the reaction [Cholesterol analog results in increased expression of CASP8 mRNA]; Cholesterol promotes the reaction [Hydrogen Peroxide results in increased expression of CASP8 protein]; Hydrogen Peroxide promotes the reaction [Cholesterol results in increased expression of CASP8 protein] Cholesterol analog results in increased expression of CASP8 mRNA; Cholesterol results in increased expression of CASP8 protein |
CTD |
PMID:19477266 PMID:20946910 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases expression increases activity |
EXP ISO |
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Cholesterol analog results in increased activity of CASP9 protein]; 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Cholesterol analog results in increased expression of CASP9 mRNA]; Acetylcysteine inhibits the reaction [Cholesterol analog results in increased activity of CASP9 protein]; Acetylcysteine inhibits the reaction [Cholesterol analog results in increased expression of CASP9 mRNA] [[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in increased activity of CASP9 protein; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds results in increased activity of CASP9 protein]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] promotes the reaction [Silver Compounds results in increased activity of CASP9 protein] |
CTD |
PMID:19477266 PMID:35385781 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions increases expression |
EXP ISO |
[Cholesterol co-treated with Cholic Acid] results in decreased activity of CAT protein; lupeol inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased activity of CAT protein]; lupeol linoleate inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased activity of CAT protein] [[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in decreased activity of CAT protein; [[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in decreased expression of CAT mRNA; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the expression of CAT mRNA; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds affects the expression of CAT mRNA]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds results in decreased activity of CAT protein]; [EGF protein co-treated with [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]]] inhibits the reaction [[EGF protein co-treated with Silver Compounds] results in increased activity of CAT protein] Cholesterol results in increased expression of CAT protein |
CTD |
PMID:16933029 PMID:29486218 PMID:35385781 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cav1 |
caveolin 1 |
increases transport multiple interactions |
ISO EXP |
CAV1 protein results in increased transport of Cholesterol CAV1 protein affects the reaction [Cholesterol affects the localization of APOE protein] Cholesterol promotes the reaction [APOE protein binds to CAV1 protein] |
CTD |
PMID:12640124 PMID:21169230 |
|
NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705
|
|
G |
Cav3 |
caveolin 3 |
affects import |
ISO |
CAV3 protein affects the import of Cholesterol |
CTD |
PMID:19221014 |
|
NCBI chr 4:145,582,168...145,598,142
Ensembl chr 4:145,582,060...145,598,137
|
|
G |
Ccl1 |
C-C motif chemokine ligand 1 |
increases expression |
ISO |
Cholesterol results in increased expression of CCL1 mRNA |
CTD |
PMID:26296894 |
|
NCBI chr10:67,128,331...67,131,109
Ensembl chr10:67,128,331...67,131,159
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions increases expression |
ISO EXP |
[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of CCL2 mRNA; [Dietary Fats co-treated with bisphenol A co-treated with Cholesterol] results in increased secretion of CCL2 protein; Cholesterol inhibits the reaction [Irbesartan results in increased expression of CCL2 mRNA]; Cholesterol inhibits the reaction [Irbesartan results in increased expression of CCL2 protein] [Cholesterol co-treated with Ergosterol] results in increased expression of CCL2 mRNA; [Cholesterol co-treated with Ergosterol] results in increased expression of CCL2 protein; [cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of CCL2 mRNA; Resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of CCL2 mRNA]; Resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of CCL2 protein] Cholesterol results in increased expression of CCL2 mRNA; Cholesterol results in increased expression of CCL2 protein |
CTD |
PMID:19028402 PMID:22129739 PMID:25833014 PMID:26606054 PMID:33239236 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
multiple interactions increases expression |
ISO |
CLEC4E protein promotes the reaction [Cholesterol results in increased expression of CCL4 mRNA] |
CTD |
PMID:26296894 |
|
NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231
|
|
G |
Ccl7 |
C-C motif chemokine ligand 7 |
multiple interactions |
ISO |
[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of CCL7 mRNA |
CTD |
PMID:22129739 |
|
NCBI chr10:67,016,446...67,018,296
Ensembl chr10:67,016,446...67,018,303
|
|
G |
Cd36 |
CD36 molecule |
multiple interactions |
ISO |
[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased expression of CD36 protein; [Dietary Fats co-treated with Cholesterol] results in increased expression of CD36 mRNA; Acetylcysteine inhibits the reaction [[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased expression of CD36 protein]; Losartan promotes the reaction [[Dietary Fats co-treated with Cholesterol] results in increased expression of CD36 mRNA]; Rosiglitazone inhibits the reaction [[Dietary Fats co-treated with Cholesterol] results in increased expression of CD36 mRNA] |
CTD |
PMID:18302760 PMID:35622622 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Cd40lg |
CD40 ligand |
multiple interactions increases expression |
EXP |
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Cholesterol analog results in increased expression of CD40LG mRNA]; Acetylcysteine inhibits the reaction [Cholesterol analog results in increased expression of CD40LG mRNA] |
CTD |
PMID:19477266 |
|
NCBI chr X:135,127,052...135,138,768
Ensembl chr X:135,126,969...135,138,306
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
multiple interactions |
ISO |
Cholesterol inhibits the reaction [arachidonyl dopamine results in decreased expression of CDK4 mRNA] |
CTD |
PMID:33393692 |
|
NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdk5r2 |
cyclin-dependent kinase 5 regulatory subunit 2 |
multiple interactions |
ISO |
[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of CDK5R2 mRNA |
CTD |
PMID:22129739 |
|
NCBI chr 9:76,416,251...76,417,719
Ensembl chr 9:76,416,062...76,418,344
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
ISO |
[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of CDKN1A mRNA |
CTD |
PMID:22129739 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
multiple interactions |
ISO |
[[artemisic acid results in decreased expression of CEBPA mRNA] which results in decreased expression of HMGCR mRNA] which results in decreased chemical synthesis of Cholesterol |
CTD |
PMID:23063590 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Ces1d |
carboxylesterase 1D |
increases metabolic processing increases abundance increases expression |
ISO EXP |
CES1 protein results in increased metabolism of Cholesterol CES1 protein results in increased abundance of Cholesterol Cholesterol results in increased expression of CES1 mRNA |
CTD |
PMID:8049197 PMID:11015575 PMID:12773168 PMID:15825828 |
|
NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035
|
|
G |
Clec4e |
C-type lectin domain family 4, member E |
multiple interactions increases response to substance |
ISO |
[Cholesterol co-treated with CLEC4E] results in increased expression of CXCL2 protein; [Cholesterol co-treated with CLEC4E] results in increased expression of TNF protein; Cholesterol binds to and results in increased activity of CLEC4E protein; CLEC4E protein inhibits the reaction [Cholesterol results in increased expression of TIMP3 mRNA]; CLEC4E protein promotes the reaction [[Cholesterol co-treated with Lipopolysaccharides] results in increased expression of IL1B protein]; CLEC4E protein promotes the reaction [Cholesterol results in increased expression of AREG mRNA]; CLEC4E protein promotes the reaction [Cholesterol results in increased expression of CCL4 mRNA]; CLEC4E protein promotes the reaction [Cholesterol results in increased expression of CLEC5A mRNA]; CLEC4E protein promotes the reaction [Cholesterol results in increased expression of CSF1 mRNA]; CLEC4E protein promotes the reaction [Cholesterol results in increased expression of DCSTAMP mRNA] CLEC4E protein results in increased susceptibility to Cholesterol |
CTD |
PMID:26296894 |
|
NCBI chr 4:156,606,927...156,612,911
Ensembl chr 4:156,607,614...156,612,767
|
|
G |
Clec5a |
C-type lectin domain containing 5A |
increases expression multiple interactions |
ISO |
Cholesterol results in increased expression of CLEC5A mRNA CLEC4E protein promotes the reaction [Cholesterol results in increased expression of CLEC5A mRNA] |
CTD |
PMID:26296894 |
|
NCBI chr 4:69,407,125...69,416,872
Ensembl chr 4:69,407,835...69,416,859
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
multiple interactions |
ISO |
[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of CPT1A mRNA; Atrazine promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of CPT1A mRNA]; cypermethrin promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of CPT1A mRNA]; Ethinyl Estradiol promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of CPT1A mRNA] |
CTD |
PMID:24440342 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
EXP |
[Dietary Fats co-treated with Cholesterol] results in decreased expression of CREB1 protein; Selenium inhibits the reaction [[Dietary Fats co-treated with Cholesterol] results in decreased expression of CREB1 protein] |
CTD |
PMID:30695686 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Crybb3 |
crystallin, beta B3 |
multiple interactions |
ISO |
[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of CRYBB3 mRNA |
CTD |
PMID:22129739 |
|
NCBI chr12:43,557,103...43,562,120
Ensembl chr12:43,557,103...43,562,120
|
|
G |
Cs |
citrate synthase |
multiple interactions |
ISO |
[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of CS mRNA |
CTD |
PMID:24440342 |
|
NCBI chr 7:758,074...791,421
Ensembl chr 7:758,345...791,421
|
|
G |
Csf1 |
colony stimulating factor 1 |
increases expression multiple interactions |
ISO |
Cholesterol results in increased expression of CSF1 mRNA CLEC4E protein promotes the reaction [Cholesterol results in increased expression of CSF1 mRNA] |
CTD |
PMID:26296894 |
|
NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704
|
|
G |
Cst3 |
cystatin C |
multiple interactions |
EXP |
[cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of CST3 protein |
CTD |
PMID:26606054 |
|
NCBI chr 3:136,336,923...136,340,796
Ensembl chr 3:136,336,920...136,340,822
|
|
G |
Ctsb |
cathepsin B |
decreases activity |
ISO |
Cholesterol results in decreased activity of CTSB protein |
CTD |
PMID:28275691 |
|
NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions |
ISO |
[Cholesterol co-treated with CLEC4E] results in increased expression of CXCL2 protein |
CTD |
PMID:26296894 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cxcl9 |
C-X-C motif chemokine ligand 9 |
multiple interactions |
ISO |
[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of CXCL9 mRNA |
CTD |
PMID:22129739 |
|
NCBI chr14:15,722,868...15,727,779
Ensembl chr14:15,722,908...15,728,435
|
|
G |
Cybb |
cytochrome b-245 beta chain |
multiple interactions affects localization |
EXP ISO |
[Cholesterol co-treated with Particulate Matter] results in increased expression of CYBB protein; [cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of CYBB mRNA; alpha-Linolenic Acid inhibits the reaction [[Cholesterol co-treated with Particulate Matter] results in increased expression of CYBB protein] Cholesterol analog affects the localization of CYBB protein |
CTD |
PMID:26606054 PMID:28633109 PMID:30672636 |
|
NCBI chr X:13,358,101...13,392,570
Ensembl chr X:13,359,430...13,392,586
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
affects metabolic processing increases metabolic processing |
ISO |
CYP11A1 protein affects the metabolism of Cholesterol CYP11A1 protein results in increased metabolism of Cholesterol |
CTD |
PMID:16054388 PMID:19900470 |
|
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
affects chemical synthesis |
ISO |
CYP17A1 protein affects the chemical synthesis of Cholesterol |
CTD |
PMID:15761033 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases activity |
ISO |
Cholesterol results in decreased activity of CYP1A1 protein |
CTD |
PMID:18420780 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
decreases chemical synthesis multiple interactions increases secretion |
ISO EXP |
CYP27A1 protein results in decreased chemical synthesis of Cholesterol [[CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 27-hydroxycholesterol] which results in increased activity of HMGCR protein; [CYP27A1 protein results in increased chemical synthesis of Bile Acids and Salts] promotes the reaction [LDLR protein results in increased uptake of Cholesterol]; [CYP27A1 protein results in increased hydroxylation of Cholesterol] which results in increased chemical synthesis of 27-hydroxycholesterol; [CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 25-hydroxycholesterol; [CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 27-hydroxycholesterol; [CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 3-hydroxy-5-cholestenoic acid; CYP27A1 protein promotes the reaction [APOA1 protein results in increased secretion of Cholesterol]; CYP27A1 protein results in increased hydroxylation of and results in decreased abundance of Cholesterol [Cholesterol deficiency co-treated with Dietary Fats] results in decreased expression of CYP27A1 mRNA CYP27A1 protein results in increased secretion of Cholesterol |
CTD |
PMID:8078928 PMID:8496670 PMID:9215552 PMID:9660774 PMID:11408283 PMID:11714861 PMID:12117727 PMID:12531903 PMID:16477808 PMID:18356535 More...
|
|
NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551
|
|
G |
Cyp2a3 |
cytochrome P450, family 2, subfamily a, polypeptide 3 |
decreases activity |
ISO |
Cholesterol results in decreased activity of CYP2A4 protein |
CTD |
PMID:18420780 |
|
NCBI chr 1:82,171,914...82,179,980
Ensembl chr 1:82,169,949...82,179,979
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
decreases activity |
ISO |
Cholesterol results in decreased activity of CYP2B10 protein |
CTD |
PMID:18420780 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
decreases activity |
ISO |
Cholesterol results in decreased activity of CYP2E1 protein |
CTD |
PMID:18420780 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions |
ISO EXP |
[CYP3A4 protein results in increased oxidation of Cholesterol] which results in increased chemical synthesis of cholest-5-ene-3,4-diol; Cholesterol promotes the reaction [CYP3A4 protein results in increased oxidation of 7-benzyloxy-4-trifluoromethylcoumarin] [CYP3A23-3A1 gene mutant form co-treated with CYP3A2 gene mutant form] results in decreased abundance of Cholesterol |
CTD |
PMID:11514559 PMID:19299527 PMID:34461081 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
multiple interactions |
EXP |
[CYP3A23-3A1 gene mutant form co-treated with CYP3A2 gene mutant form] results in decreased abundance of Cholesterol |
CTD |
PMID:34461081 |
|
NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030 Ensembl chr12:9,254,475...9,285,030
|
|
G |
Cyp46a1 |
cytochrome P450, family 46, subfamily a, polypeptide 1 |
multiple interactions increases hydroxylation |
ISO |
CYP46A1 gene SNP affects the metabolism of and affects the abundance of Cholesterol CYP46A1 protein results in increased hydroxylation of Cholesterol |
CTD |
PMID:14640697 PMID:19286353 |
|
NCBI chr 6:127,247,543...127,274,765
Ensembl chr 6:127,243,315...127,274,760
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
affects metabolic processing multiple interactions increases metabolic processing increases expression |
ISO EXP |
CYP7A1 protein affects the metabolism of Cholesterol CYP7A1 mRNA inhibits the reaction [Cholesterol results in increased phosphorylation of EIF4EBP1 protein]; CYP7A1 mRNA inhibits the reaction [Cholesterol results in increased phosphorylation of GSK3B protein]; CYP7A1 mRNA inhibits the reaction [Cholesterol results in increased phosphorylation of RPS6 protein]; CYP7A1 mRNA inhibits the reaction [Tretinoin results in increased abundance of Cholesterol] CYP7A1 protein results in increased metabolism of Cholesterol Cholesterol results in increased expression of CYP7A1 mRNA turmeric extract promotes the reaction [Cholesterol results in increased expression of CYP7A1 mRNA] |
CTD |
PMID:1175606 PMID:7925343 PMID:11013305 PMID:15696852 PMID:21535835 PMID:28275691 PMID:30709899 More...
|
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Cyp7b1 |
cytochrome P450 family 7 subfamily B member 1 |
increases activity increases expression |
EXP |
Cholesterol results in increased activity of CYP7B1 protein Cholesterol results in increased expression of CYP7B1 mRNA |
CTD |
PMID:12029625 |
|
NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698
|
|
G |
Cyp8b1 |
cytochrome P450 family 8 subfamily B member 1 |
decreases expression |
EXP |
cholesterol decreases expression of Cyp8b1 mRNA in liver |
RGD |
PMID:25263431 |
RGD:15045610 |
NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166
|
|
G |
Dapk1 |
death associated protein kinase 1 |
multiple interactions increases expression |
EXP |
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Cholesterol analog results in increased expression of DAPK1 mRNA]; Acetylcysteine inhibits the reaction [Cholesterol analog results in increased expression of DAPK1 mRNA] |
CTD |
PMID:19477266 |
|
NCBI chr17:3,930,223...4,090,991
Ensembl chr17:3,930,213...4,090,991
|
|
G |
Dcstamp |
dendrocyte expressed seven transmembrane protein |
multiple interactions increases expression |
ISO |
CLEC4E protein promotes the reaction [Cholesterol results in increased expression of DCSTAMP mRNA] |
CTD |
PMID:26296894 |
|
NCBI chr 7:70,807,455...70,822,067
Ensembl chr 7:70,807,581...70,822,078
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
ISO |
[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased expression of DDIT3 protein; Acetylcysteine inhibits the reaction [[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased expression of DDIT3 protein] |
CTD |
PMID:35622622 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Dgat1 |
diacylglycerol O-acyltransferase 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol co-treated with Sucrose co-treated with cypermethrin] results in increased expression of DGAT1 mRNA; [lard co-treated with Cholesterol co-treated with Sucrose co-treated with Ethinyl Estradiol] results in increased expression of DGAT1 mRNA |
CTD |
PMID:24440342 |
|
NCBI chr 7:108,223,860...108,235,413
Ensembl chr 7:108,218,524...108,234,299
|
|
G |
Dgat2 |
diacylglycerol O-acyltransferase 2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of DGAT2 mRNA; Atrazine promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of DGAT2 mRNA]; Ethinyl Estradiol promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of DGAT2 mRNA] |
CTD |
PMID:24440342 |
|
NCBI chr 1:153,454,078...153,484,432
Ensembl chr 1:153,454,080...153,484,428
|
|
G |
Dhcr24 |
24-dehydrocholesterol reductase |
affects abundance multiple interactions |
ISO |
DHCR24 protein affects the abundance of Cholesterol [DHCR24 protein results in increased metabolism of Desmosterol] which results in increased abundance of Cholesterol |
CTD |
PMID:19260826 PMID:23042211 |
|
NCBI chr 5:121,344,552...121,371,124
Ensembl chr 5:121,344,575...121,371,137
|
|
G |
Dhcr7 |
7-dehydrocholesterol reductase |
decreases abundance multiple interactions increases chemical synthesis affects response to substance |
ISO |
DHCR7 mutant form results in decreased abundance of Cholesterol Simvastatin promotes the reaction [DHCR7 results in increased chemical synthesis of Cholesterol] DHCR7 mutant form affects the susceptibility to Cholesterol |
CTD |
PMID:15896653 PMID:16446309 PMID:19365639 |
|
NCBI chr 1:199,015,081...199,031,055
Ensembl chr 1:199,015,081...199,031,055
|
|
G |
Dio1 |
iodothyronine deiodinase 1 |
affects expression decreases expression decreases activity |
EXP |
Cholesterol affects the expression of DIO1 mRNA Cholesterol results in decreased expression of DIO1 mRNA Cholesterol results in decreased activity of DIO1 protein |
CTD |
PMID:16271152 PMID:16874406 |
|
NCBI chr 5:122,074,285...122,090,983
Ensembl chr 5:122,074,279...122,090,970
|
|
G |
Dio2 |
iodothyronine deiodinase 2 |
increases degradation |
ISO |
Cholesterol results in increased degradation of DIO2 protein |
CTD |
PMID:30545937 |
|
NCBI chr 6:109,665,523...109,679,809
Ensembl chr 6:109,665,523...109,679,809
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
[[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] affects the abundance of Reactive Oxygen Species; [[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] affects the expression of SOD2 mRNA; [[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in decreased activity of CAT protein; [[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in decreased expression of CAT mRNA; [[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in decreased expression of MKI67 protein; [[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in decreased expression of TP53 mRNA; [[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in increased activity of CASP3 protein; [[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in increased activity of CASP9 protein; [[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in increased expression of MKI67 mRNA; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the abundance of Reactive Oxygen Species; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the expression of CAT mRNA; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the expression of MKI67 mRNA; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the expression of SOD2 mRNA; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds affects the abundance of Reactive Oxygen Species]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds affects the expression of CAT mRNA]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds affects the expression of MKI67 mRNA]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds affects the expression of SOD2 mRNA]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds affects the expression of TP53 mRNA]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds results in decreased activity of CAT protein]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds results in decreased expression of MKI67 protein]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds results in increased activity of CASP9 protein]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] inhibits the reaction [Silver Compounds results in increased activity of CASP3 protein]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] promotes the reaction [Silver Compounds results in increased activity of CASP3 protein]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] promotes the reaction [Silver Compounds results in increased activity of CASP9 protein]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] results in decreased activity of CASP3 protein; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] results in increased expression of MKI67 protein; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] results in increased expression of TP53 mRNA; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] results in increased susceptibility to Silver Compounds; [EGF protein co-treated with [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]]] inhibits the reaction [[EGF protein co-treated with Silver Compounds] results in decreased expression of MKI67 protein]; [EGF protein co-treated with [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]]] inhibits the reaction [[EGF protein co-treated with Silver Compounds] results in increased activity of CAT protein]; EGF protein affects the susceptibility to [[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds]; EGF protein inhibits the reaction [[[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] affects the abundance of Reactive Oxygen Species] |
CTD |
PMID:35385781 |
|
NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of EGFR mRNA |
CTD |
PMID:22129739 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
decreases abundance |
ISO |
EIF2S1 protein modified form results in decreased abundance of Cholesterol |
CTD |
PMID:16330322 |
|
NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225
|
|
G |
Eif4a1 |
eukaryotic translation initiation factor 4A1 |
multiple interactions |
ISO |
[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of EIF4A1 mRNA |
CTD |
PMID:22129739 |
|
NCBI chr10:54,384,345...54,389,855
Ensembl chr10:54,384,347...54,389,858
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
increases phosphorylation multiple interactions |
ISO |
Cholesterol results in increased phosphorylation of EIF4EBP1 protein CYP7A1 mRNA inhibits the reaction [Cholesterol results in increased phosphorylation of EIF4EBP1 protein] |
CTD |
PMID:28275691 |
|
NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Epb41 |
erythrocyte membrane protein band 4.1 |
multiple interactions |
EXP |
[Hydrogen Peroxide co-treated with Cholesterol] results in decreased expression of and affects the localization of EPB41 protein; [Hydrogen Peroxide co-treated with Cholesterol] results in increased degradation of EPB41 protein; benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [[Hydrogen Peroxide co-treated with Cholesterol] results in decreased expression of and affects the localization of EPB41 protein]; benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [[Hydrogen Peroxide co-treated with Cholesterol] results in increased degradation of EPB41 protein] |
CTD |
PMID:20946910 |
|
NCBI chr 5:144,110,010...144,264,037
Ensembl chr 5:144,111,906...144,237,821
|
|
G |
Esm1 |
endothelial cell-specific molecule 1 |
multiple interactions |
ISO |
[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of ESM1 mRNA |
CTD |
PMID:22129739 |
|
NCBI chr 2:44,876,067...44,884,805
Ensembl chr 2:44,876,067...44,884,804
|
|
G |
Fabp1 |
fatty acid binding protein 1 |
multiple interactions |
EXP |
[cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of FABP1 protein |
CTD |
PMID:26606054 |
|
NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788
|
|
G |
Fadd |
Fas associated via death domain |
multiple interactions increases expression |
EXP |
Cholesterol promotes the reaction [Hydrogen Peroxide results in increased expression of FADD protein]; Hydrogen Peroxide promotes the reaction [Cholesterol results in increased expression of FADD protein] |
CTD |
PMID:20946910 |
|
NCBI chr 1:199,743,200...199,745,746
Ensembl chr 1:199,739,994...199,745,653
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions increases expression |
ISO EXP |
Cholesterol inhibits the reaction [FGF7 protein results in increased expression of FAS mRNA] [Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of FAS mRNA Cholesterol analog results in increased expression of FAS mRNA 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Cholesterol analog results in increased expression of FAS mRNA]; Acetylcysteine inhibits the reaction [Cholesterol analog results in increased expression of FAS mRNA] |
CTD |
PMID:16162944 PMID:19477266 PMID:22129739 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Faslg |
Fas ligand |
increases expression |
EXP |
Cholesterol analog results in increased expression of FASLG protein |
CTD |
PMID:19477266 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fdft1 |
farnesyl diphosphate farnesyl transferase 1 |
increases chemical synthesis |
ISO |
FDFT1 protein results in increased chemical synthesis of Cholesterol |
CTD |
PMID:17483544 |
|
NCBI chr15:37,412,143...37,440,198
Ensembl chr15:37,412,146...37,440,287
|
|
G |
Fgf19 |
fibroblast growth factor 19 |
multiple interactions |
ISO |
[FGF19 protein results in increased phosphorylation of NR1H4 protein] which results in increased export of Cholesterol; Dasatinib inhibits the reaction [[FGF19 protein results in increased phosphorylation of NR1H4 protein] which results in increased export of Cholesterol]; NR1H4 protein mutant form inhibits the reaction [[FGF19 protein results in increased phosphorylation of NR1H4 protein] which results in increased export of Cholesterol]; SRC protein promotes the reaction [[FGF19 protein results in increased phosphorylation of NR1H4 protein] which results in increased export of Cholesterol] |
CTD |
PMID:30996006 |
|
NCBI chr 1:200,056,526...200,060,980
Ensembl chr 1:200,056,644...200,060,287
|
|
G |
Fgf7 |
fibroblast growth factor 7 |
multiple interactions |
ISO EXP |
Cholesterol inhibits the reaction [FGF7 protein results in increased expression of FAS mRNA]; Cholesterol inhibits the reaction [FGF7 protein results in increased expression of SCD mRNA] [1,2-dioleoyloxy-3-(trimethylammonium)propane co-treated with Cholesterol] results in increased expression of FGF7 protein |
CTD |
PMID:16034455 PMID:16162944 |
|
NCBI chr 3:113,280,448...113,333,279
Ensembl chr 3:113,281,283...113,332,929
|
|
G |
Fgfr4 |
fibroblast growth factor receptor 4 |
affects metabolic processing decreases metabolic processing |
ISO |
FGFR4 protein affects the metabolism of Cholesterol FGFR4 protein results in decreased metabolism of Cholesterol |
CTD |
PMID:11956156 PMID:15750181 |
|
NCBI chr17:9,461,541...9,476,268
Ensembl chr17:9,461,547...9,476,242
|
|
G |
Flt1 |
Fms related receptor tyrosine kinase 1 |
increases expression |
ISO |
Cholesterol results in increased expression of FLT1 mRNA |
CTD |
PMID:26296894 |
|
NCBI chr12:7,296,899...7,468,626
Ensembl chr12:7,297,292...7,468,626
|
|
G |
Gadd45g |
growth arrest and DNA-damage-inducible, gamma |
multiple interactions |
ISO |
[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of GADD45G mRNA |
CTD |
PMID:22129739 |
|
NCBI chr17:13,376,842...13,378,587
Ensembl chr17:13,376,839...13,378,610
|
|
G |
Gbp2 |
guanylate binding protein 2 |
multiple interactions |
ISO |
[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of GBP2 mRNA |
CTD |
PMID:22129739 |
|
NCBI chr 2:231,332,488...231,348,573
Ensembl chr 2:231,332,284...231,348,571
|
|
G |
Gbp4 |
guanylate binding protein 4 |
multiple interactions |
ISO |
[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of GBP4 mRNA |
CTD |
PMID:22129739 |
|
NCBI chr 2:231,304,910...231,318,883
Ensembl chr 2:231,305,244...231,318,879
|
|
G |
Gbp6 |
guanylate binding protein family member 6 |
multiple interactions |
ISO |
[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of GBP9 mRNA |
CTD |
PMID:22129739 |
|
NCBI chr14:4,730,286...4,756,508
Ensembl chr14:4,730,453...4,839,062 Ensembl chr14:4,730,453...4,839,062
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression |
ISO |
Cholesterol results in increased expression of GCLC protein |
CTD |
PMID:29486218 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gjb1 |
gap junction protein, beta 1 |
decreases abundance |
ISO |
GJB1 protein results in decreased abundance of Cholesterol |
CTD |
PMID:27859493 |
|
NCBI chr X:66,501,848...66,509,783
Ensembl chr X:66,501,820...66,509,925
|
|
G |
Gnai3 |
G protein subunit alpha i3 |
multiple interactions |
ISO |
Cholesterol inhibits the reaction [Progesterone results in decreased expression of GNAI3 protein] |
CTD |
PMID:19221014 |
|
NCBI chr 2:195,742,765...195,780,720
Ensembl chr 2:195,742,642...195,780,742
|
|
G |
Gnas |
GNAS complex locus |
multiple interactions |
ISO |
Cholesterol inhibits the reaction [Progesterone results in increased expression of GNAS protein] |
CTD |
PMID:19221014 |
|
NCBI chr 3:163,071,003...163,136,350
Ensembl chr 3:163,071,417...163,127,262 Ensembl chr 3:163,071,417...163,127,262
|
|
G |
Gp1ba |
glycoprotein Ib platelet subunit alpha |
increases expression |
ISO |
Cholesterol results in increased expression of GP1BA mRNA |
CTD |
PMID:26296894 |
|
NCBI chr10:55,352,938...55,355,804
Ensembl chr10:55,352,899...55,356,774
|
|
G |
Gpam |
glycerol-3-phosphate acyltransferase, mitochondrial |
multiple interactions |
ISO |
[lard co-treated with Cholesterol co-treated with Sucrose co-treated with Atrazine] results in increased expression of GPAM mRNA; [lard co-treated with Cholesterol co-treated with Sucrose co-treated with Ethinyl Estradiol] results in increased expression of GPAM mRNA |
CTD |
PMID:24440342 |
|
NCBI chr 1:254,106,323...254,170,755
Ensembl chr 1:254,106,331...254,142,639
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
multiple interactions |
EXP |
[cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of GPX2 mRNA |
CTD |
PMID:26606054 |
|
NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
increases phosphorylation multiple interactions |
ISO EXP |
Cholesterol results in increased phosphorylation of GSK3B protein [Streptozocin co-treated with Coconut Oil co-treated with Cholesterol] results in decreased phosphorylation of GSK3B protein; Metformin inhibits the reaction [[Streptozocin co-treated with Coconut Oil co-treated with Cholesterol] results in decreased phosphorylation of GSK3B protein]; Plant Extracts inhibits the reaction [[Streptozocin co-treated with Coconut Oil co-treated with Cholesterol] results in decreased phosphorylation of GSK3B protein] CYP7A1 mRNA inhibits the reaction [Cholesterol results in increased phosphorylation of GSK3B protein] |
CTD |
PMID:28275691 PMID:31877369 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Gtf3c6 |
general transcription factor 3C subunit 6 |
multiple interactions |
ISO |
[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of GTF3C6 mRNA |
CTD |
PMID:22129739 |
|
NCBI chr20:43,656,400...43,668,382
Ensembl chr20:43,655,875...43,667,873
|
|
G |
Gzma |
granzyme A |
multiple interactions |
ISO |
[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of GZMA mRNA |
CTD |
PMID:22129739 |
|
NCBI chr 2:44,740,569...44,752,502
Ensembl chr 2:44,740,569...44,752,493
|
|
G |
Gzmb |
granzyme B |
multiple interactions |
ISO |
[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of GZMB mRNA |
CTD |
PMID:22129739 |
|
NCBI chr15:30,343,352...30,346,814
Ensembl chr15:30,173,603...30,346,814
|
|
G |
H2ax |
H2A.X variant histone |
increases phosphorylation multiple interactions |
ISO |
Cholesterol results in increased phosphorylation of H2AX protein bisphenol A promotes the reaction [Cholesterol results in increased phosphorylation of H2AX protein]; Resveratrol inhibits the reaction [bisphenol A promotes the reaction [Cholesterol results in increased phosphorylation of H2AX protein]] |
CTD |
PMID:33239236 |
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
|
|
G |
Hacl1 |
2-hydroxyacyl-CoA lyase 1 |
multiple interactions |
ISO |
[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of HACL1 mRNA |
CTD |
PMID:22129739 |
|
NCBI chr16:6,826,881...6,863,027
Ensembl chr16:6,824,906...6,863,027
|
|
G |
Havcr1 |
hepatitis A virus cellular receptor 1 |
multiple interactions |
EXP |
[cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of HAVCR1 mRNA |
CTD |
PMID:26606054 |
|
NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698
|
|
G |
Hbegf |
heparin-binding EGF-like growth factor |
increases expression |
ISO |
Cholesterol results in increased expression of HBEGF mRNA |
CTD |
PMID:26296894 |
|
NCBI chr18:28,106,284...28,116,167
Ensembl chr18:28,105,760...28,116,441
|
|
G |
Hcar2 |
hydroxycarboxylic acid receptor 2 |
multiple interactions |
ISO |
[HCAR2 protein results in decreased expression of ABCA1 protein] which results in decreased export of Cholesterol |
CTD |
PMID:20655299 |
|
NCBI chr12:32,726,252...32,728,238
Ensembl chr12:32,726,184...32,728,504
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
EXP |
[cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of HIF1A mRNA |
CTD |
PMID:26606054 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
decreases activity decreases expression multiple interactions |
ISO EXP |
Cholesterol results in decreased activity of HMGCR protein cholesterol decreases expression of Hmgcr mRNA in liver [Cholesterol co-treated with Cholic Acid] results in decreased expression of HMGCR mRNA; [Cholesterol co-treated with Cholic Acid] results in increased activity of HMGCR protein; [turmeric extract co-treated with Cholesterol] results in decreased expression of HMGCR mRNA; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of HMGCR mRNA]; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of HMGCR protein]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of HMGCR mRNA]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of HMGCR protein]; Selenium promotes the reaction [Cholesterol results in decreased expression of HMGCR mRNA] [25-hydroxycholesterol co-treated with Cholesterol] results in decreased activity of HMGCR protein; [[artemisic acid results in decreased expression of CEBPA mRNA] which results in decreased expression of HMGCR mRNA] which results in decreased chemical synthesis of Cholesterol; [[CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 27-hydroxycholesterol] which results in increased activity of HMGCR protein; [artemisic acid results in decreased expression of HMGCR protein] which results in decreased chemical synthesis of Cholesterol; [Clozapine results in increased activity of HMGCR protein] which results in increased abundance of Cholesterol; [Haloperidol results in increased activity of HMGCR protein] which results in increased abundance of Cholesterol; LDLR gene mutant form promotes the reaction [[25-hydroxycholesterol co-treated with Cholesterol] results in decreased activity of HMGCR protein] |
CTD RGD |
PMID:11408283 PMID:12477733 PMID:16027736 PMID:16581047 PMID:17516993 PMID:18024962 PMID:21535835 PMID:23063590 PMID:30273964 PMID:25263431 More...
|
RGD:15045610 |
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression decreases expression |
EXP |
[Cholesterol co-treated with Particulate Matter] results in increased expression of HMOX1 mRNA; [cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of HMOX1 mRNA; alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [Cholesterol results in increased expression of HMOX1 mRNA]]; Particulate Matter promotes the reaction [Cholesterol results in increased expression of HMOX1 mRNA]; turmeric extract inhibits the reaction [Cholesterol results in decreased expression of HMOX1 mRNA] |
CTD |
PMID:21535835 PMID:26606054 PMID:30672636 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hnf4a |
hepatocyte nuclear factor 4, alpha |
multiple interactions |
EXP |
[Cholesterol co-treated with Cholic Acid] results in decreased expression of HNF4A mRNA; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of HNF4A mRNA]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of HNF4A mRNA] |
CTD |
PMID:30273964 |
|
NCBI chr 3:152,186,787...152,248,320
Ensembl chr 3:152,186,787...152,248,320
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
EXP |
[Cholesterol co-treated with Ergosterol] results in increased expression of ICAM1 mRNA; [Cholesterol co-treated with Ergosterol] results in increased expression of ICAM1 protein; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of ICAM1 mRNA]; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of ICAM1 protein] |
CTD |
PMID:25833014 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Ifi44 |
interferon-induced protein 44 |
multiple interactions |
ISO |
[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of IFI44 mRNA |
CTD |
PMID:22129739 |
|
NCBI chr 2:240,626,058...240,643,879
Ensembl chr 2:240,626,066...240,643,844
|
|
G |
Ifit3 |
interferon-induced protein with tetratricopeptide repeats 3 |
multiple interactions |
ISO |
[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of IFIT3 mRNA |
CTD |
PMID:22129739 |
|
NCBI chr 1:232,114,166...232,119,311
Ensembl chr 1:232,114,166...232,119,307
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
EXP |
[Cholesterol co-treated with Particulate Matter] results in increased expression of IFNG protein; alpha-Linolenic Acid inhibits the reaction [[Cholesterol co-treated with Particulate Matter] results in increased expression of IFNG protein] |
CTD |
PMID:30672636 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Igf1 |
insulin-like growth factor 1 |
multiple interactions |
EXP |
[1,2-dioleoyloxy-3-(trimethylammonium)propane co-treated with Cholesterol] results in increased expression of IGF1 protein |
CTD |
PMID:16034455 |
|
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Igf2r |
insulin-like growth factor 2 receptor |
multiple interactions |
EXP |
[IGF2R protein alternative form results in increased susceptibility to Streptozocin] which results in increased abundance of Cholesterol |
CTD |
PMID:35993117 |
|
NCBI chr 1:47,979,109...48,067,501
Ensembl chr 1:47,979,109...48,067,501
|
|
G |
Igfbp1 |
insulin-like growth factor binding protein 1 |
multiple interactions |
ISO |
[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of IGFBP1 mRNA |
CTD |
PMID:22129739 |
|
NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482
|
|
G |
Igfbp3 |
insulin-like growth factor binding protein 3 |
multiple interactions |
EXP |
[1,2-dioleoyloxy-3-(trimethylammonium)propane co-treated with Cholesterol] results in increased expression of IGFBP3 protein |
CTD |
PMID:16034455 |
|
NCBI chr14:82,056,347...82,064,083
Ensembl chr14:82,056,347...82,064,083
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
[Dietary Fats co-treated with bisphenol A co-treated with Cholesterol] results in decreased secretion of IL10 protein |
CTD |
PMID:33239236 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il18bp |
interleukin 18 binding protein |
multiple interactions |
ISO |
[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of IL18BP mRNA |
CTD |
PMID:22129739 |
|
NCBI chr 1:156,372,923...156,374,963
Ensembl chr 1:156,372,883...156,374,963
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases expression |
ISO EXP |
[Cholesterol co-treated with Lipopolysaccharides] results in increased expression of IL1B protein; CLEC4E protein promotes the reaction [[Cholesterol co-treated with Lipopolysaccharides] results in increased expression of IL1B protein] Cholesterol results in increased expression of IL1B protein Cholesterol analog results in increased expression of IL1B protein [Cholesterol co-treated with Lipopolysaccharides] results in increased secretion of IL1B protein; [Dietary Fats co-treated with bisphenol A co-treated with Cholesterol] results in increased secretion of IL1B protein; Amitriptyline inhibits the reaction [Cholesterol analog results in increased expression of IL1B protein]; bisphenol A promotes the reaction [[Cholesterol co-treated with Lipopolysaccharides] results in increased secretion of IL1B protein]; Cholesterol promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; NBN protein inhibits the reaction [bisphenol A promotes the reaction [Cholesterol results in increased secretion of IL1B protein]]; Quercetin inhibits the reaction [Cholesterol promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]]; Resveratrol inhibits the reaction [bisphenol A promotes the reaction [Cholesterol results in increased secretion of IL1B protein]]; SMPD1 protein affects the reaction [Cholesterol analog results in increased expression of IL1B protein] [Cholesterol co-treated with Ergosterol] results in increased expression of and results in increased secretion of IL1B protein; [Cholesterol co-treated with Ergosterol] results in increased expression of IL1B mRNA; [Cholesterol co-treated with Particulate Matter] results in increased expression of IL1B protein; [cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of IL1B mRNA; alpha-Linolenic Acid inhibits the reaction [[Cholesterol co-treated with Particulate Matter] results in increased expression of IL1B protein]; Resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of and results in increased secretion of IL1B protein]; Resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of IL1B mRNA] Cholesterol results in increased expression of IL1B mRNA |
CTD |
PMID:22869926 PMID:25833014 PMID:26296894 PMID:26606054 PMID:28633109 PMID:30672636 PMID:33239236 More...
|
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il1rn |
interleukin 1 receptor antagonist |
increases expression |
ISO |
Cholesterol results in increased expression of IL1RN mRNA |
CTD |
PMID:26296894 |
|
NCBI chr 3:7,111,567...7,127,451
Ensembl chr 3:7,111,550...7,127,445
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases expression |
ISO EXP |
[Dietary Fats co-treated with bisphenol A co-treated with Cholesterol] results in increased secretion of IL6 protein; Cholesterol inhibits the reaction [Irbesartan results in increased expression of IL6 mRNA]; Cholesterol inhibits the reaction [Irbesartan results in increased expression of IL6 protein] [Cholesterol co-treated with Particulate Matter] results in increased expression of IL6 mRNA; alpha-Linolenic Acid inhibits the reaction [Cholesterol promotes the reaction [Particulate Matter results in increased expression of IL6 protein]]; Cholesterol promotes the reaction [Particulate Matter results in increased expression of IL6 protein] Cholesterol results in increased expression of IL6 mRNA; Cholesterol results in increased expression of IL6 protein |
CTD |
PMID:19028402 PMID:30672636 PMID:33239236 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Inhba |
inhibin subunit beta A |
increases expression |
ISO |
Cholesterol results in increased expression of INHBA mRNA |
CTD |
PMID:26296894 |
|
NCBI chr17:49,091,635...49,111,573
Ensembl chr17:49,095,920...49,108,982
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
EXP |
[Streptozocin co-treated with Coconut Oil co-treated with Cholesterol] results in increased expression of INS1 protein; Metformin inhibits the reaction [[Streptozocin co-treated with Coconut Oil co-treated with Cholesterol] results in increased expression of INS1 protein]; Plant Extracts inhibits the reaction [[Streptozocin co-treated with Coconut Oil co-treated with Cholesterol] results in increased expression of INS1 protein] |
CTD |
PMID:31877369 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
[1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of Cholesterol analog |
CTD |
PMID:26820058 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Irf7 |
interferon regulatory factor 7 |
multiple interactions |
ISO |
[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of IRF7 mRNA |
CTD |
PMID:22129739 |
|
NCBI chr 1:196,367,380...196,370,943
Ensembl chr 1:196,367,361...196,370,832
|
|
G |
Irs1 |
insulin receptor substrate 1 |
affects abundance |
ISO |
IRS1 gene polymorphism affects the abundance of Cholesterol |
CTD |
PMID:10591678 |
|
NCBI chr 9:83,552,964...83,605,797
Ensembl chr 9:83,548,944...83,606,122
|
|
G |
Isg15 |
ISG15 ubiquitin-like modifier |
multiple interactions |
ISO |
[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of ISG15 mRNA |
CTD |
PMID:22129739 |
|
NCBI chr 5:166,784,148...166,785,435
Ensembl chr 5:166,784,148...166,785,435
|
|
G |
Itgam |
integrin subunit alpha M |
increases expression |
ISO |
Cholesterol increases expression of ITGAM protein on monocytes and granulocytes |
RGD |
PMID:26026058 |
RGD:329853768 |
NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases localization |
EXP |
Cholesterol results in decreased localization of KCNH2 protein |
CTD |
PMID:21525004 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Kitlg |
KIT ligand |
increases expression |
ISO |
Cholesterol results in increased expression of KITLG mRNA |
CTD |
PMID:26296894 |
|
NCBI chr 7:34,896,075...34,977,215
Ensembl chr 7:34,896,053...34,977,214
|
|
G |
Krt19 |
keratin 19 |
multiple interactions |
ISO |
Cholesterol inhibits the reaction [arachidonyl dopamine results in increased expression of KRT19 mRNA] |
CTD |
PMID:33393692 |
|
NCBI chr10:85,075,835...85,080,552
Ensembl chr10:85,066,802...85,171,799
|
|
G |
Lamp1 |
lysosomal-associated membrane protein 1 |
increases expression |
ISO |
Cholesterol results in increased expression of LAMP1 protein |
CTD |
PMID:28275691 |
|
NCBI chr16:76,355,982...76,380,700
Ensembl chr16:76,355,984...76,381,883
|
|
G |
Lcat |
lecithin cholesterol acyltransferase |
increases acylation multiple interactions |
ISO EXP |
LCAT protein results in increased acylation of Cholesterol [Cholesterol co-treated with Cholic Acid] results in increased activity of LCAT protein; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of LCAT protein]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of LCAT protein] |
CTD |
PMID:4847537 PMID:30273964 |
|
NCBI chr19:33,834,748...33,838,214
Ensembl chr19:33,834,403...33,838,231
|
|
G |
Lcn2 |
lipocalin 2 |
multiple interactions |
ISO |
[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of LCN2 mRNA |
CTD |
PMID:22129739 |
|
NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095
|
|
G |
Ldlr |
low density lipoprotein receptor |
increases uptake affects abundance increases response to substance multiple interactions decreases expression decreases activity |
ISO EXP |
LDLR protein results in increased uptake of Cholesterol LDLR protein affects the abundance of Cholesterol LDLR gene mutant form results in increased susceptibility to Cholesterol (+)-JQ1 compound inhibits the reaction [LDLR gene mutant form results in increased susceptibility to Cholesterol]; [LDLR gene mutant form results in increased susceptibility to Dietary Fats] which results in increased abundance of Cholesterol; [Tobacco Smoke Pollution promotes the reaction [LDLR protein affects the susceptibility to Dietary Fats]] which results in increased abundance of Cholesterol; argatroban inhibits the reaction [[LDLR gene mutant form results in increased susceptibility to Dietary Fats] which results in increased abundance of Cholesterol]; Chloroquine affects the reaction [SORT1 protein affects the reaction [LDLR protein affects the abundance of Cholesterol]]; SORT1 protein affects the reaction [LDLR protein affects the abundance of Cholesterol] Cholesterol results in decreased expression of LDLR mRNA [Cholesterol co-treated with Cholic Acid] results in decreased expression of LDLR mRNA; [Cholesterol deficiency co-treated with Lovastatin] results in increased expression of LDLR mRNA; [turmeric extract co-treated with Cholesterol] results in increased expression of LDLR mRNA; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of LDLR mRNA]; Cholesterol inhibits the reaction [[Cholesterol deficiency co-treated with Lovastatin] results in increased expression of LDLR mRNA]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of LDLR mRNA]; Selenium inhibits the reaction [Cholesterol results in decreased activity of LDLR protein]; Selenium inhibits the reaction [Cholesterol results in decreased expression of LDLR mRNA]; turmeric extract inhibits the reaction [Cholesterol results in decreased expression of LDLR mRNA] [CYP27A1 protein results in increased chemical synthesis of Bile Acids and Salts] promotes the reaction [LDLR protein results in increased uptake of Cholesterol]; LDLR gene mutant form promotes the reaction [[25-hydroxycholesterol co-treated with Cholesterol] results in decreased activity of HMGCR protein]; LDLR gene mutant form results in increased susceptibility to [25-hydroxycholesterol co-treated with Cholesterol] |
CTD |
PMID:12477733 PMID:16271152 PMID:16317514 PMID:16477808 PMID:16937255 PMID:20578043 PMID:21535835 PMID:22659316 PMID:22841818 PMID:25263595 PMID:30273964 PMID:30950489 More...
|
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Lepr |
leptin receptor |
multiple interactions increases abundance |
ISO |
Glucagon analog inhibits the reaction [LEPR gene mutant form results in increased abundance of Cholesterol] |
CTD |
PMID:29988851 |
|
NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908
|
|
G |
Lpl |
lipoprotein lipase |
increases expression multiple interactions |
ISO EXP |
Cholesterol results in increased expression of LPL mRNA [Cholesterol co-treated with Cholic Acid] results in increased activity of LPL protein; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of LPL protein]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of LPL protein] |
CTD |
PMID:26296894 PMID:30273964 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Lrp1 |
LDL receptor related protein 1 |
multiple interactions |
ISO |
[Capsaicin results in decreased expression of LRP1 protein] which results in decreased uptake of Cholesterol; [Capsaicin results in decreased expression of LRP1 protein] which results in increased secretion of Cholesterol |
CTD |
PMID:21908651 |
|
NCBI chr 7:63,380,325...63,461,029
Ensembl chr 7:63,380,356...63,460,910
|
|
G |
Ly6a |
lymphocyte antigen 6 family member A |
multiple interactions |
ISO |
[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of LY6A mRNA |
CTD |
PMID:22129739 |
|
NCBI chr 7:107,177,191...107,189,436
Ensembl chr 7:107,183,469...107,189,981
|
|
G |
Ly6e |
lymphocyte antigen 6 family member E |
multiple interactions |
ISO |
[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of LY6E mRNA |
CTD |
PMID:22129739 |
|
NCBI chr 7:106,935,530...106,939,689
Ensembl chr 7:106,935,761...106,939,689
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
increases expression multiple interactions |
ISO |
Cholesterol results in increased expression of MAP1LC3B protein modified form Cholesterol inhibits the reaction [Cadmium Chloride results in increased cleavage of MAP1LC3B protein] |
CTD |
PMID:28275691 PMID:29486218 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions |
EXP |
[Cholesterol co-treated with Ergosterol] results in increased expression of MAPK14 mRNA; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of MAPK14 mRNA] |
CTD |
PMID:25833014 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mapt |
microtubule-associated protein tau |
multiple interactions |
EXP |
[Dietary Fats co-treated with Cholesterol] results in increased expression of MAPT protein modified form; Selenium inhibits the reaction [[Dietary Fats co-treated with Cholesterol] results in increased expression of MAPT protein modified form] |
CTD |
PMID:30695686 |
|
NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129
|
|
G |
Marchf6 |
membrane associated ring-CH-type finger 6 |
increases stability multiple interactions |
ISO |
Cholesterol results in increased stability of MARCHF6 protein Cholesterol inhibits the reaction [Betaine results in decreased stability of MARCHF6 protein]; Cholesterol inhibits the reaction [Glycerol results in decreased stability of MARCHF6 protein]; Cholesterol inhibits the reaction [MARCHF6 protein results in increased ubiquitination of and results in increased degradation of MARCHF6 protein]; MARCHF6 promotes the reaction [Cholesterol results in increased degradation of SQLE protein] |
CTD |
PMID:30545937 |
|
NCBI chr 2:82,455,686...82,532,917
Ensembl chr 2:82,455,689...82,532,910
|
|
G |
Marco |
macrophage receptor with collagenous structure |
multiple interactions |
ISO |
[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of MARCO mRNA |
CTD |
PMID:22129739 |
|
NCBI chr13:31,616,278...31,648,521
Ensembl chr13:31,616,278...31,648,521
|
|
G |
Mia2 |
MIA SH3 domain ER export factor 2 |
multiple interactions |
ISO |
[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of MIA2 mRNA |
CTD |
PMID:22129739 |
|
NCBI chr 6:76,787,508...76,885,246
Ensembl chr 6:76,787,508...76,885,211
|
|
G |
Mir125a |
microRNA 125a |
decreases export |
ISO |
MIR125A mRNA results in decreased export of Cholesterol |
CTD |
PMID:33952798 |
|
NCBI chr 1:58,677,626...58,677,710
Ensembl chr 1:58,677,626...58,677,710
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
multiple interactions |
ISO |
[[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in decreased expression of MKI67 protein; [[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in increased expression of MKI67 mRNA; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the expression of MKI67 mRNA; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds affects the expression of MKI67 mRNA]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds results in decreased expression of MKI67 protein]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] results in increased expression of MKI67 protein; [EGF protein co-treated with [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]]] inhibits the reaction [[EGF protein co-treated with Silver Compounds] results in decreased expression of MKI67 protein] |
CTD |
PMID:35385781 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mlxipl |
MLX interacting protein-like |
multiple interactions |
ISO |
[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of MLXIPL mRNA; Atrazine promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of MLXIPL mRNA] |
CTD |
PMID:24440342 |
|
NCBI chr12:21,541,608...21,577,120
Ensembl chr12:21,543,576...21,577,112
|
|
G |
Mpeg1 |
macrophage expressed 1 |
multiple interactions |
ISO |
[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of MPEG1 mRNA |
CTD |
PMID:22129739 |
|
NCBI chr 1:209,452,176...209,456,692
Ensembl chr 1:209,452,133...209,458,855
|
|
G |
Msr1 |
macrophage scavenger receptor 1 |
multiple interactions |
ISO |
[resveratrol results in decreased expression of MSR1 protein] which results in decreased uptake of Cholesterol |
CTD |
PMID:20372816 |
|
NCBI chr16:52,717,775...52,803,602
Ensembl chr16:52,717,732...52,799,676
|
|
G |
Mt2A |
metallothionein 2A |
multiple interactions increases expression |
ISO |
[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of MT2 mRNA Cholesterol results in increased expression of MT2 protein |
CTD |
PMID:22129739 PMID:29486218 |
|
NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
increases phosphorylation |
ISO |
Cholesterol results in increased phosphorylation of MTOR protein |
CTD |
PMID:29486218 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Mvk |
mevalonate kinase |
decreases chemical synthesis |
ISO |
MVK protein mutant form results in decreased chemical synthesis of Cholesterol |
CTD |
PMID:24073415 |
|
NCBI chr12:42,141,391...42,158,893
Ensembl chr12:42,141,384...42,158,882
|
|
G |
Nab2 |
Ngfi-A binding protein 2 |
multiple interactions |
ISO |
[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of NAB2 mRNA |
CTD |
PMID:22129739 |
|
NCBI chr 7:63,497,589...63,504,105
Ensembl chr 7:63,497,589...63,503,989
|
|
G |
Naglu |
N-acetyl-alpha-glucosaminidase |
multiple interactions |
EXP |
[cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of NAGLU protein |
CTD |
PMID:26606054 |
|
NCBI chr10:86,001,545...86,009,049
Ensembl chr10:86,001,566...86,008,972
|
|
G |
Nbn |
nibrin |
multiple interactions |
ISO |
[Cholesterol co-treated with Resveratrol] inhibits the reaction [bisphenol A results in decreased expression of NBN protein]; NBN protein inhibits the reaction [[Cholesterol co-treated with bisphenol A] results in increased expression of NLRP3 protein]; NBN protein inhibits the reaction [bisphenol A promotes the reaction [Cholesterol results in increased cleavage of CASP1 protein]]; NBN protein inhibits the reaction [bisphenol A promotes the reaction [Cholesterol results in increased secretion of IL1B protein]] |
CTD |
PMID:33239236 |
|
NCBI chr 5:29,459,574...29,494,152
Ensembl chr 5:29,459,457...29,494,150
|
|
G |
Ncf1 |
neutrophil cytosolic factor 1 |
multiple interactions increases expression |
ISO |
Cholesterol inhibits the reaction [irbesartan results in increased expression of NCF1 mRNA]; Cholesterol inhibits the reaction [irbesartan results in increased expression of NCF1 protein] Cholesterol results in increased expression of NCF1 mRNA; Cholesterol results in increased expression of NCF1 protein |
CTD |
PMID:19028402 |
|
NCBI chr12:22,485,382...22,494,647
Ensembl chr12:22,485,451...22,494,646
|
|
G |
Ncoa2 |
nuclear receptor coactivator 2 |
affects metabolic processing |
ISO |
NCOA2 protein affects the metabolism of Cholesterol |
CTD |
PMID:14993927 |
|
NCBI chr 5:5,835,642...6,069,693
Ensembl chr 5:5,835,706...6,067,451
|
|
G |
Nectin2 |
nectin cell adhesion molecule 2 |
affects expression |
ISO |
Cholesterol affects the expression of NECTIN2 |
CTD |
PMID:28062492 |
|
NCBI chr 1:79,372,123...79,407,379
Ensembl chr 1:79,372,119...79,407,360
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
increases expression multiple interactions |
EXP |
Cholesterol results in increased expression of NFE2L2 mRNA alpha-Linolenic Acid inhibits the reaction [Cholesterol promotes the reaction [Particulate Matter results in increased expression of NFE2L2 mRNA]]; alpha-Linolenic Acid inhibits the reaction [Cholesterol results in increased expression of NFE2L2 mRNA]; alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [Cholesterol results in increased expression of NFE2L2 mRNA]]; Cholesterol promotes the reaction [Particulate Matter results in increased expression of NFE2L2 protein]; Particulate Matter promotes the reaction [Cholesterol results in increased expression of NFE2L2 mRNA] |
CTD |
PMID:30672636 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
increases expression multiple interactions |
ISO |
Cholesterol results in increased expression of NFKB1 protein Cholesterol inhibits the reaction [irbesartan results in increased expression of NFKB1 protein] |
CTD |
PMID:19028402 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbib |
NFKB inhibitor beta |
multiple interactions increases phosphorylation |
ISO |
Cholesterol inhibits the reaction [irbesartan results in increased phosphorylation of NFKBIB protein] Cholesterol results in increased phosphorylation of NFKBIB protein |
CTD |
PMID:19028402 |
|
NCBI chr 1:84,046,292...84,053,862
Ensembl chr 1:84,046,295...84,053,862
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions affects localization |
EXP ISO |
[Cholesterol co-treated with Ergosterol] results in increased expression of NLRP3 mRNA; [Cholesterol co-treated with Ergosterol] results in increased expression of NLRP3 protein; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of NLRP3 mRNA]; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of NLRP3 protein] Cholesterol analog affects the localization of NLRP3 protein [Cholesterol co-treated with bisphenol A] results in increased expression of NLRP3 protein; Amitriptyline inhibits the reaction [Cholesterol analog affects the localization of NLRP3 protein]; NBN protein inhibits the reaction [[Cholesterol co-treated with bisphenol A] results in increased expression of NLRP3 protein]; Resveratrol inhibits the reaction [[Cholesterol co-treated with bisphenol A] results in increased expression of NLRP3 protein]; SMPD1 protein affects the reaction [Cholesterol analog affects the localization of NLRP3 protein] |
CTD |
PMID:25833014 PMID:28633109 PMID:33239236 |
|
NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Npc1 |
NPC intracellular cholesterol transporter 1 |
increases secretion affects localization affects abundance multiple interactions |
ISO |
NPC1 protein results in increased secretion of Cholesterol NPC1 affects the localization of Cholesterol NPC1 protein affects the abundance of Cholesterol Progesterone inhibits the reaction [NPC1 protein results in increased secretion of Cholesterol] |
CTD |
PMID:12183525 PMID:16174794 PMID:18483620 |
|
NCBI chr18:3,379,482...3,425,100
Ensembl chr18:3,379,482...3,425,049
|
|
G |
Npc1l1 |
NPC1 like intracellular cholesterol transporter 1 |
multiple interactions |
ISO |
[Cholesterol deficiency co-treated with Dietary Fats] results in decreased expression of NPC1L1 mRNA |
CTD |
PMID:18356535 |
|
NCBI chr14:81,071,448...81,091,113
Ensembl chr14:81,071,451...81,091,113
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression multiple interactions |
EXP |
Cholesterol results in increased expression of NQO1 mRNA alpha-Linolenic Acid inhibits the reaction [Particulate Matter promotes the reaction [Cholesterol results in increased expression of NQO1 mRNA]]; Cholesterol promotes the reaction [Particulate Matter results in increased expression of NQO1 protein]; Particulate Matter promotes the reaction [Cholesterol results in increased expression of NQO1 mRNA] |
CTD |
PMID:30672636 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr1h2 |
nuclear receptor subfamily 1, group H, member 2 |
multiple interactions increases activity |
ISO |
[RXRB protein binds to NR1H2 protein] which affects the metabolism of Cholesterol; NR1H2 gene mutant form inhibits the reaction [pitavastatin inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased export of Cholesterol]]; NR1H2 gene mutant form inhibits the reaction [pitavastatin results in decreased export of Cholesterol] Cholesterol results in increased activity of NR1H2 protein |
CTD |
PMID:14993927 PMID:16415093 PMID:21543282 |
|
NCBI chr 1:95,041,967...95,047,358
Ensembl chr 1:95,041,967...95,047,377
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
multiple interactions increases expression decreases expression |
ISO EXP |
[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased transport of Cholesterol; [9-deoxy-delta-9-prostaglandin D2 binds to and results in increased activity of PPARG protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased transport of Cholesterol]; [Bezafibrate binds to and results in increased activity of PPARA protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased transport of Cholesterol]; [Cholesterol co-treated with Ozone] results in increased lipidation of NR1H3 protein Cholesterol increases expression of NR1H3 mRNA in epithelial cells cholesterol decreases expression of LXR mRNA in liver NR1H3 gene mutant form inhibits the reaction [pitavastatin inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased export of Cholesterol]]; NR1H3 gene mutant form inhibits the reaction [pitavastatin results in decreased export of Cholesterol] |
CTD RGD |
PMID:12595494 PMID:16415093 PMID:27703007 PMID:37061692 PMID:25263431 |
RGD:401842388, RGD:15045610 |
NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions decreases expression increases export |
ISO EXP |
[FGF19 protein results in increased phosphorylation of NR1H4 protein] which results in increased export of Cholesterol; Dasatinib inhibits the reaction [[FGF19 protein results in increased phosphorylation of NR1H4 protein] which results in increased export of Cholesterol]; NR1H4 protein mutant form inhibits the reaction [[FGF19 protein results in increased phosphorylation of NR1H4 protein] which results in increased export of Cholesterol]; SRC protein promotes the reaction [[FGF19 protein results in increased phosphorylation of NR1H4 protein] which results in increased export of Cholesterol] cholesterol decreases expression of Nr1h4 mRNA in liver NR1H4 protein results in increased export of Cholesterol |
CTD RGD |
PMID:30996006 PMID:25263431 |
RGD:15045610 |
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
affects metabolic processing |
ISO |
NR1I2 protein affects the metabolism of Cholesterol |
CTD |
PMID:15684063 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
affects metabolic processing multiple interactions affects binding |
ISO |
NR1I3 protein affects the metabolism of Cholesterol [1,4-bis(2-(3,5-dichloropyridyloxy))benzene results in increased activity of NR1I3 protein] which results in increased abundance of Cholesterol Cholesterol metabolite binds to NR1I3 protein |
CTD |
PMID:15684063 PMID:16051528 PMID:22101211 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Nr5a2 |
nuclear receptor subfamily 5, group A, member 2 |
affects abundance |
ISO |
NR5A2 gene mutant form affects the abundance of Cholesterol |
CTD |
PMID:29515023 |
|
NCBI chr13:48,313,634...48,433,494
Ensembl chr13:48,316,301...48,433,326
|
|
G |
Oas3 |
2'-5'-oligoadenylate synthetase 3 |
multiple interactions |
ISO |
[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of OAS3 mRNA |
CTD |
PMID:22129739 |
|
NCBI chr12:35,779,028...35,802,781
Ensembl chr12:35,779,022...35,802,781
|
|
G |
Ocstamp |
osteoclast stimulatory transmembrane protein |
increases expression |
ISO |
Cholesterol results in increased expression of OCSTAMP mRNA |
CTD |
PMID:26296894 |
|
NCBI chr 3:154,131,113...154,141,611
Ensembl chr 3:154,132,328...154,136,991
|
|
G |
Olr1 |
oxidized low density lipoprotein receptor 1 |
multiple interactions |
EXP |
[Cholesterol co-treated with Ergosterol] results in increased expression of OLR1 mRNA; [Cholesterol co-treated with Ergosterol] results in increased expression of OLR1 protein; Resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of OLR1 mRNA]; Resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of OLR1 protein] |
CTD |
PMID:25833014 |
|
NCBI chr 4:162,926,436...162,949,057
Ensembl chr 4:162,926,439...162,948,523
|
|
G |
Or52r1c |
olfactory receptor family 52 subfamily R member 1C |
multiple interactions |
ISO |
[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of OR52R1 mRNA |
CTD |
PMID:22129739 |
|
NCBI chr 1:157,475,119...157,476,063
Ensembl chr 1:157,471,250...157,476,301
|
|
G |
Otof |
otoferlin |
multiple interactions |
ISO |
[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of OTOF mRNA |
CTD |
PMID:22129739 |
|
NCBI chr 6:25,928,018...26,024,631
Ensembl chr 6:25,928,055...26,024,631
|
|
G |
P2rx1 |
purinergic receptor P2X 1 |
decreases activity multiple interactions |
ISO |
Cholesterol deficiency results in decreased activity of P2RX1 protein jasplakinolide inhibits the reaction [Cholesterol deficiency results in decreased activity of P2RX1 protein] |
CTD |
PMID:21757694 |
|
NCBI chr10:57,618,586...57,633,648
Ensembl chr10:57,618,586...57,633,623
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases cleavage |
ISO |
bisphenol A promotes the reaction [Cholesterol results in increased cleavage of PARP1 protein]; Resveratrol inhibits the reaction [bisphenol A promotes the reaction [Cholesterol results in increased cleavage of PARP1 protein]] |
CTD |
PMID:33239236 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pcbp1 |
poly(rC) binding protein 1 |
multiple interactions |
ISO |
[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of PCBP1 mRNA |
CTD |
PMID:22129739 |
|
NCBI chr 4:118,972,698...118,974,705
Ensembl chr 4:118,972,661...118,976,500
|
|
G |
Pklr |
pyruvate kinase L/R |
multiple interactions |
ISO |
[lard co-treated with Cholesterol co-treated with Sucrose co-treated with Atrazine] results in increased expression of PKLR mRNA; [lard co-treated with Cholesterol co-treated with Sucrose co-treated with cypermethrin] results in increased expression of PKLR mRNA; [lard co-treated with Cholesterol co-treated with Sucrose co-treated with Ethinyl Estradiol] results in increased expression of PKLR mRNA |
CTD |
PMID:24440342 |
|
NCBI chr 2:174,543,008...174,551,863
Ensembl chr 2:174,543,039...174,551,870
|
|
G |
Pld2 |
phospholipase D2 |
multiple interactions |
ISO |
PLD2 protein affects the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased export of Cholesterol]]; PLD2 protein inhibits the reaction [Linoleic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased export of Cholesterol]]] |
CTD |
PMID:16118212 |
|
NCBI chr10:55,256,326...55,274,192
Ensembl chr10:55,256,359...55,272,808
|
|
G |
Pon1 |
paraoxonase 1 |
decreases chemical synthesis multiple interactions increases export decreases activity |
ISO EXP |
PON1 protein results in decreased chemical synthesis of Cholesterol [Cholesterol co-treated with Cholic Acid] results in decreased secretion of PON1 protein; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased secretion of PON1 protein]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased secretion of PON1 protein] PON1 protein results in increased export of Cholesterol Cholesterol results in decreased activity of PON1 protein |
CTD |
PMID:12615663 PMID:16115471 PMID:16229851 PMID:16331452 PMID:30273964 |
|
NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions decreases expression |
ISO |
[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of PPARA mRNA; Atrazine promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of PPARA mRNA]; cypermethrin promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of PPARA mRNA]; Ethinyl Estradiol promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of PPARA mRNA]; PPARA affects the reaction [Aspirin promotes the reaction [APOA1 affects the transport of Cholesterol]] Cholesterol results in decreased expression of PPARA mRNA [Bezafibrate binds to and results in increased activity of PPARA protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased transport of Cholesterol]; [Bezafibrate binds to and results in increased activity of PPARA protein] promotes the reaction [APOA1 protein results in increased transport of Cholesterol]; [pirinixic acid binds to and results in increased activity of PPARA protein] promotes the reaction [APOA1 protein results in increased transport of Cholesterol]; Cholesterol inhibits the reaction [cerivastatin promotes the reaction [Bezafibrate results in increased activity of [PPARA protein binds to RXRA protein]]] |
CTD |
PMID:11779144 PMID:12595494 PMID:21088444 PMID:24440342 PMID:25689681 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
[2-chloro-5-nitrobenzanilide binds to and results in decreased activity of PPARG protein] inhibits the reaction [resveratrol results in decreased abundance of Cholesterol]; [9-deoxy-delta-9-prostaglandin D2 binds to and results in increased activity of PPARG protein] promotes the reaction [[25-hydroxycholesterol binds to and results in increased activity of NR1H3 protein] which results in increased transport of Cholesterol]; [9-deoxy-delta-9-prostaglandin D2 binds to and results in increased activity of PPARG protein] promotes the reaction [APOA1 protein results in increased transport of Cholesterol]; [[troglitazone binds to and results in increased activity of PPARG protein] which results in decreased expression of SREBF2 protein] which results in decreased abundance of Cholesterol; [troglitazone binds to and results in increased activity of PPARG protein] which results in decreased abundance of Cholesterol; [troglitazone binds to and results in increased activity of PPARG protein] which results in increased abundance of Cholesterol; Pravastatin inhibits the reaction [[troglitazone binds to and results in increased activity of PPARG protein] which results in increased abundance of Cholesterol] [Dietary Fats co-treated with Cholesterol] results in increased expression of PPARG mRNA; [lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of PPARG mRNA; Atrazine promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of PPARG mRNA]; Losartan inhibits the reaction [[Dietary Fats co-treated with Cholesterol] results in increased expression of PPARG mRNA]; PPARG protein promotes the reaction [Niacin promotes the reaction [APOA1 protein results in increased export of Cholesterol]]; Rosiglitazone inhibits the reaction [[Dietary Fats co-treated with Cholesterol] results in increased expression of PPARG mRNA] |
CTD |
PMID:12044893 PMID:12595494 PMID:16946405 PMID:18302760 PMID:19797938 PMID:20372816 PMID:24440342 More...
|
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppp1r3g |
protein phosphatase 1, regulatory subunit 3G |
multiple interactions |
ISO |
[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of PPP1R3G mRNA |
CTD |
PMID:22129739 |
|
NCBI chr17:28,874,956...28,878,288
Ensembl chr17:28,876,482...28,877,525
|
|
G |
Psat1 |
phosphoserine aminotransferase 1 |
increases expression |
ISO |
Cholesterol results in increased expression of PSAT1 mRNA |
CTD |
PMID:26296894 |
|
NCBI chr 1:213,196,709...213,218,564
Ensembl chr 1:213,196,709...213,218,682
|
|
G |
Psrc1 |
proline and serine rich coiled-coil 1 |
multiple interactions |
ISO |
[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of PSRC1 mRNA |
CTD |
PMID:22129739 |
|
NCBI chr 2:196,022,361...196,026,874
Ensembl chr 2:196,022,361...196,026,874
|
|
G |
Pycard |
PYD and CARD domain containing |
increases expression affects localization multiple interactions |
EXP ISO |
Cholesterol analog results in increased expression of PYCARD mRNA Cholesterol analog affects the localization of PYCARD protein [Cholesterol co-treated with Ergosterol] results in increased expression of PYCARD mRNA; [Cholesterol co-treated with Ergosterol] results in increased expression of PYCARD protein; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of PYCARD mRNA]; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of PYCARD protein] [Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of PYCARD mRNA; Amitriptyline inhibits the reaction [Cholesterol analog affects the localization of PYCARD protein]; SMPD1 protein affects the reaction [Cholesterol analog affects the localization of PYCARD protein] |
CTD |
PMID:19477266 PMID:22129739 PMID:25833014 PMID:28633109 |
|
NCBI chr 1:182,601,657...182,603,013
Ensembl chr 1:182,601,174...182,602,955
|
|
G |
Rac1 |
Rac family small GTPase 1 |
multiple interactions increases expression |
ISO |
Cholesterol inhibits the reaction [Simvastatin affects the localization of and results in decreased activity of RAC1 protein] Cholesterol results in increased expression of RAC1 mRNA; Cholesterol results in increased expression of RAC1 protein Cholesterol inhibits the reaction [irbesartan results in increased expression of RAC1 mRNA] |
CTD |
PMID:19028402 PMID:21334995 |
|
NCBI chr12:11,037,028...11,057,251
Ensembl chr12:11,036,698...11,057,251
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions increases expression |
ISO EXP |
Cholesterol inhibits the reaction [irbesartan results in increased expression of RELA protein] [Cholesterol co-treated with Ergosterol] results in increased expression of RELA mRNA; [Cholesterol co-treated with Ergosterol] results in increased expression of RELA protein; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of RELA mRNA]; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of RELA protein] [methyl-beta-cyclodextrin results in decreased abundance of Cholesterol] inhibits the reaction [Polystyrenes inhibits the reaction [TNF protein affects the localization of RELA protein]] Cholesterol results in increased expression of RELA protein |
CTD |
PMID:19028402 PMID:23274767 PMID:25833014 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rgcc |
regulator of cell cycle |
increases expression |
ISO |
Cholesterol results in increased expression of RGCC mRNA |
CTD |
PMID:26296894 |
|
NCBI chr15:54,662,483...54,675,320
Ensembl chr15:54,662,483...54,681,141
|
|
G |
Rgs2 |
regulator of G-protein signaling 2 |
increases degradation |
ISO |
Cholesterol results in increased degradation of RGS2 protein |
CTD |
PMID:30545937 |
|
NCBI chr13:55,799,749...55,802,354
Ensembl chr13:55,798,829...55,802,385
|
|
G |
Ripk2 |
receptor-interacting serine-threonine kinase 2 |
multiple interactions increases expression |
EXP |
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Cholesterol analog results in increased expression of RIPK2 mRNA]; Acetylcysteine inhibits the reaction [Cholesterol analog results in increased expression of RIPK2 mRNA] |
CTD |
PMID:19477266 |
|
NCBI chr 5:29,630,806...29,662,804
Ensembl chr 5:29,631,570...29,662,657
|
|
G |
Rps21-ps1 |
ribosomal protein S21, pseudogene 1 |
multiple interactions |
ISO |
[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of RPS21 mRNA |
CTD |
PMID:22129739 |
|
NCBI chr 5:153,387,133...153,387,476
Ensembl chr 5:153,387,176...153,387,427
|
|
G |
Rps6 |
ribosomal protein S6 |
multiple interactions increases phosphorylation |
ISO |
CYP7A1 mRNA inhibits the reaction [Cholesterol results in increased phosphorylation of RPS6 protein] Cholesterol inhibits the reaction [Nicotine results in increased phosphorylation of RPS6 protein] |
CTD |
PMID:28275691 PMID:31629012 |
|
NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602 Ensembl chr 5:101,371,136...101,374,602
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
multiple interactions increases phosphorylation |
ISO |
Trehalose inhibits the reaction [Cholesterol inhibits the reaction [Cadmium Chloride results in increased cleavage of RPS6KB1 protein]]; Trehalose inhibits the reaction [Cholesterol results in increased phosphorylation of RPS6KB1 protein] |
CTD |
PMID:29486218 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Rptor |
regulatory associated protein of MTOR, complex 1 |
increases expression |
ISO |
Cholesterol results in increased expression of RPTOR protein |
CTD |
PMID:29486218 |
|
NCBI chr10:104,878,487...105,176,986
Ensembl chr10:104,878,487...105,176,983
|
|
G |
Rxra |
retinoid X receptor alpha |
multiple interactions |
ISO |
Cholesterol inhibits the reaction [cerivastatin promotes the reaction [Bezafibrate results in increased activity of [PPARA protein binds to RXRA protein]]] |
CTD |
PMID:11779144 |
|
NCBI chr 3:10,989,832...11,076,366
Ensembl chr 3:10,989,832...11,073,712
|
|
G |
Rxrb |
retinoid X receptor beta |
multiple interactions |
ISO |
[RXRB protein binds to NR1H2 protein] which affects the metabolism of Cholesterol |
CTD |
PMID:14993927 |
|
NCBI chr20:4,816,813...4,823,267
Ensembl chr20:4,816,815...4,828,773
|
|
G |
S100a8 |
S100 calcium binding protein A8 |
multiple interactions |
EXP |
[cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of S100A8 mRNA |
CTD |
PMID:26606054 |
|
NCBI chr 2:176,166,517...176,167,645
Ensembl chr 2:176,167,124...176,167,643
|
|
G |
Scarb1 |
scavenger receptor class B, member 1 |
multiple interactions affects transport |
ISO |
[Dietary Fats co-treated with Cholesterol] results in decreased expression of SCARB1 mRNA; Losartan inhibits the reaction [[Dietary Fats co-treated with Cholesterol] results in decreased expression of SCARB1 mRNA] SCARB1 protein affects the transport of Cholesterol |
CTD |
PMID:18302760 PMID:26651060 |
|
NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647
|
|
G |
Scd |
stearoyl-CoA desaturase |
increases expression multiple interactions |
ISO |
Cholesterol results in increased expression of SCD1 mRNA [lard co-treated with Cholesterol co-treated with Sucrose co-treated with Atrazine] results in increased expression of SCD1 mRNA; [lard co-treated with Cholesterol co-treated with Sucrose co-treated with cypermethrin] results in increased expression of SCD1 mRNA Cholesterol inhibits the reaction [FGF7 protein results in increased expression of SCD mRNA] |
CTD |
PMID:16162944 PMID:19260826 PMID:24440342 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Shisa5 |
shisa family member 5 |
multiple interactions |
ISO |
[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of SHISA5 mRNA |
CTD |
PMID:22129739 |
|
NCBI chr 8:109,691,504...109,706,411
Ensembl chr 8:109,691,522...109,706,408
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions |
EXP ISO |
[6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased abundance of Cholesterol]; [Cholesterol co-treated with Ergosterol] results in decreased expression of SIRT1 mRNA; [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased abundance of Cholesterol]; Resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in decreased expression of SIRT1 mRNA] [Dietary Fats co-treated with bisphenol A co-treated with Cholesterol] results in decreased expression of SIRT1 protein; Resveratrol inhibits the reaction [[Dietary Fats co-treated with bisphenol A co-treated with Cholesterol] results in decreased expression of SIRT1 protein] |
CTD |
PMID:21212096 PMID:25833014 PMID:33239236 |
|
NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Slc1a3 |
solute carrier family 1 member 3 |
increases expression |
ISO |
Cholesterol results in increased expression of SLC1A3 mRNA |
CTD |
PMID:26296894 |
|
NCBI chr 2:57,755,495...57,830,605
Ensembl chr 2:57,755,497...57,830,605
|
|
G |
Slc28a3 |
solute carrier family 28 member 3 |
increases expression |
ISO |
Cholesterol results in increased expression of SLC28A3 mRNA |
CTD |
PMID:26296894 |
|
NCBI chr17:6,062,563...6,112,965
Ensembl chr17:6,062,549...6,114,038
|
|
G |
Slc2a2 |
solute carrier family 2 member 2 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of SLC2A2 mRNA; Atrazine promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of SLC2A2 mRNA]; cypermethrin promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of SLC2A2 mRNA]; Ethinyl Estradiol promotes the reaction [[lard co-treated with Cholesterol co-treated with Sucrose] results in increased expression of SLC2A2 mRNA] |
CTD |
PMID:24440342 |
|
NCBI chr 2:111,609,798...111,639,930
Ensembl chr 2:111,611,774...111,639,933
|
|
G |
Slc4a1 |
solute carrier family 4 member 1 (Diego blood group) |
multiple interactions |
EXP |
[Hydrogen Peroxide co-treated with Cholesterol] affects the localization of SLC4A1 protein; benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [[Hydrogen Peroxide co-treated with Cholesterol] affects the localization of SLC4A1 protein] |
CTD |
PMID:20946910 |
|
NCBI chr10:87,306,865...87,323,132
Ensembl chr10:87,306,872...87,323,117
|
|
G |
Slc7a5 |
solute carrier family 7 member 5 |
increases expression |
ISO |
Cholesterol results in increased expression of SLC7A5 mRNA |
CTD |
PMID:26296894 |
|
NCBI chr19:49,935,220...49,963,823
Ensembl chr19:49,935,220...49,963,823
|
|
G |
Smad3 |
SMAD family member 3 |
multiple interactions |
ISO |
[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of SMAD3 mRNA |
CTD |
PMID:22129739 |
|
NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960
|
|
G |
Smpd1 |
sphingomyelin phosphodiesterase 1 |
multiple interactions |
ISO |
SMPD1 protein affects the reaction [Cholesterol analog affects the localization of CASP1 protein]; SMPD1 protein affects the reaction [Cholesterol analog affects the localization of NLRP3 protein]; SMPD1 protein affects the reaction [Cholesterol analog affects the localization of PYCARD protein]; SMPD1 protein affects the reaction [Cholesterol analog results in increased activity of CASP1 protein]; SMPD1 protein affects the reaction [Cholesterol analog results in increased expression of IL1B protein] |
CTD |
PMID:28633109 |
|
NCBI chr 1:159,892,946...159,896,789
Ensembl chr 1:159,892,859...159,896,794
|
|
G |
Smpd3 |
sphingomyelin phosphodiesterase 3 |
multiple interactions |
ISO |
[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of SMPD3 mRNA |
CTD |
PMID:22129739 |
|
NCBI chr19:34,162,337...34,245,786
Ensembl chr19:34,162,341...34,245,749
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
ISO |
[[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] affects the expression of SOD2 mRNA; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the expression of SOD2 mRNA; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds affects the expression of SOD2 mRNA] |
CTD |
PMID:35385781 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sort1 |
sortilin 1 |
decreases abundance multiple interactions |
ISO |
SORT1 protein results in decreased abundance of Cholesterol Chloroquine affects the reaction [SORT1 protein affects the reaction [LDLR protein affects the abundance of Cholesterol]]; SORT1 protein affects the reaction [LDLR protein affects the abundance of Cholesterol] |
CTD |
PMID:25805502 PMID:30950489 |
|
NCBI chr 2:195,924,033...196,002,354
Ensembl chr 2:195,924,099...196,002,354
|
|
G |
Spmip11 |
sperm microtubule inner protein 11 |
multiple interactions |
EXP |
[cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in decreased expression of NPHS1 mRNA |
CTD |
PMID:26606054 |
|
NCBI chr 7:129,720,950...129,742,485
Ensembl chr 7:129,720,950...129,742,485
|
|
G |
Sqle |
squalene epoxidase |
increases degradation multiple interactions |
ISO |
Cholesterol results in increased degradation of SQLE protein Cholesterol inhibits the reaction [Hydroxymethylglutaryl-CoA Reductase Inhibitors results in decreased degradation of SQLE protein]; MARCHF6 promotes the reaction [Cholesterol results in increased degradation of SQLE protein] |
CTD |
PMID:30545937 |
|
NCBI chr 7:90,867,973...90,883,623
Ensembl chr 7:90,868,011...90,883,618
|
|
G |
Sqstm1 |
sequestosome 1 |
increases expression multiple interactions |
ISO |
Cholesterol results in increased expression of SQSTM1 protein Cholesterol inhibits the reaction [Cadmium Chloride results in decreased expression of SQSTM1 protein] |
CTD |
PMID:28275691 PMID:29486218 |
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
multiple interactions |
ISO |
SRC protein promotes the reaction [[FGF19 protein results in increased phosphorylation of NR1H4 protein] which results in increased export of Cholesterol] |
CTD |
PMID:30996006 |
|
NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
ISO |
[lard co-treated with Cholesterol co-treated with Sucrose co-treated with Atrazine] results in increased expression of SREBF1 mRNA; [lard co-treated with Cholesterol co-treated with Sucrose co-treated with Ethinyl Estradiol] results in increased expression of SREBF1 mRNA [25-hydroxycholesterol co-treated with Cholesterol] results in decreased cleavage of SREBF1 protein |
CTD |
PMID:24440342 PMID:27324795 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Srebf2 |
sterol regulatory element binding transcription factor 2 |
multiple interactions increases abundance |
ISO EXP |
[25-hydroxycholesterol co-treated with Cholesterol] results in decreased cleavage of SREBF2 protein; [[Troglitazone binds to and results in increased activity of PPARG protein] which results in decreased expression of SREBF2 protein] which results in decreased abundance of Cholesterol; betadex inhibits the reaction [SREBF2 protein results in increased abundance of Cholesterol]; SREBF2 promotes the reaction [bisphenol A results in increased import of Cholesterol]; SREBF2 protein affects the reaction [Lipopolysaccharides results in increased abundance of Cholesterol] [Cholesterol deficiency co-treated with Lovastatin] results in increased activity of SREBF2 protein; Cholesterol inhibits the reaction [[Cholesterol deficiency co-treated with Lovastatin] results in increased activity of SREBF2 protein] |
CTD |
PMID:16946405 PMID:20578043 PMID:27324795 PMID:28057006 PMID:33677747 |
|
NCBI chr 7:113,663,202...113,720,850
Ensembl chr 7:113,663,202...113,720,848
|
|
G |
Star |
steroidogenic acute regulatory protein |
affects transport increases transport increases export multiple interactions |
ISO EXP |
STAR protein affects the transport of Cholesterol STAR protein results in increased transport of Cholesterol STAR protein results in increased export of Cholesterol [[Niacin co-treated with Chromium] results in increased expression of STAR protein] which results in increased export of Cholesterol; Cholesterol inhibits the reaction [bisphenol A results in increased expression of STAR mRNA]; Cholesterol inhibits the reaction [bisphenol A results in increased expression of STAR protein] 27-hydroxycholesterol promotes the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]; Probucol inhibits the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]; STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol] |
CTD |
PMID:14630719 PMID:15819722 PMID:17934701 PMID:19900470 PMID:20083572 PMID:28859904 More...
|
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
increases expression |
ISO |
Cholesterol results in increased expression of STAT1 protein |
CTD |
PMID:17507688 |
|
NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540
|
|
G |
Stat5a |
signal transducer and activator of transcription 5A |
multiple interactions |
ISO |
Cholesterol inhibits the reaction [Nicotine results in decreased phosphorylation of STAT5 protein] |
CTD |
PMID:31629012 |
|
NCBI chr10:85,785,537...85,809,869
Ensembl chr10:85,785,537...85,809,866
|
|
G |
Sv2a |
synaptic vesicle glycoprotein 2a |
multiple interactions |
ISO |
[methyl-beta-cyclodextrin results in decreased abundance of Cholesterol] promotes the reaction [SV2A protein binds to Botulinum Toxins, Type A] |
CTD |
PMID:28645175 |
|
NCBI chr 2:183,741,489...183,757,290
Ensembl chr 2:183,741,547...183,756,927
|
|
G |
Synpo |
synaptopodin |
multiple interactions |
ISO |
[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of SYNPO mRNA |
CTD |
PMID:22129739 |
|
NCBI chr18:54,048,299...54,106,388
Ensembl chr18:54,026,152...54,102,126
|
|
G |
Tafa2 |
TAFA chemokine like family member 2 |
multiple interactions |
ISO |
[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of TAFA2 mRNA |
CTD |
PMID:22129739 |
|
NCBI chr 7:58,942,598...59,418,640
Ensembl chr 7:58,942,610...59,417,299
|
|
G |
Tfap2e |
transcription factor AP-2 epsilon |
multiple interactions |
ISO |
[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of TFAP2E mRNA |
CTD |
PMID:22129739 |
|
NCBI chr 5:139,009,447...139,030,695
Ensembl chr 5:139,009,453...139,031,108
|
|
G |
Tff3 |
trefoil factor 3 |
multiple interactions |
ISO |
[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of TFF3 mRNA |
CTD |
PMID:22129739 |
|
NCBI chr20:9,193,259...9,197,969
Ensembl chr20:9,193,262...9,198,054
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
increases expression multiple interactions |
ISO EXP |
Cholesterol results in increased expression of TGFB1 mRNA [cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of TGFB1 mRNA |
CTD |
PMID:19110552 PMID:26606054 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Timp3 |
TIMP metallopeptidase inhibitor 3 |
multiple interactions increases expression |
ISO |
CLEC4E protein inhibits the reaction [Cholesterol results in increased expression of TIMP3 mRNA] |
CTD |
PMID:26296894 |
|
NCBI chr 7:17,520,827...17,571,850
Ensembl chr 7:17,521,919...17,571,839
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
EXP |
[cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of TLR4 mRNA |
CTD |
PMID:26606054 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tm4sf19 |
transmembrane 4 L six family member 19 |
increases expression |
ISO |
Cholesterol results in increased expression of TM4SF19 mRNA |
CTD |
PMID:26296894 |
|
NCBI chr11:68,372,945...68,386,192
Ensembl chr11:68,371,647...68,384,591
|
|
G |
Tmem97 |
transmembrane protein 97 |
affects metabolic processing |
ISO |
TMEM97 protein affects the metabolism of Cholesterol |
CTD |
PMID:18070364 |
|
NCBI chr10:63,438,228...63,447,311
Ensembl chr10:63,438,222...63,589,730
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases expression |
ISO EXP |
[Dietary Fats co-treated with bisphenol A co-treated with Cholesterol] results in increased secretion of TNF protein; Cholesterol inhibits the reaction [Irbesartan results in increased expression of TNF mRNA]; Cholesterol inhibits the reaction [Irbesartan results in increased expression of TNF protein] [Cholesterol co-treated with CLEC4E] results in increased expression of TNF protein; [methyl-beta-cyclodextrin results in decreased abundance of Cholesterol] inhibits the reaction [Polystyrenes inhibits the reaction [TNF protein affects the localization of RELA protein]]; [methyl-beta-cyclodextrin results in decreased abundance of Cholesterol] inhibits the reaction [Polystyrenes inhibits the reaction [TNF protein results in increased expression of CXCL8 mRNA]] Cholesterol analog results in increased expression of TNF mRNA [Cholesterol co-treated with Particulate Matter] results in increased expression of TNF mRNA; [cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of TNF mRNA; Acetylcysteine inhibits the reaction [Cholesterol analog results in increased expression of TNF mRNA]; alpha-Linolenic Acid inhibits the reaction [Cholesterol promotes the reaction [Particulate Matter results in increased expression of TNF protein]]; Cholesterol promotes the reaction [Particulate Matter results in increased expression of TNF protein] Cholesterol results in increased expression of TNF mRNA; Cholesterol results in increased expression of TNF protein |
CTD |
PMID:19028402 PMID:19477266 PMID:23274767 PMID:26296894 PMID:26606054 PMID:30672636 PMID:33239236 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf1a |
TNF receptor superfamily member 1A |
increases expression |
EXP |
Cholesterol analog results in increased expression of TNFRSF1A protein |
CTD |
PMID:19477266 |
|
NCBI chr 4:158,150,815...158,163,592
Ensembl chr 4:158,150,820...158,163,591
|
|
G |
Tnfsf10 |
TNF superfamily member 10 |
increases expression |
EXP |
Cholesterol analog results in increased expression of TNFSF10 mRNA; Cholesterol analog results in increased expression of TNFSF10 protein |
CTD |
PMID:19477266 |
|
NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
[[[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] co-treated with Silver Compounds] results in decreased expression of TP53 mRNA; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] affects the reaction [Silver Compounds affects the expression of TP53 mRNA]; [[EGF protein binds to 1,2-dioleoyl-3-phosphoethanolamine-n-(poly(ethyleneglycol))-hydroxy succinamide] co-treated with [1,2-distearoyllecithin co-treated with Cholesterol co-treated with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy-poly(ethylene glycol 2000)]] results in increased expression of TP53 mRNA |
CTD |
PMID:35385781 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Traf1 |
TNF receptor-associated factor 1 |
increases expression |
EXP |
Cholesterol analog results in increased expression of TRAF1 mRNA |
CTD |
PMID:19477266 |
|
NCBI chr 3:18,222,024...18,242,163
Ensembl chr 3:18,222,054...18,241,807
|
|
G |
Trib3 |
tribbles pseudokinase 3 |
multiple interactions |
ISO |
TRIB3 protein results in increased abundance of and results in increased secretion of Cholesterol |
CTD |
PMID:32929351 |
|
NCBI chr 3:140,809,634...140,815,230
Ensembl chr 3:140,809,043...140,814,497
|
|
G |
Ubd |
ubiquitin D |
multiple interactions |
ISO |
[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of UBD mRNA |
CTD |
PMID:22129739 |
|
NCBI chr20:1,385,487...1,387,438
Ensembl chr20:1,385,864...1,408,639 Ensembl chr20:1,385,864...1,408,639
|
|
G |
Ube2i |
ubiquitin-conjugating enzyme E2I |
multiple interactions |
ISO |
UBE2I protein inhibits the reaction [Lipopolysaccharides results in increased abundance of Cholesterol] |
CTD |
PMID:33677747 |
|
NCBI chr10:14,277,749...14,294,681
Ensembl chr10:69,701,618...69,702,443 Ensembl chr10:69,701,618...69,702,443
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
increases expression multiple interactions |
ISO EXP |
Cholesterol results in increased expression of VCAM1 mRNA; Cholesterol results in increased expression of VCAM1 protein [cocoa butter co-treated with Sodium Cholate co-treated with Cholesterol] results in increased expression of VCAM1 mRNA Cholesterol inhibits the reaction [irbesartan results in increased expression of VCAM1 mRNA]; Cholesterol inhibits the reaction [irbesartan results in increased expression of VCAM1 protein] |
CTD |
PMID:19028402 PMID:26606054 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
G |
Vdr |
vitamin D receptor |
affects binding affects abundance |
ISO |
Cholesterol metabolite binds to VDR protein VDR gene SNP affects the abundance of Cholesterol |
CTD |
PMID:16051528 PMID:25498546 |
|
NCBI chr 7:128,987,981...129,037,677
Ensembl chr 7:128,987,981...129,037,677
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
EXP |
[1,2-dioleoyloxy-3-(trimethylammonium)propane co-treated with Cholesterol] results in increased expression of VEGFA protein |
CTD |
PMID:16034455 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vim |
vimentin |
multiple interactions |
ISO |
Cholesterol inhibits the reaction [arachidonyl dopamine results in decreased expression of VIM mRNA] |
CTD |
PMID:33393692 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
G |
Vwf |
von Willebrand factor |
multiple interactions |
EXP |
[Cholesterol co-treated with Ergosterol] results in increased expression of and results in increased secretion of VWF protein; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of and results in increased secretion of VWF protein] |
CTD |
PMID:25833014 |
|
NCBI chr 4:158,360,152...158,491,539
Ensembl chr 4:158,360,152...158,491,539
|
|
G |
Zbp1 |
Z-DNA binding protein 1 |
multiple interactions |
ISO |
[Cholesterol co-treated with 1,2-dioleoyloxy-3-(trimethylammonium)propane] results in increased expression of ZBP1 mRNA |
CTD |
PMID:22129739 |
|
NCBI chr 3:161,993,351...162,009,297
Ensembl chr 3:161,993,351...162,003,870
|
|
G |
Zeb1 |
zinc finger E-box binding homeobox 1 |
multiple interactions |
ISO |
Cholesterol inhibits the reaction [arachidonyl dopamine results in decreased expression of ZEB1 mRNA] |
CTD |
PMID:33393692 |
|
NCBI chr17:51,948,948...52,116,018
Ensembl chr17:51,948,948...52,115,214
|
|
G |
Zeb2 |
zinc finger E-box binding homeobox 2 |
multiple interactions |
ISO |
Cholesterol inhibits the reaction [arachidonyl dopamine results in decreased expression of ZEB2 mRNA] |
CTD |
PMID:33393692 |
|
NCBI chr 3:29,214,581...29,344,890
Ensembl chr 3:29,218,301...29,345,157
|
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
decreases expression |
ISO |
cholesteryl sulfate results in decreased expression of CYP11A1 mRNA |
CTD |
PMID:18490834 |
|
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Star |
steroidogenic acute regulatory protein |
decreases expression |
ISO |
cholesteryl sulfate results in decreased expression of STAR mRNA; cholesteryl sulfate results in decreased expression of STAR protein |
CTD |
PMID:18490834 |
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Sult2b1 |
sulfotransferase family 2B member 1 |
increases abundance |
ISO |
SULT2B1 protein results in increased abundance of cholesteryl sulfate |
CTD |
PMID:27052460 |
|
NCBI chr 1:96,200,155...96,261,295
Ensembl chr 1:96,200,156...96,261,295
|
|
|
G |
Lipc |
lipase C, hepatic type |
multiple interactions |
ISO |
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl arachidonate |
CTD |
PMID:24777581 |
|
NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464
|
|
G |
Lipg |
lipase G, endothelial type |
multiple interactions decreases abundance |
ISO |
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl arachidonate LIPG gene mutant form results in decreased abundance of cholesteryl arachidonate |
CTD |
PMID:24777581 |
|
NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260
|
|
|
G |
Lipc |
lipase C, hepatic type |
multiple interactions |
ISO |
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl linoleate |
CTD |
PMID:24777581 |
|
NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464
|
|
G |
Lipg |
lipase G, endothelial type |
multiple interactions affects abundance |
ISO |
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl linoleate LIPG gene mutant form affects the abundance of cholesteryl linoleate |
CTD |
PMID:24777581 |
|
NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260
|
|
|
G |
Lipc |
lipase C, hepatic type |
multiple interactions |
ISO |
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl linolenate |
CTD |
PMID:24777581 |
|
NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464
|
|
G |
Lipg |
lipase G, endothelial type |
multiple interactions increases abundance |
ISO |
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl linolenate LIPG gene mutant form results in increased abundance of cholesteryl linolenate |
CTD |
PMID:24777581 |
|
NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260
|
|
|
G |
Lipc |
lipase C, hepatic type |
multiple interactions |
ISO |
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl myristate |
CTD |
PMID:24777581 |
|
NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464
|
|
G |
Lipg |
lipase G, endothelial type |
affects abundance multiple interactions |
ISO |
LIPG gene mutant form affects the abundance of cholesteryl myristate [LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl myristate |
CTD |
PMID:24777581 |
|
NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260
|
|
|
G |
Lipc |
lipase C, hepatic type |
multiple interactions |
ISO |
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl oleate |
CTD |
PMID:24777581 |
|
NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464
|
|
G |
Lipg |
lipase G, endothelial type |
multiple interactions increases abundance |
ISO |
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl oleate LIPG gene mutant form results in increased abundance of cholesteryl oleate |
CTD |
PMID:24777581 |
|
NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260
|
|
|
G |
Lipc |
lipase C, hepatic type |
multiple interactions |
ISO |
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl palmitate |
CTD |
PMID:24777581 |
|
NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464
|
|
G |
Lipg |
lipase G, endothelial type |
multiple interactions increases abundance |
ISO |
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl palmitate LIPG gene mutant form results in increased abundance of cholesteryl palmitate |
CTD |
PMID:24777581 |
|
NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260
|
|
|
G |
Lipg |
lipase G, endothelial type |
decreases abundance |
ISO |
LIPG gene mutant form results in decreased abundance of cholesterol stearate |
CTD |
PMID:24777581 |
|
NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260
|
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
cycloartenol inhibits the reaction [Benzoyl Peroxide results in decreased activity of CAT protein] |
CTD |
PMID:12804013 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cryz |
crystallin zeta |
multiple interactions |
ISO |
cycloartenol inhibits the reaction [Benzoyl Peroxide results in decreased activity of CRYZ protein] |
CTD |
PMID:12804013 |
|
NCBI chr 2:243,552,037...243,580,369
Ensembl chr 2:243,552,119...243,579,758
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
multiple interactions |
ISO |
cycloartenol inhibits the reaction [Benzoyl Peroxide results in decreased activity of G6PD protein] |
CTD |
PMID:12804013 |
|
NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
ISO |
cycloartenol inhibits the reaction [Benzoyl Peroxide results in decreased activity of GSR protein] |
CTD |
PMID:12804013 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Odc1 |
ornithine decarboxylase 1 |
multiple interactions |
ISO |
cycloartenol inhibits the reaction [Benzoyl Peroxide results in increased activity of ODC1 protein] |
CTD |
PMID:12804013 |
|
NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440
|
|
G |
Xdh |
xanthine dehydrogenase |
multiple interactions |
ISO |
cycloartenol inhibits the reaction [Benzoyl Peroxide results in increased activity of XDH protein] |
CTD |
PMID:12804013 |
|
NCBI chr 6:21,530,463...21,592,172
Ensembl chr 6:21,530,113...21,592,268
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
increases expression |
ISO |
Desmosterol results in increased expression of ABCA1 mRNA |
CTD |
PMID:19260826 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Clec4e |
C-type lectin domain family 4, member E |
increases activity |
ISO |
Desmosterol results in increased activity of CLEC4E protein |
CTD |
PMID:26296894 |
|
NCBI chr 4:156,606,927...156,612,911
Ensembl chr 4:156,607,614...156,612,767
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
increases metabolic processing |
ISO |
CYP27A1 protein results in increased metabolism of Desmosterol |
CTD |
PMID:14622972 |
|
NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551
|
|
G |
Dhcr24 |
24-dehydrocholesterol reductase |
increases metabolic processing multiple interactions |
ISO |
DHCR24 protein results in increased metabolism of Desmosterol [DHCR24 protein results in increased metabolism of Desmosterol] which results in increased abundance of Cholesterol |
CTD |
PMID:23042211 |
|
NCBI chr 5:121,344,552...121,371,124
Ensembl chr 5:121,344,575...121,371,137
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
decreases expression |
ISO |
Desmosterol results in decreased expression of HMGCR protein |
CTD |
PMID:19260826 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
[1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of Desmosterol analog; [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased abundance of Desmosterol analog |
CTD |
PMID:26820058 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Insig1 |
insulin induced gene 1 |
decreases expression |
ISO |
Desmosterol results in decreased expression of INSIG1 protein |
CTD |
PMID:19260826 |
|
NCBI chr 4:7,315,494...7,323,972
Ensembl chr 4:7,315,495...7,323,952
|
|
G |
Ldlr |
low density lipoprotein receptor |
decreases expression |
ISO |
Desmosterol results in decreased expression of LDLR protein |
CTD |
PMID:19260826 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Marchf6 |
membrane associated ring-CH-type finger 6 |
increases stability |
ISO |
Desmosterol results in increased stability of MARCHF6 protein |
CTD |
PMID:30545937 |
|
NCBI chr 2:82,455,686...82,532,917
Ensembl chr 2:82,455,689...82,532,910
|
|
G |
Scd |
stearoyl-CoA desaturase |
increases expression |
ISO |
Desmosterol results in increased expression of SCD1 mRNA |
CTD |
PMID:19260826 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
increases expression |
ISO |
Desmosterol results in increased expression of SREBF1 mRNA; Desmosterol results in increased expression of SREBF1 protein |
CTD |
PMID:19260826 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases transport |
ISO |
ABCB1 protein results in increased transport of Digoxigenin |
CTD |
PMID:26708294 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases expression |
ISO |
Digoxigenin results in decreased expression of CCL2 protein |
CTD |
PMID:20116850 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
decreases expression |
ISO |
Digoxigenin results in decreased expression of CCL4 protein |
CTD |
PMID:20116850 |
|
NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions increases expression |
ISO |
Digoxigenin promotes the reaction [RORC protein binds to G6PC1 promoter] Digoxigenin results in increased expression of G6PC1 mRNA |
CTD |
PMID:29981919 |
|
NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
|
|
G |
Il17a |
interleukin 17A |
multiple interactions |
ISO |
Digoxigenin results in increased expression of and results in increased secretion of IL17A protein |
CTD |
PMID:29981919 |
|
NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889
|
|
G |
Il17f |
interleukin 17F |
multiple interactions |
ISO |
Digoxigenin results in increased expression of and results in increased secretion of IL17F protein |
CTD |
PMID:29981919 |
|
NCBI chr 9:23,190,094...23,201,482
Ensembl chr 9:23,190,100...23,201,482
|
|
G |
Il6r |
interleukin 6 receptor |
decreases expression |
ISO |
Digoxigenin results in decreased expression of IL6R protein modified form |
CTD |
PMID:20116850 |
|
NCBI chr 2:175,289,157...175,347,719
Ensembl chr 2:175,298,686...175,347,536
|
|
G |
Npas2 |
neuronal PAS domain protein 2 |
increases expression multiple interactions |
ISO |
Digoxigenin results in increased expression of NPAS2 mRNA Digoxigenin promotes the reaction [RORC protein binds to NPAS2 promoter] |
CTD |
PMID:29981919 |
|
NCBI chr 9:41,463,361...41,642,322
Ensembl chr 9:41,463,830...41,642,320
|
|
G |
Rorc |
RAR-related orphan receptor C |
increases expression multiple interactions |
ISO |
Digoxigenin results in increased expression of RORC mRNA Digoxigenin promotes the reaction [RORC protein binds to G6PC1 promoter]; Digoxigenin promotes the reaction [RORC protein binds to NPAS2 promoter]; RORC protein promotes the reaction [Digoxigenin results in increased expression of RORC mRNA] |
CTD |
PMID:29981919 |
|
NCBI chr 2:182,009,707...182,034,910
Ensembl chr 2:182,009,286...182,034,907
|
|
G |
Vegfa |
vascular endothelial growth factor A |
decreases expression |
ISO |
Digoxigenin results in decreased expression of VEGFA protein |
CTD |
PMID:20116850 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions |
EXP |
dioscin promotes the reaction [1-Naphthylisothiocyanate results in increased expression of ABCB11 mRNA]; dioscin promotes the reaction [1-Naphthylisothiocyanate results in increased expression of ABCB11 protein] |
CTD |
PMID:27317372 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
decreases expression |
ISO EXP |
dioscin results in decreased expression of ABCB1 mRNA; dioscin results in decreased expression of ABCB1 protein |
CTD |
PMID:24680847 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions |
EXP |
dioscin promotes the reaction [1-Naphthylisothiocyanate results in increased expression of ABCC2 mRNA]; dioscin promotes the reaction [1-Naphthylisothiocyanate results in increased expression of ABCC2 protein] |
CTD |
PMID:27317372 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Acadm |
acyl-CoA dehydrogenase medium chain |
multiple interactions |
EXP ISO |
dioscin inhibits the reaction [Ethanol results in decreased expression of ACADM protein] |
CTD |
PMID:24146112 |
|
NCBI chr 2:242,858,865...242,883,036
Ensembl chr 2:242,858,865...242,883,147
|
|
G |
Acads |
acyl-CoA dehydrogenase short chain |
multiple interactions |
ISO EXP |
dioscin inhibits the reaction [Ethanol results in decreased expression of ACADS protein] |
CTD |
PMID:24146112 |
|
NCBI chr12:41,493,650...41,502,897
Ensembl chr12:41,493,626...41,502,898
|
|
G |
Acox1 |
acyl-CoA oxidase 1 |
multiple interactions |
EXP ISO |
dioscin inhibits the reaction [Ethanol results in decreased expression of ACOX1 mRNA] |
CTD |
PMID:24146112 |
|
NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232
|
|
G |
Acsl1 |
acyl-CoA synthetase long-chain family member 1 |
multiple interactions |
ISO EXP |
dioscin inhibits the reaction [Ethanol results in decreased expression of ACSL1 protein] |
CTD |
PMID:24146112 |
|
NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541
|
|
G |
Acsl5 |
acyl-CoA synthetase long-chain family member 5 |
multiple interactions |
ISO EXP |
dioscin inhibits the reaction [Ethanol results in decreased expression of ACSL5 protein] |
CTD |
PMID:24146112 |
|
NCBI chr 1:254,289,513...254,336,608
Ensembl chr 1:254,292,521...254,336,607
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO |
dioscin inhibits the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of ACTA2 protein] |
CTD |
PMID:35481609 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions decreases expression |
ISO |
dioscin inhibits the reaction [TGFB1 protein results in increased phosphorylation of AKT1 protein]; dioscin inhibits the reaction [VEGFA protein results in increased phosphorylation of AKT1 protein] dioscin inhibits the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased phosphorylation of AKT1 protein] dioscin results in decreased expression of AKT1 mRNA |
CTD |
PMID:25111127 PMID:29990575 PMID:35481609 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Aldh7a1 |
aldehyde dehydrogenase 7 family, member A1 |
multiple interactions |
ISO EXP |
dioscin inhibits the reaction [Ethanol results in decreased expression of ALDH7A1 protein] |
CTD |
PMID:24146112 |
|
NCBI chr18:50,003,242...50,042,193
Ensembl chr18:50,009,934...50,042,193
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
decreases expression |
ISO |
dioscin results in decreased expression of APAF1 mRNA |
CTD |
PMID:33359023 |
|
NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540
|
|
G |
Atf6 |
activating transcription factor 6 |
multiple interactions |
EXP ISO |
dioscin inhibits the reaction [Ethanol results in increased expression of ATF6 protein] |
CTD |
PMID:24146112 |
|
NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177
|
|
G |
Bad |
BCL2-associated agonist of cell death |
increases expression |
ISO |
dioscin results in increased expression of BAD mRNA |
CTD |
PMID:33359023 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
multiple interactions increases expression |
ISO |
dioscin inhibits the reaction [Acetaminophen results in increased expression of BAK1 protein] dioscin results in increased expression of BAK1 mRNA; dioscin results in increased expression of BAK1 protein |
CTD |
PMID:22334414 PMID:22939915 PMID:29990575 PMID:33359023 |
|
NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
ISO |
dioscin inhibits the reaction [Acetaminophen results in increased expression of BAX protein] dioscin results in increased expression of BAX mRNA; dioscin results in increased expression of BAX protein |
CTD |
PMID:22334414 PMID:22939915 PMID:33359023 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
increases expression |
ISO |
dioscin results in increased expression of BBC3 mRNA; dioscin results in increased expression of BBC3 protein |
CTD |
PMID:29990575 PMID:33359023 |
|
NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions increases expression decreases expression |
ISO |
dioscin inhibits the reaction [Acetaminophen results in decreased expression of BCL2 protein] dioscin results in increased expression of BCL2 protein dioscin results in decreased expression of BCL2 mRNA; dioscin results in decreased expression of BCL2 protein |
CTD |
PMID:22334414 PMID:22939915 PMID:24742230 PMID:29990575 PMID:33359023 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
decreases expression |
ISO |
dioscin results in decreased expression of BCL2L1 mRNA; dioscin results in decreased expression of BCL2L1 protein |
CTD |
PMID:22334414 PMID:29990575 PMID:33359023 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions decreases expression |
ISO |
[Acetaminophen co-treated with dioscin] results in increased expression of BID protein dioscin results in decreased expression of BID mRNA; dioscin results in decreased expression of BID protein |
CTD |
PMID:22334414 PMID:22939915 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
increases expression |
ISO |
dioscin results in increased expression of BIRC5 mRNA |
CTD |
PMID:29990575 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Casp3 |
caspase 3 |
multiple interactions decreases expression increases expression increases activity |
EXP ISO |
dioscin inhibits the reaction [Ethanol results in increased expression of CASP3 protein] dioscin results in decreased expression of CASP3 mRNA; dioscin results in decreased expression of CASP3 protein dioscin results in increased expression of CASP3 mRNA; dioscin results in increased expression of CASP3 protein benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [dioscin results in increased expression of CASP3 protein]; benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone inhibits the reaction [dioscin results in increased expression of CASP3 protein] dioscin results in increased activity of CASP3 protein |
CTD |
PMID:22334414 PMID:24146112 PMID:29990575 PMID:33359023 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
increases expression |
ISO |
dioscin results in increased expression of CASP7 mRNA |
CTD |
PMID:29990575 |
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp8 |
caspase 8 |
increases activity multiple interactions decreases expression increases expression |
ISO |
dioscin results in increased activity of CASP8 protein dioscin results in decreased expression of and results in increased cleavage of CASP8 protein dioscin results in decreased expression of CASP8 mRNA dioscin results in increased expression of CASP8 mRNA; dioscin results in increased expression of CASP8 protein |
CTD |
PMID:22334414 PMID:29990575 PMID:33359023 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions decreases expression increases expression |
EXP ISO |
dioscin inhibits the reaction [Ethanol results in increased expression of CASP9 protein] dioscin results in decreased expression of CASP9 mRNA; dioscin results in decreased expression of CASP9 protein dioscin results in increased expression of CASP9 mRNA; dioscin results in increased expression of CASP9 protein |
CTD |
PMID:24146112 PMID:29990575 PMID:33359023 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ccna2 |
cyclin A2 |
decreases expression |
ISO |
dioscin results in decreased expression of CCNA2 mRNA; dioscin results in decreased expression of CCNA2 protein |
CTD |
PMID:33359023 |
|
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccnb1 |
cyclin B1 |
decreases expression |
ISO |
dioscin results in decreased expression of CCNB1 mRNA; dioscin results in decreased expression of CCNB1 protein |
CTD |
PMID:29990575 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnd1 |
cyclin D1 |
increases expression decreases expression |
ISO |
dioscin results in increased expression of CCND1 mRNA dioscin results in decreased expression of CCND1 mRNA; dioscin results in decreased expression of CCND1 protein |
CTD |
PMID:29990575 PMID:33359023 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccne1 |
cyclin E1 |
decreases expression |
ISO |
dioscin results in decreased expression of CCNE1 mRNA; dioscin results in decreased expression of CCNE1 protein |
CTD |
PMID:33359023 |
|
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
decreases expression |
ISO |
dioscin results in decreased expression of CDK1 mRNA; dioscin results in decreased expression of CDK1 protein |
CTD |
PMID:29990575 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases expression |
ISO |
dioscin results in decreased expression of CDK2 mRNA; dioscin results in decreased expression of CDK2 protein |
CTD |
PMID:33359023 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
decreases expression |
ISO |
dioscin results in decreased expression of CDK4 mRNA |
CTD |
PMID:33359023 |
|
NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdk6 |
cyclin-dependent kinase 6 |
decreases expression |
ISO |
dioscin results in decreased expression of CDK6 mRNA; dioscin results in decreased expression of CDK6 protein |
CTD |
PMID:33359023 |
|
NCBI chr 4:30,637,650...30,829,688
Ensembl chr 4:30,646,460...30,829,634
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
dioscin results in increased expression of CDKN1A mRNA; dioscin results in increased expression of CDKN1A protein |
CTD |
PMID:29990575 PMID:33359023 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
increases expression |
ISO |
dioscin results in increased expression of CDKN1B mRNA; dioscin results in increased expression of CDKN1B protein |
CTD |
PMID:33359023 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
increases expression |
ISO |
dioscin results in increased expression of CDKN2A mRNA; dioscin results in increased expression of CDKN2A protein |
CTD |
PMID:33359023 |
|
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Chek1 |
checkpoint kinase 1 |
decreases expression |
ISO |
dioscin results in decreased expression of CHEK1 mRNA; dioscin results in decreased expression of CHEK1 protein |
CTD |
PMID:33359023 |
|
NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009
|
|
G |
Chek2 |
checkpoint kinase 2 |
decreases expression |
ISO |
dioscin results in decreased expression of CHEK2 mRNA; dioscin results in decreased expression of CHEK2 protein |
CTD |
PMID:29990575 |
|
NCBI chr12:45,788,823...45,821,382
Ensembl chr12:45,788,827...45,821,286
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
multiple interactions |
ISO EXP |
dioscin inhibits the reaction [Ethanol results in decreased expression of CPT1A mRNA] |
CTD |
PMID:24146112 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Ctnnb1 |
catenin beta 1 |
increases expression multiple interactions |
ISO |
dioscin results in increased expression of CTNNB1 mRNA; dioscin results in increased expression of CTNNB1 protein fulvestrant inhibits the reaction [dioscin results in increased expression of CTNNB1 mRNA] |
CTD |
PMID:24742230 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Cycs |
cytochrome c, somatic |
increases expression |
ISO |
dioscin results in increased expression of CYCS mRNA |
CTD |
PMID:33359023 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
ISO EXP |
dioscin inhibits the reaction [Acetaminophen results in increased expression of and results in increased activity of CYP2E1 protein]; dioscin inhibits the reaction [Ethanol results in increased expression of and results in increased activity of CYP2E1 protein] |
CTD |
PMID:22939915 PMID:24146112 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Dgat1 |
diacylglycerol O-acyltransferase 1 |
multiple interactions |
ISO EXP |
dioscin inhibits the reaction [Ethanol results in increased expression of DGAT1 mRNA] |
CTD |
PMID:24146112 |
|
NCBI chr 7:108,223,860...108,235,413
Ensembl chr 7:108,218,524...108,234,299
|
|
G |
Dgat2 |
diacylglycerol O-acyltransferase 2 |
multiple interactions |
ISO EXP |
dioscin inhibits the reaction [Ethanol results in increased expression of DGAT2 mRNA] |
CTD |
PMID:24146112 |
|
NCBI chr 1:153,454,078...153,484,432
Ensembl chr 1:153,454,080...153,484,428
|
|
G |
Diablo |
diablo, IAP-binding mitochondrial protein |
increases expression |
ISO |
dioscin results in increased expression of DIABLO mRNA |
CTD |
PMID:29990575 |
|
NCBI chr12:33,055,784...33,070,401
Ensembl chr12:33,055,263...33,070,387
|
|
G |
Esr1 |
estrogen receptor 1 |
increases expression multiple interactions |
ISO |
dioscin results in increased expression of ESR1 protein fulvestrant inhibits the reaction [dioscin results in increased expression of ESR1 protein] |
CTD |
PMID:24742230 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions increases expression |
ISO |
fulvestrant inhibits the reaction [dioscin results in increased expression of ESR2 protein] |
CTD |
PMID:24742230 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Fadd |
Fas associated via death domain |
increases expression |
ISO |
dioscin results in increased expression of FADD mRNA; dioscin results in increased expression of FADD protein |
CTD |
PMID:22334414 PMID:29990575 PMID:33359023 |
|
NCBI chr 1:199,743,200...199,745,746
Ensembl chr 1:199,739,994...199,745,653
|
|
G |
Fas |
Fas cell surface death receptor |
increases expression |
ISO |
dioscin results in increased expression of FAS mRNA; dioscin results in increased expression of FAS protein |
CTD |
PMID:22334414 PMID:33359023 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Faslg |
Fas ligand |
increases expression |
ISO |
dioscin results in increased expression of FASLG mRNA; dioscin results in increased expression of FASLG protein |
CTD |
PMID:22334414 PMID:29990575 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Foxo1 |
forkhead box O1 |
increases expression |
ISO |
dioscin results in increased expression of FOXO1 mRNA |
CTD |
PMID:33359023 |
|
NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP |
dioscin inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of GPT protein] |
CTD |
PMID:27317372 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
EXP ISO |
dioscin inhibits the reaction [Ethanol results in decreased expression of GSR protein] |
CTD |
PMID:24146112 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Hmgb1 |
high mobility group box 1 |
multiple interactions |
EXP |
dioscin inhibits the reaction [Doxorubicin results in increased expression of HMGB1 protein] dioscin inhibited the reaction [thioacetamide increased expression of Hmgb1 protein in liver] |
CTD RGD |
PMID:28082111 PMID:29091898 |
RGD:15090820 |
NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565 Ensembl chr16:5,901,586...5,978,565
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
EXP |
dioscin inhibits the reaction [Doxorubicin results in decreased expression of HMOX1 protein] dioscin inhibited the reaction [thioacetamide decreased expression of Hmox1 protein in liver] |
CTD RGD |
PMID:28082111 PMID:29091898 |
RGD:15090820 |
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
EXP ISO |
dioscin inhibits the reaction [Ethanol results in increased expression of HSPA5 protein] |
CTD |
PMID:24146112 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
EXP |
dioscin inhibited the reaction [thioacetamide increased expression of Icam1 protein in liver] |
RGD |
PMID:29091898 |
RGD:15090820 |
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Il13 |
interleukin 13 |
multiple interactions |
ISO |
dioscin inhibits the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of IL13 protein] |
CTD |
PMID:35481609 |
|
NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
dioscin inhibits the reaction [Doxorubicin results in increased expression of IL1B mRNA]; NR1H4 protein affects the reaction [dioscin inhibits the reaction [Doxorubicin results in increased expression of IL1B mRNA]] dioscin inhibited the reaction [thioacetamide increased expression of IL-1b mRNA in liver] |
CTD RGD |
PMID:28082111 PMID:29091898 |
RGD:15090820 |
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
ISO |
dioscin inhibits the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of IL4 protein] |
CTD |
PMID:35481609 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il5 |
interleukin 5 |
multiple interactions |
ISO |
dioscin inhibits the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of IL5 protein] |
CTD |
PMID:35481609 |
|
NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO EXP |
dioscin inhibits the reaction [Ethanol results in increased expression of IL6 mRNA] dioscin inhibited the reaction [thioacetamide increased expression of IL-6 mRNA in liver] dioscin inhibits the reaction [Doxorubicin results in increased expression of IL6 mRNA]; dioscin inhibits the reaction [Ethanol results in increased expression of IL6 mRNA]; NR1H4 protein affects the reaction [dioscin inhibits the reaction [Doxorubicin results in increased expression of IL6 mRNA]] |
CTD RGD |
PMID:24146112 PMID:28082111 PMID:29091898 |
RGD:15090820 |
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Kdr |
kinase insert domain receptor |
multiple interactions |
ISO |
dioscin inhibits the reaction [VEGFA protein results in increased phosphorylation of KDR protein] |
CTD |
PMID:25111127 |
|
NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
multiple interactions |
EXP |
dioscin inhibits the reaction [Doxorubicin results in increased expression of KEAP1 protein] |
CTD |
PMID:28082111 |
|
NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862
|
|
G |
Krt18 |
keratin 18 |
multiple interactions |
ISO EXP |
dioscin inhibits the reaction [Acetaminophen results in increased expression of KRT18 protein]; dioscin inhibits the reaction [Ethanol results in increased expression of KRT18 protein] |
CTD |
PMID:22939915 PMID:24146112 |
|
NCBI chr 7:133,157,486...133,161,162
Ensembl chr 7:133,157,475...133,161,166
|
|
G |
Lrp5 |
LDL receptor related protein 5 |
multiple interactions increases expression |
ISO |
fulvestrant inhibits the reaction [dioscin results in increased expression of LRP5 mRNA]; LRP5 protein affects the reaction [dioscin results in increased expression of TNFRSF11B mRNA]; LRP5 protein affects the reaction [dioscin results in increased expression of TNFSF11 mRNA] |
CTD |
PMID:24742230 |
|
NCBI chr 1:200,814,247...200,917,581
Ensembl chr 1:200,814,250...200,917,581
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
EXP ISO |
dioscin inhibits the reaction [Ethanol results in increased phosphorylation of MAPK1 protein] dioscin inhibits the reaction [VEGFA protein results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:24146112 PMID:25111127 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
EXP ISO |
dioscin inhibits the reaction [Ethanol results in increased phosphorylation of MAPK3 protein] dioscin inhibits the reaction [VEGFA protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:24146112 PMID:25111127 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
increases expression |
ISO |
dioscin results in increased expression of MAPK8 mRNA |
CTD |
PMID:29990575 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
increases expression |
ISO |
dioscin results in increased expression of MAPK9 mRNA |
CTD |
PMID:29990575 |
|
NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Mdh1 |
malate dehydrogenase 1 |
multiple interactions |
ISO |
dioscin inhibits the reaction [Acetaminophen results in decreased expression of MDH1 protein] |
CTD |
PMID:22939915 |
|
NCBI chr14:95,630,625...95,645,920
Ensembl chr14:95,630,306...95,645,925
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
decreases expression |
ISO |
dioscin results in decreased expression of MTOR mRNA |
CTD |
PMID:29990575 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Muc5ac |
mucin 5AC, oligomeric mucus/gel-forming |
multiple interactions |
ISO |
dioscin inhibits the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of MUC5AC mRNA] |
CTD |
PMID:35481609 |
|
NCBI chr 1:196,864,336...196,896,475
Ensembl chr 1:196,864,336...196,896,475
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
EXP |
dioscin inhibits the reaction [Doxorubicin results in decreased expression of and affects the localization of NFE2L2 protein]; NR1H4 protein affects the reaction [dioscin inhibits the reaction [Doxorubicin results in decreased expression of NFE2L2 protein]] dioscin inhibited the reaction [thioacetamide decreased expression of Nfe2L2 protein in liver] |
CTD RGD |
PMID:28082111 PMID:29091898 |
RGD:15090820 |
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
EXP |
dioscin inhibited the reaction [thioacetamide increased expression of Nfkb1 protein in liver] |
RGD |
PMID:29091898 |
RGD:15090820 |
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
decreases degradation |
ISO |
dioscin results in decreased degradation of NFKBIA protein |
CTD |
PMID:24680847 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
EXP |
dioscin inhibited the reaction [thioacetamide decreased expression of Nqo1 protein in liver] |
RGD |
PMID:29091898 |
RGD:15090820 |
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
multiple interactions increases expression |
EXP |
dioscin promotes the reaction [1-Naphthylisothiocyanate results in increased expression of NR0B2 mRNA] dioscin results in increased expression of NR0B2 mRNA |
CTD |
PMID:27317372 |
|
NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions |
EXP |
dioscin inhibits the reaction [Doxorubicin results in decreased expression of NR1H4 protein]; NR1H4 protein affects the reaction [dioscin inhibits the reaction [Doxorubicin results in decreased expression of NFE2L2 protein]]; NR1H4 protein affects the reaction [dioscin inhibits the reaction [Doxorubicin results in increased expression of IL1B mRNA]]; NR1H4 protein affects the reaction [dioscin inhibits the reaction [Doxorubicin results in increased expression of IL6 mRNA]]; NR1H4 protein affects the reaction [dioscin inhibits the reaction [Doxorubicin results in increased expression of RELA protein]]; NR1H4 protein affects the reaction [dioscin inhibits the reaction [Doxorubicin results in increased expression of TNF mRNA]] dioscin inhibited the reaction [thioacetamide decreased expression of Nr1h4 protein in liver] |
CTD RGD |
PMID:28082111 PMID:29091898 |
RGD:15090820 |
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases expression decreases expression |
ISO EXP |
dioscin inhibits the reaction [Ethanol results in increased expression of PARP1 protein] dioscin results in increased expression of PARP1 mRNA dioscin results in decreased expression of PARP1 mRNA; dioscin results in decreased expression of PARP1 protein |
CTD |
PMID:24146112 PMID:29990575 PMID:33359023 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pik3cb |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta |
decreases expression |
ISO |
dioscin results in decreased expression of PIK3CB mRNA |
CTD |
PMID:29990575 |
|
NCBI chr 8:99,594,600...99,699,772
Ensembl chr 8:99,594,644...99,699,663
|
|
G |
Pnp |
purine nucleoside phosphorylase |
multiple interactions |
ISO |
dioscin inhibits the reaction [Acetaminophen results in decreased expression of PNP protein] |
CTD |
PMID:22939915 |
|
NCBI chr15:24,170,607...24,178,269
Ensembl chr15:24,170,602...24,203,986
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
EXP ISO |
dioscin inhibits the reaction [Ethanol results in decreased expression of PPARA protein] |
CTD |
PMID:24146112 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Prdx1 |
peroxiredoxin 1 |
multiple interactions |
ISO |
dioscin inhibits the reaction [Acetaminophen results in decreased expression of PRDX1 protein] |
CTD |
PMID:22939915 |
|
NCBI chr 5:130,147,258...130,162,856
Ensembl chr 5:130,147,204...130,162,856
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
multiple interactions |
EXP |
dioscin inhibited the reaction [thioacetamide decreased expression of Prkaa1 protein in liver] |
RGD |
PMID:29091898 |
RGD:15090820 |
NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978
|
|
G |
Prkab1 |
protein kinase AMP-activated non-catalytic subunit beta 1 |
increases expression |
ISO |
dioscin results in increased expression of PRKAB1 mRNA |
CTD |
PMID:29990575 |
|
NCBI chr12:40,588,140...40,598,673
Ensembl chr12:40,588,211...40,598,661
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
dioscin inhibited the reaction [thioacetamide increased expression of Ptgs2 protein in liver] |
RGD |
PMID:29091898 |
RGD:15090820 |
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptk2 |
protein tyrosine kinase 2 |
multiple interactions |
ISO |
dioscin inhibits the reaction [VEGFA protein results in increased phosphorylation of PTK2 protein] |
CTD |
PMID:25111127 |
|
NCBI chr 7:105,126,725...105,331,848
Ensembl chr 7:105,126,728...105,331,783
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
dioscin inhibits the reaction [Doxorubicin results in increased expression of RELA protein]; NR1H4 protein affects the reaction [dioscin inhibits the reaction [Doxorubicin results in increased expression of RELA protein]] |
CTD |
PMID:28082111 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rgn |
regucalcin |
multiple interactions |
ISO |
dioscin inhibits the reaction [Acetaminophen results in decreased expression of RGN protein] |
CTD |
PMID:22939915 |
|
NCBI chr X:1,619,030...1,634,456
Ensembl chr X:1,619,032...1,634,450
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
decreases expression |
ISO |
dioscin results in decreased expression of RPS6KB1 mRNA |
CTD |
PMID:29990575 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Slc10a1 |
solute carrier family 10 member 1 |
multiple interactions |
EXP |
dioscin inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SLC10A1 mRNA] |
CTD |
PMID:27317372 |
|
NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670
|
|
G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
increases expression |
EXP |
dioscin results in increased expression of SLCO1A2 mRNA |
CTD |
PMID:27317372 |
|
NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
multiple interactions increases expression |
EXP |
dioscin inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SLCO1B2 mRNA]; dioscin inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SLCO1B2 protein] dioscin results in increased expression of SLCO1B2 mRNA |
CTD |
PMID:27317372 |
|
NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
multiple interactions |
ISO |
dioscin inhibits the reaction [VEGFA protein results in increased phosphorylation of SRC protein] |
CTD |
PMID:25111127 |
|
NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476
|
|
G |
Suox |
sulfite oxidase |
multiple interactions |
ISO |
dioscin inhibits the reaction [Acetaminophen results in decreased expression of SUOX protein] |
CTD |
PMID:22939915 |
|
NCBI chr 7:1,103,149...1,107,156
Ensembl chr 7:1,103,151...1,107,038
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
dioscin inhibits the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of TGFB1 protein] dioscin inhibits the reaction [TGFB1 protein results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:35481609 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases expression |
ISO EXP |
dioscin inhibits the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of TNF protein]; dioscin inhibits the reaction [Ethanol results in increased expression of TNF mRNA] dioscin inhibited the reaction [thioacetamide increased expression of Tnfa mRNA in liver] dioscin results in increased expression of TNF mRNA; dioscin results in increased expression of TNF protein dioscin inhibits the reaction [Doxorubicin results in increased expression of TNF mRNA]; dioscin inhibits the reaction [Ethanol results in increased expression of TNF mRNA]; NR1H4 protein affects the reaction [dioscin inhibits the reaction [Doxorubicin results in increased expression of TNF mRNA]] |
CTD RGD |
PMID:22334414 PMID:24146112 PMID:28082111 PMID:29990575 PMID:33359023 PMID:35481609 PMID:29091898 More...
|
RGD:15090820 |
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf11b |
TNF receptor superfamily member 11B |
increases expression multiple interactions |
ISO |
dioscin results in increased expression of TNFRSF11B mRNA fulvestrant inhibits the reaction [dioscin results in increased expression of TNFRSF11B mRNA]; LRP5 protein affects the reaction [dioscin results in increased expression of TNFRSF11B mRNA] |
CTD |
PMID:24742230 |
|
NCBI chr 7:85,566,520...85,594,526
Ensembl chr 7:85,566,520...85,594,538
|
|
G |
Tnfrsf1a |
TNF receptor superfamily member 1A |
increases expression |
ISO |
dioscin results in increased expression of TNFRSF1A mRNA; dioscin results in increased expression of TNFRSF1A protein |
CTD |
PMID:22334414 PMID:29990575 PMID:33359023 |
|
NCBI chr 4:158,150,815...158,163,592
Ensembl chr 4:158,150,820...158,163,591
|
|
G |
Tnfrsf25 |
TNF receptor superfamily member 25 |
increases expression |
ISO |
dioscin results in increased expression of TNFRSF25 mRNA |
CTD |
PMID:29990575 PMID:33359023 |
|
NCBI chr 5:162,621,669...162,626,341
Ensembl chr 5:162,622,075...162,626,341
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
decreases expression multiple interactions |
ISO |
dioscin results in decreased expression of TNFSF11 mRNA fulvestrant inhibits the reaction [dioscin results in increased expression of TNFSF11 mRNA]; LRP5 protein affects the reaction [dioscin results in increased expression of TNFSF11 mRNA] |
CTD |
PMID:24742230 |
|
NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions increases expression |
ISO EXP |
dioscin inhibits the reaction [Acetaminophen results in increased expression of TRP53 protein]; dioscin inhibits the reaction [Ethanol results in increased expression of TRP53 protein] dioscin results in increased expression of TP53 mRNA; dioscin results in increased expression of TP53 protein |
CTD |
PMID:22334414 PMID:22939915 PMID:24146112 PMID:29990575 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tradd |
TNFRSF1A-associated via death domain |
increases expression |
ISO |
dioscin results in increased expression of TRADD mRNA |
CTD |
PMID:29990575 PMID:33359023 |
|
NCBI chr19:33,136,148...33,142,714
Ensembl chr19:33,136,138...33,142,638
|
|
G |
Traf1 |
TNF receptor-associated factor 1 |
increases expression |
ISO |
dioscin results in increased expression of TRAF1 protein |
CTD |
PMID:22334414 |
|
NCBI chr 3:18,222,024...18,242,163
Ensembl chr 3:18,222,054...18,241,807
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
dioscin inhibits the reaction [VEGFA protein results in increased phosphorylation of AKT1 protein]; dioscin inhibits the reaction [VEGFA protein results in increased phosphorylation of KDR protein]; dioscin inhibits the reaction [VEGFA protein results in increased phosphorylation of MAPK1 protein]; dioscin inhibits the reaction [VEGFA protein results in increased phosphorylation of MAPK3 protein]; dioscin inhibits the reaction [VEGFA protein results in increased phosphorylation of PTK2 protein]; dioscin inhibits the reaction [VEGFA protein results in increased phosphorylation of SRC protein] |
CTD |
PMID:25111127 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Wee1 |
WEE1 G2 checkpoint kinase |
increases expression |
ISO |
dioscin results in increased expression of WEE1 mRNA |
CTD |
PMID:29990575 |
|
NCBI chr 1:164,173,681...164,197,688
Ensembl chr 1:164,174,779...164,197,688
|
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions increases expression |
EXP |
[Ethinyl Estradiol co-treated with Diosgenin] results in increased expression of ABCC2 mRNA Diosgenin results in increased expression of ABCC2 mRNA |
CTD |
PMID:16105132 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
increases expression multiple interactions |
EXP |
Diosgenin results in increased expression of ABCC3 mRNA [Ethinyl Estradiol co-treated with Diosgenin] results in increased expression of ABCC3 mRNA |
CTD |
PMID:16105132 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
increases expression multiple interactions |
EXP ISO |
Diosgenin results in increased expression of ABCG5 mRNA [Diosgenin results in increased expression of ABCG5 mRNA] which results in increased secretion of Cholesterol; [Ethinyl Estradiol co-treated with Diosgenin] results in decreased expression of ABCG5 mRNA Diosgenin promotes the reaction [ABCG5 protein results in increased secretion of Cholesterol] |
CTD |
PMID:12963437 PMID:15611112 PMID:16105132 |
|
NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563
|
|
G |
Abcg8 |
ATP binding cassette subfamily G member 8 |
increases expression multiple interactions |
EXP ISO |
Diosgenin results in increased expression of ABCG8 mRNA [Diosgenin results in increased expression of ABCG8 mRNA] which results in increased secretion of Cholesterol; [Ethinyl Estradiol co-treated with Diosgenin] results in decreased expression of ABCG8 mRNA Diosgenin promotes the reaction [ABCG8 protein results in increased secretion of Cholesterol] |
CTD |
PMID:12963437 PMID:15611112 PMID:16105132 |
|
NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
decreases expression |
ISO |
Diosgenin results in decreased expression of ACACA mRNA |
CTD |
PMID:32347045 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Acp5 |
acid phosphatase 5, tartrate resistant |
multiple interactions |
ISO |
Diosgenin inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 protein] |
CTD |
PMID:16331273 |
|
NCBI chr 8:20,663,984...20,670,604
Ensembl chr 8:20,663,985...20,667,929
|
|
G |
Adam17 |
ADAM metallopeptidase domain 17 |
multiple interactions |
EXP |
Diosgenin inhibits the reaction [Streptozocin results in increased expression of ADAM17 mRNA]; Diosgenin inhibits the reaction [Streptozocin results in increased expression of ADAM17 protein] |
CTD |
PMID:35305976 |
|
NCBI chr 6:40,872,936...40,920,700
Ensembl chr 6:40,872,856...40,920,639
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
Diosgenin inhibits the reaction [TNF protein results in increased activity of AKT1 protein] |
CTD |
PMID:16331273 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
multiple interactions |
ISO |
3-methyladenine inhibits the reaction [Diosgenin inhibits the reaction [alpha-Chlorohydrin results in increased expression of APAF1 protein]]; Diosgenin inhibits the reaction [alpha-Chlorohydrin results in increased expression of APAF1 protein] |
CTD |
PMID:35149085 |
|
NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
[morroniside co-treated with Diosgenin] inhibits the reaction [Glucose results in increased expression of BAX protein]; Diosgenin inhibits the reaction [Glucose results in increased expression of BAX protein] |
CTD |
PMID:28106847 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression |
ISO EXP |
Diosgenin inhibits the reaction [TNF protein results in increased expression of BCL2 protein] [morroniside co-treated with Diosgenin] inhibits the reaction [Glucose results in decreased expression of BCL2 protein]; Diosgenin inhibits the reaction [Glucose results in decreased expression of BCL2 protein] Diosgenin results in decreased expression of BCL2 protein |
CTD |
PMID:16331273 PMID:28106847 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2a1 |
BCL2-related protein A1 |
multiple interactions decreases expression |
ISO |
Diosgenin inhibits the reaction [TNF protein results in increased expression of BCL2A1 protein] Diosgenin results in decreased expression of BCL2A1 protein |
CTD |
PMID:16331273 |
|
NCBI chr 8:89,716,914...89,724,998
Ensembl chr 8:89,716,914...89,724,998
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
decreases expression multiple interactions |
ISO |
Diosgenin results in decreased expression of BCL2L1 protein Diosgenin inhibits the reaction [TNF protein results in increased expression of BCL2L1 protein] |
CTD |
PMID:16331273 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Birc2 |
baculoviral IAP repeat-containing 2 |
multiple interactions decreases expression |
ISO |
Diosgenin inhibits the reaction [TNF protein results in increased expression of BIRC2 protein] Diosgenin results in decreased expression of BIRC2 protein |
CTD |
PMID:16331273 |
|
NCBI chr 8:4,968,856...4,989,325
Ensembl chr 8:4,968,842...4,988,732
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO EXP |
Diosgenin inhibits the reaction [alpha-Chlorohydrin results in increased activity of CASP3 protein] [morroniside co-treated with Diosgenin] inhibits the reaction [Glucose results in increased expression of and results in increased activity of CASP3 protein]; Diosgenin inhibits the reaction [Glucose results in increased expression of and results in increased activity of CASP3 protein] |
CTD |
PMID:28106847 PMID:35149085 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
3-methyladenine inhibits the reaction [Diosgenin inhibits the reaction [alpha-Chlorohydrin results in increased activity of CASP9 protein]]; 3-methyladenine inhibits the reaction [Diosgenin inhibits the reaction [alpha-Chlorohydrin results in increased cleavage of CASP9 protein]]; Diosgenin inhibits the reaction [alpha-Chlorohydrin results in increased activity of CASP9 protein]; Diosgenin inhibits the reaction [alpha-Chlorohydrin results in increased cleavage of CASP9 protein]; Diosgenin promotes the reaction [alpha-Chlorohydrin results in increased expression of CASP9 protein] |
CTD |
PMID:35149085 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases expression multiple interactions |
ISO |
Diosgenin results in decreased expression of CCL2 mRNA Diosgenin inhibits the reaction [Dietary Fats results in increased expression of CCL2 mRNA] |
CTD |
PMID:26408789 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO |
Diosgenin inhibits the reaction [TNF protein results in increased expression of CCND1 protein] |
CTD |
PMID:16331273 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ces1d |
carboxylesterase 1D |
multiple interactions |
EXP |
Diosgenin affects the reaction [Dietary Fats affects the expression of CES1 mRNA]; Diosgenin affects the reaction [Dietary Fats affects the expression of CES1 protein] |
CTD |
PMID:33383043 |
|
NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
decreases expression multiple interactions |
ISO |
Diosgenin results in decreased expression of CFLAR protein Diosgenin inhibits the reaction [TNF protein results in increased expression of CFLAR protein] |
CTD |
PMID:16331273 |
|
NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034
|
|
G |
Ctnnb1 |
catenin beta 1 |
decreases expression |
ISO |
Diosgenin results in decreased expression of CTNNB1 mRNA |
CTD |
PMID:26408789 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
multiple interactions |
EXP |
Diosgenin promotes the reaction [Dietary Fats results in increased expression of CYP27A1 mRNA] |
CTD |
PMID:33383043 |
|
NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
multiple interactions |
EXP |
[Ethinyl Estradiol co-treated with Diosgenin] results in increased expression of CYP7A1 mRNA; Diosgenin promotes the reaction [Dietary Fats results in increased expression of CYP7A1 mRNA]; Diosgenin promotes the reaction [Dietary Fats results in increased expression of CYP7A1 protein] |
CTD |
PMID:12963437 PMID:33383043 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Dnm1l |
dynamin 1-like |
multiple interactions |
ISO EXP |
Diosgenin affects the reaction [alpha-Chlorohydrin affects the localization of DNM1L protein] Diosgenin inhibits the reaction [alpha-Chlorohydrin results in increased expression of DNM1L protein] |
CTD |
PMID:35149085 |
|
NCBI chr11:84,581,216...84,632,382
Ensembl chr11:84,581,216...84,631,482
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
multiple interactions |
ISO |
3-methyladenine inhibits the reaction [Diosgenin promotes the reaction [alpha-Chlorohydrin results in decreased phosphorylation of EIF4EBP1 protein]]; Diosgenin promotes the reaction [alpha-Chlorohydrin results in decreased phosphorylation of EIF4EBP1 protein] |
CTD |
PMID:35149085 |
|
NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions increases expression |
ISO |
Diosgenin inhibits the reaction [Dietary Fats results in decreased expression of ESR2 protein]; Diosgenin promotes the reaction [RXRA protein binds to ESR2 protein] Diosgenin results in increased expression of ESR2 protein |
CTD |
PMID:26408789 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
decreases expression multiple interactions |
ISO |
Diosgenin results in decreased expression of FABP4 mRNA Diosgenin inhibits the reaction [Dietary Fats results in increased expression of FABP4 mRNA]; fulvestrant inhibits the reaction [Diosgenin results in decreased expression of FABP4 mRNA]; PPARG protein inhibits the reaction [Diosgenin results in decreased expression of FABP4 mRNA]; rosiglitazone inhibits the reaction [Diosgenin results in decreased expression of FABP4 mRNA] |
CTD |
PMID:26408789 |
|
NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Fas |
Fas cell surface death receptor |
decreases expression |
ISO |
Diosgenin results in decreased expression of FAS mRNA |
CTD |
PMID:32347045 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Fgf19 |
fibroblast growth factor 19 |
multiple interactions |
EXP |
Diosgenin inhibits the reaction [Dietary Fats results in increased expression of FGF19 mRNA] |
CTD |
PMID:33383043 |
|
NCBI chr 1:200,056,526...200,060,980
Ensembl chr 1:200,056,644...200,060,287
|
|
G |
Fis1 |
fission, mitochondrial 1 |
multiple interactions |
ISO |
Diosgenin inhibits the reaction [alpha-Chlorohydrin results in increased expression of FIS1 protein] |
CTD |
PMID:35149085 |
|
NCBI chr12:19,708,560...19,723,392
Ensembl chr12:19,708,558...19,723,377
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
Diosgenin inhibits the reaction [Streptozocin results in increased expression of IL1B mRNA]; Diosgenin inhibits the reaction [Streptozocin results in increased expression of IL1B protein] |
CTD |
PMID:35305976 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions decreases expression |
ISO EXP |
Diosgenin inhibits the reaction [Dietary Fats results in increased expression of IL6 mRNA] Diosgenin inhibits the reaction [Streptozocin results in increased expression of IL6 mRNA]; Diosgenin inhibits the reaction [Streptozocin results in increased expression of IL6 protein] Diosgenin results in decreased expression of IL6 mRNA |
CTD |
PMID:26408789 PMID:35305976 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
EXP |
Diosgenin inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in decreased expression of INS1 protein]; Diosgenin inhibits the reaction [Streptozocin results in decreased expression of INS1 protein] |
CTD |
PMID:24001619 PMID:35305976 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Lipc |
lipase C, hepatic type |
increases activity |
EXP |
Diosgenin results in increased activity of LIPC protein |
CTD |
PMID:20149787 |
|
NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions decreases lipidation |
EXP ISO |
[alpha-Chlorohydrin co-treated with Diosgenin] results in increased lipidation of MAP1LC3B protein; alpha-Chlorohydrin inhibits the reaction [Diosgenin results in decreased lipidation of MAP1LC3B protein] 3-methyladenine inhibits the reaction [[alpha-Chlorohydrin co-treated with Diosgenin] results in increased lipidation of MAP1LC3B protein]; [alpha-Chlorohydrin co-treated with Diosgenin] results in increased lipidation of MAP1LC3B protein; alpha-Chlorohydrin inhibits the reaction [Diosgenin results in decreased lipidation of MAP1LC3B protein]; bafilomycin A1 promotes the reaction [[alpha-Chlorohydrin co-treated with Diosgenin] results in increased lipidation of MAP1LC3B protein]; Diosgenin promotes the reaction [alpha-Chlorohydrin results in increased lipidation of MAP1LC3B protein] |
CTD |
PMID:35149085 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
|
|
G |
Mest |
mesoderm specific transcript |
multiple interactions decreases expression |
ISO |
Diosgenin inhibits the reaction [Dietary Fats results in increased expression of MEST mRNA] Diosgenin results in decreased expression of MEST mRNA |
CTD |
PMID:26408789 |
|
NCBI chr 4:59,354,445...59,364,919
Ensembl chr 4:59,354,447...59,366,145
|
|
G |
Mfn1 |
mitofusin 1 |
multiple interactions |
ISO |
Diosgenin inhibits the reaction [alpha-Chlorohydrin results in decreased expression of MFN1 protein] |
CTD |
PMID:35149085 |
|
NCBI chr 2:115,313,380...115,359,651
Ensembl chr 2:115,313,401...115,359,640
|
|
G |
Mfn2 |
mitofusin 2 |
multiple interactions |
EXP ISO |
Diosgenin inhibits the reaction [alpha-Chlorohydrin results in decreased expression of MFN2 protein] |
CTD |
PMID:35149085 |
|
NCBI chr 5:158,304,285...158,335,502
Ensembl chr 5:158,304,287...158,335,342
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
increases activity increases expression |
EXP |
Diosgenin results in increased activity of MMP2 protein Diosgenin results in increased expression of MMP2 mRNA |
CTD |
PMID:21814480 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions decreases expression decreases activity |
ISO EXP |
Diosgenin inhibits the reaction [TNF protein results in increased expression of MMP9 protein] Diosgenin results in decreased expression of MMP9 mRNA Diosgenin results in decreased activity of MMP9 protein |
CTD |
PMID:16331273 PMID:21814480 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
ISO |
3-methyladenine inhibits the reaction [Diosgenin promotes the reaction [alpha-Chlorohydrin results in decreased phosphorylation of MTOR protein]]; Diosgenin promotes the reaction [alpha-Chlorohydrin results in decreased phosphorylation of MTOR protein] |
CTD |
PMID:35149085 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions |
ISO |
Diosgenin inhibits the reaction [TNF protein results in increased expression of MYC protein] |
CTD |
PMID:16331273 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
Diosgenin inhibits the reaction [TNF protein results in increased activity of NFKB1 protein] |
CTD |
PMID:16331273 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
Diosgenin inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]; Diosgenin inhibits the reaction [TNF protein results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:16331273 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions |
EXP |
Diosgenin affects the reaction [Dietary Fats affects the expression of NR1H4 mRNA]; Diosgenin affects the reaction [Dietary Fats affects the expression of NR1H4 protein] |
CTD |
PMID:33383043 |
|
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity |
ISO |
Diosgenin results in increased activity of NR1I2 protein |
CTD |
PMID:15611112 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression decreases response to substance decreases expression multiple interactions |
ISO |
Diosgenin results in increased expression of PPARG protein Diosgenin results in increased expression of PPARG mRNA PPARG protein results in decreased susceptibility to Diosgenin Diosgenin results in decreased expression of PPARG mRNA [Diosgenin inhibits the reaction [RXRA protein binds to PPARG protein]] which results in decreased activity of PPARG protein; Diosgenin inhibits the reaction [Dietary Fats results in increased expression of PPARG mRNA]; Diosgenin inhibits the reaction [RXRA protein binds to PPARG protein]; fulvestrant inhibits the reaction [Diosgenin results in decreased expression of PPARG mRNA]; PPARG protein inhibits the reaction [Diosgenin results in decreased expression of FABP4 mRNA]; PPARG protein inhibits the reaction [Diosgenin results in decreased expression of PPARG mRNA] |
CTD |
PMID:24001619 PMID:26408789 PMID:32347045 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
Diosgenin inhibits the reaction [TNF protein results in increased expression of PTGS2 protein] |
CTD |
PMID:16331273 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO EXP |
Diosgenin inhibits the reaction [TNF protein results in increased activity of RELA protein]; Diosgenin inhibits the reaction [TNF protein results in increased phosphorylation of and affects the localization of RELA protein] Diosgenin inhibits the reaction [Streptozocin results in increased expression of RELA mRNA] |
CTD |
PMID:16331273 PMID:35305976 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rhbdf2 |
rhomboid 5 homolog 2 |
multiple interactions |
EXP |
Diosgenin inhibits the reaction [Streptozocin results in increased expression of RHBDF2 mRNA]; Diosgenin inhibits the reaction [Streptozocin results in increased expression of RHBDF2 protein] |
CTD |
PMID:35305976 |
|
NCBI chr10:101,833,157...101,860,283
Ensembl chr10:101,833,157...101,860,283
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
multiple interactions |
ISO |
3-methyladenine inhibits the reaction [[Diosgenin co-treated with alpha-Chlorohydrin] results in decreased phosphorylation of RPS6KB1 protein]; [Diosgenin co-treated with alpha-Chlorohydrin] results in decreased phosphorylation of RPS6KB1 protein |
CTD |
PMID:35149085 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Rxra |
retinoid X receptor alpha |
multiple interactions |
ISO |
[Diosgenin inhibits the reaction [RXRA protein binds to PPARG protein]] which results in decreased activity of PPARG protein; Diosgenin inhibits the reaction [RXRA protein binds to PPARG protein]; Diosgenin promotes the reaction [RXRA protein binds to ESR2 protein] |
CTD |
PMID:26408789 |
|
NCBI chr 3:10,989,832...11,076,366
Ensembl chr 3:10,989,832...11,073,712
|
|
G |
Scarb1 |
scavenger receptor class B, member 1 |
multiple interactions |
EXP |
Diosgenin inhibits the reaction [Dietary Fats results in decreased expression of SCARB1 mRNA]; Diosgenin inhibits the reaction [Dietary Fats results in decreased expression of SCARB1 protein] |
CTD |
PMID:33383043 |
|
NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647
|
|
G |
Stk11 |
serine/threonine kinase 11 |
multiple interactions |
ISO |
Diosgenin inhibits the reaction [alpha-Chlorohydrin results in decreased phosphorylation of STK11 protein] |
CTD |
PMID:35149085 |
|
NCBI chr 7:9,574,553...9,591,315
Ensembl chr 7:9,575,269...9,591,315
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases activity |
ISO EXP |
Diosgenin inhibits the reaction [TNF protein results in increased activity of AKT1 protein]; Diosgenin inhibits the reaction [TNF protein results in increased activity of NFKB1 protein]; Diosgenin inhibits the reaction [TNF protein results in increased activity of RELA protein]; Diosgenin inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]; Diosgenin inhibits the reaction [TNF protein results in increased expression of BCL2 protein]; Diosgenin inhibits the reaction [TNF protein results in increased expression of BCL2A1 protein]; Diosgenin inhibits the reaction [TNF protein results in increased expression of BCL2L1 protein]; Diosgenin inhibits the reaction [TNF protein results in increased expression of BIRC2 protein]; Diosgenin inhibits the reaction [TNF protein results in increased expression of CCND1 protein]; Diosgenin inhibits the reaction [TNF protein results in increased expression of CFLAR protein]; Diosgenin inhibits the reaction [TNF protein results in increased expression of MMP9 protein]; Diosgenin inhibits the reaction [TNF protein results in increased expression of MYC protein]; Diosgenin inhibits the reaction [TNF protein results in increased expression of PTGS2 protein]; Diosgenin inhibits the reaction [TNF protein results in increased expression of VEGFA protein]; Diosgenin inhibits the reaction [TNF protein results in increased phosphorylation of and affects the localization of RELA protein]; Diosgenin inhibits the reaction [TNF protein results in increased phosphorylation of NFKBIA protein] Diosgenin inhibits the reaction [Streptozocin results in increased expression of TNF mRNA]; Diosgenin inhibits the reaction [Streptozocin results in increased expression of TNF protein] Diosgenin results in decreased activity of TNF protein |
CTD |
PMID:16331273 PMID:35305976 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
multiple interactions decreases activity |
ISO |
Diosgenin inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 protein] Diosgenin results in decreased activity of TNFSF11 protein |
CTD |
PMID:16331273 |
|
NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445
|
|
G |
Ulk1 |
unc-51 like autophagy activating kinase 1 |
multiple interactions |
ISO |
3-methyladenine inhibits the reaction [[Diosgenin co-treated with alpha-Chlorohydrin] results in decreased phosphorylation of ULK1 protein]; [Diosgenin co-treated with alpha-Chlorohydrin] results in decreased phosphorylation of ULK1 protein |
CTD |
PMID:35149085 |
|
NCBI chr12:45,851,710...45,877,966
Ensembl chr12:45,851,710...45,877,966
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
Diosgenin inhibits the reaction [TNF protein results in increased expression of VEGFA protein] |
CTD |
PMID:16331273 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Wnt10b |
Wnt family member 10B |
decreases expression |
ISO |
Diosgenin results in decreased expression of WNT10B mRNA |
CTD |
PMID:26408789 |
|
NCBI chr 7:129,922,088...129,927,892
Ensembl chr 7:129,922,088...129,927,892
|
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
EXP |
[Cholesterol co-treated with Ergosterol] results in increased expression of CASP1 mRNA; [Cholesterol co-treated with Ergosterol] results in increased expression of CASP1 protein; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of CASP1 mRNA]; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of CASP1 protein] |
CTD |
PMID:25833014 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
EXP |
[Cholesterol co-treated with Ergosterol] results in increased expression of CCL2 mRNA; [Cholesterol co-treated with Ergosterol] results in increased expression of CCL2 protein; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of CCL2 mRNA]; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of CCL2 protein] |
CTD |
PMID:25833014 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Cyp51 |
cytochrome P450, family 51 |
multiple interactions |
ISO |
CYP51A1 gene inhibits the reaction [Fluconazole results in decreased chemical synthesis of Ergosterol]; CYP51A1 gene inhibits the reaction [Itraconazole results in decreased chemical synthesis of Ergosterol]; CYP51A1 gene inhibits the reaction [Ketoconazole results in decreased chemical synthesis of Ergosterol]; CYP51A1 gene inhibits the reaction [Voriconazole results in decreased chemical synthesis of Ergosterol] |
CTD |
PMID:18694951 |
|
NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
EXP |
[Cholesterol co-treated with Ergosterol] results in increased expression of ICAM1 mRNA; [Cholesterol co-treated with Ergosterol] results in increased expression of ICAM1 protein; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of ICAM1 mRNA]; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of ICAM1 protein] |
CTD |
PMID:25833014 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
[Cholesterol co-treated with Ergosterol] results in increased expression of and results in increased secretion of IL1B protein; [Cholesterol co-treated with Ergosterol] results in increased expression of IL1B mRNA; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of and results in increased secretion of IL1B protein]; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of IL1B mRNA] |
CTD |
PMID:25833014 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions |
EXP |
[Cholesterol co-treated with Ergosterol] results in increased expression of MAPK14 mRNA; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of MAPK14 mRNA] |
CTD |
PMID:25833014 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
EXP |
[Cholesterol co-treated with Ergosterol] results in increased expression of NLRP3 mRNA; [Cholesterol co-treated with Ergosterol] results in increased expression of NLRP3 protein; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of NLRP3 mRNA]; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of NLRP3 protein] |
CTD |
PMID:25833014 |
|
NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Olr1 |
oxidized low density lipoprotein receptor 1 |
multiple interactions |
EXP |
[Cholesterol co-treated with Ergosterol] results in increased expression of OLR1 mRNA; [Cholesterol co-treated with Ergosterol] results in increased expression of OLR1 protein; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of OLR1 mRNA]; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of OLR1 protein] |
CTD |
PMID:25833014 |
|
NCBI chr 4:162,926,436...162,949,057
Ensembl chr 4:162,926,439...162,948,523
|
|
G |
Pycard |
PYD and CARD domain containing |
multiple interactions |
EXP |
[Cholesterol co-treated with Ergosterol] results in increased expression of PYCARD mRNA; [Cholesterol co-treated with Ergosterol] results in increased expression of PYCARD protein; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of PYCARD mRNA]; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of PYCARD protein] |
CTD |
PMID:25833014 |
|
NCBI chr 1:182,601,657...182,603,013
Ensembl chr 1:182,601,174...182,602,955
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
[Cholesterol co-treated with Ergosterol] results in increased expression of RELA mRNA; [Cholesterol co-treated with Ergosterol] results in increased expression of RELA protein; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of RELA mRNA]; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of RELA protein] |
CTD |
PMID:25833014 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions |
EXP |
[Cholesterol co-treated with Ergosterol] results in decreased expression of SIRT1 mRNA; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in decreased expression of SIRT1 mRNA] |
CTD |
PMID:25833014 |
|
NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Vwf |
von Willebrand factor |
multiple interactions |
EXP |
[Cholesterol co-treated with Ergosterol] results in increased expression of and results in increased secretion of VWF protein; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of and results in increased secretion of VWF protein] |
CTD |
PMID:25833014 |
|
NCBI chr 4:158,360,152...158,491,539
Ensembl chr 4:158,360,152...158,491,539
|
|
|
G |
Casp3 |
caspase 3 |
increases activity |
ISO |
ergosterol-5,8-peroxide results in increased activity of CASP3 protein |
CTD |
PMID:20100469 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
|
G |
Ptpn1 |
protein tyrosine phosphatase, non-receptor type 1 |
decreases activity |
ISO |
fucosterol results in decreased activity of PTPN1 protein |
CTD |
PMID:23994501 |
|
NCBI chr 3:156,638,811...156,687,503
Ensembl chr 3:156,638,769...156,687,504
|
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
ganoderol B binds to and results in decreased activity of AR protein; ganoderol B inhibits the reaction [Dihydrotestosterone binds to AR protein] |
CTD |
PMID:17499997 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Klk1c10 |
kallikrein 1-related peptidase C10 |
decreases expression |
ISO |
ganoderol B results in decreased expression of KLK3 mRNA |
CTD |
PMID:17499997 |
|
NCBI chr 1:94,402,993...94,407,052
Ensembl chr 1:94,402,993...94,407,052
|
|
G |
Srd5a1 |
steroid 5 alpha-reductase 1 |
decreases activity |
EXP |
ganoderol B results in decreased activity of SRD5A1 protein |
CTD |
PMID:17499997 |
|
NCBI chr 1:33,686,069...33,720,468
Ensembl chr 1:33,686,391...33,720,461
|
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
decreases activity |
ISO |
32-hydroxy-24,25-dihydrolanosterol results in decreased activity of HMGCR protein |
CTD |
PMID:12617470 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
increases metabolic processing |
ISO |
CYP27A1 protein results in increased metabolism of Lanosterol |
CTD |
PMID:14622972 |
|
NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551
|
|
G |
Cyp51 |
cytochrome P450, family 51 |
multiple interactions |
EXP ISO |
[Ketoconazole results in increased activity of CYP51 protein] which results in increased abundance of Lanosterol CYP51A1 gene inhibits the reaction [Fluconazole results in decreased metabolism of and results in increased abundance of Lanosterol]; CYP51A1 gene inhibits the reaction [Itraconazole results in decreased metabolism of and results in increased abundance of Lanosterol]; CYP51A1 gene inhibits the reaction [Ketoconazole results in decreased metabolism of and results in increased abundance of Lanosterol]; CYP51A1 gene inhibits the reaction [Voriconazole results in decreased metabolism of and results in increased abundance of Lanosterol] |
CTD |
PMID:12617470 PMID:18694951 |
|
NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410
|
|
G |
Ephx1 |
epoxide hydrolase 1 |
multiple interactions |
ISO |
Lanosterol analog inhibits the reaction [EPHX1 protein results in increased metabolism of cholesterol alpha-oxide] |
CTD |
PMID:2043152 |
|
NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235
|
|
G |
Ephx2 |
epoxide hydrolase 2 |
multiple interactions |
ISO |
Lanosterol analog inhibits the reaction [EPHX2 protein results in increased metabolism of stilbene oxide analog] |
CTD |
PMID:2043152 |
|
NCBI chr15:40,289,901...40,327,632
Ensembl chr15:40,289,902...40,327,615
|
|
G |
Marchf6 |
membrane associated ring-CH-type finger 6 |
increases stability |
ISO |
Lanosterol results in increased stability of MARCHF6 protein |
CTD |
PMID:30545937 |
|
NCBI chr 2:82,455,686...82,532,917
Ensembl chr 2:82,455,689...82,532,910
|
|
|
G |
Apoe |
apolipoprotein E |
multiple interactions |
ISO |
APOE gene mutant form affects the reaction [Phytosterols results in increased expression of CYP51 mRNA]; APOE gene mutant form affects the reaction [Phytosterols results in increased expression of CYP7B1 mRNA]; APOE gene mutant form affects the reaction [Phytosterols results in increased expression of FADS1 mRNA]; APOE gene mutant form affects the reaction [Phytosterols results in increased expression of FADS2 mRNA]; APOE gene mutant form affects the reaction [Phytosterols results in increased expression of HMGCR mRNA]; APOE gene mutant form affects the reaction [Phytosterols results in increased expression of HMGCS1 mRNA]; APOE gene mutant form affects the reaction [Phytosterols results in increased expression of HSD17B7 mRNA]; APOE gene mutant form affects the reaction [Phytosterols results in increased expression of LPIN1 mRNA]; APOE gene mutant form affects the reaction [Phytosterols results in increased expression of PPARGC1B mRNA]; APOE gene mutant form affects the reaction [Phytosterols results in increased expression of SQLE mRNA] |
CTD |
PMID:18155511 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
Cyp51 |
cytochrome P450, family 51 |
multiple interactions |
ISO |
APOE gene mutant form affects the reaction [Phytosterols results in increased expression of CYP51 mRNA] |
CTD |
PMID:18155511 |
|
NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410
|
|
G |
Cyp7b1 |
cytochrome P450 family 7 subfamily B member 1 |
multiple interactions |
ISO |
APOE gene mutant form affects the reaction [Phytosterols results in increased expression of CYP7B1 mRNA] |
CTD |
PMID:18155511 |
|
NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698
|
|
G |
Fads1 |
fatty acid desaturase 1 |
multiple interactions |
ISO |
APOE gene mutant form affects the reaction [Phytosterols results in increased expression of FADS1 mRNA] |
CTD |
PMID:18155511 |
|
NCBI chr 1:206,827,724...206,842,734
Ensembl chr 1:206,827,765...206,842,734
|
|
G |
Fads2 |
fatty acid desaturase 2 |
multiple interactions |
ISO |
APOE gene mutant form affects the reaction [Phytosterols results in increased expression of FADS2 mRNA] |
CTD |
PMID:18155511 |
|
NCBI chr 1:206,707,384...206,747,333
Ensembl chr 1:206,708,783...206,748,789
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions |
ISO |
APOE gene mutant form affects the reaction [Phytosterols results in increased expression of HMGCR mRNA] |
CTD |
PMID:18155511 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
multiple interactions |
ISO |
APOE gene mutant form affects the reaction [Phytosterols results in increased expression of HMGCS1 mRNA] |
CTD |
PMID:18155511 |
|
NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100
|
|
G |
Hsd17b7 |
hydroxysteroid (17-beta) dehydrogenase 7 |
multiple interactions |
ISO |
APOE gene mutant form affects the reaction [Phytosterols results in increased expression of HSD17B7 mRNA] |
CTD |
PMID:18155511 |
|
NCBI chr13:82,170,079...82,190,018
Ensembl chr13:82,173,179...82,190,017
|
|
G |
Lpin1 |
lipin 1 |
multiple interactions |
ISO |
APOE gene mutant form affects the reaction [Phytosterols results in increased expression of LPIN1 mRNA] |
CTD |
PMID:18155511 |
|
NCBI chr 6:39,309,198...39,417,034
Ensembl chr 6:39,312,748...39,417,097
|
|
G |
Ltf |
lactotransferrin |
multiple interactions |
ISO |
[LTF protein co-treated with Phosphatidylcholines co-treated with Phytosterols] inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] |
CTD |
PMID:16141546 |
|
NCBI chr 8:110,999,948...111,022,795
Ensembl chr 8:110,999,948...111,022,795
|
|
G |
Ppargc1b |
PPARG coactivator 1 beta |
multiple interactions |
ISO |
APOE gene mutant form affects the reaction [Phytosterols results in increased expression of PPARGC1B mRNA] |
CTD |
PMID:18155511 |
|
NCBI chr18:54,758,891...54,861,103
Ensembl chr18:54,758,902...54,861,194
|
|
G |
Sqle |
squalene epoxidase |
multiple interactions |
ISO |
APOE gene mutant form affects the reaction [Phytosterols results in increased expression of SQLE mRNA] |
CTD |
PMID:18155511 |
|
NCBI chr 7:90,867,973...90,883,623
Ensembl chr 7:90,868,011...90,883,618
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
[LTF protein co-treated with Phosphatidylcholines co-treated with Phytosterols] inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] |
CTD |
PMID:16141546 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions |
ISO |
[bisphenol A co-treated with Stigmasterol] results in increased expression of ABCB11 mRNA; NR1H4 gene mutant form inhibits the reaction [[bisphenol A co-treated with Stigmasterol] results in increased expression of ABCB11 mRNA] |
CTD |
PMID:30245210 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
multiple interactions decreases expression |
ISO |
[Stigmasterol co-treated with KNG1 protein modified form] results in decreased expression of ABCG5 mRNA; [Stigmasterol co-treated with Oligomycins] results in decreased expression of ABCG5 mRNA; [Stigmasterol co-treated with Rotenone] results in decreased expression of ABCG5 mRNA Stigmasterol results in decreased expression of ABCG5 mRNA |
CTD |
PMID:23454145 |
|
NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563
|
|
G |
Abcg8 |
ATP binding cassette subfamily G member 8 |
multiple interactions decreases expression |
ISO |
[Stigmasterol co-treated with Oligomycins] results in decreased expression of ABCG8 mRNA; [Stigmasterol co-treated with Rotenone] results in decreased expression of ABCG8 mRNA Stigmasterol results in decreased expression of ABCG8 mRNA |
CTD |
PMID:23454145 |
|
NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912
|
|
G |
Acat1 |
acetyl-CoA acetyltransferase 1 |
multiple interactions |
ISO |
[Stigmasterol co-treated with KNG1 protein modified form] results in decreased expression of ACAT1 mRNA; [Stigmasterol co-treated with Oligomycins] results in decreased expression of ACAT1 mRNA; [Stigmasterol co-treated with Rotenone] results in decreased expression of ACAT1 mRNA |
CTD |
PMID:23454145 |
|
NCBI chr 8:53,979,813...54,008,861
Ensembl chr 8:53,979,813...54,008,855
|
|
G |
Ankrd1 |
ankyrin repeat domain 1 |
multiple interactions |
ISO |
[NR1H4 gene mutant form affects the susceptibility to Stigmasterol] which results in decreased expression of ANKRD1 mRNA |
CTD |
PMID:30245210 |
|
NCBI chr 1:233,815,851...233,834,891
Ensembl chr 1:233,815,851...233,834,919
|
|
G |
Apoa1 |
apolipoprotein A1 |
multiple interactions |
ISO |
[bisphenol A co-treated with Stigmasterol] results in increased expression of APOA1 mRNA; NR1H4 gene mutant form inhibits the reaction [[bisphenol A co-treated with Stigmasterol] results in increased expression of APOA1 mRNA]; Stigmasterol promotes the reaction [GW 4064 results in increased expression of APOA1 mRNA] |
CTD |
PMID:30245210 |
|
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
Brinp3 |
BMP/retinoic acid inducible neural specific 3 |
multiple interactions |
ISO |
[NR1H4 gene mutant form affects the susceptibility to Stigmasterol] which results in decreased expression of BRINP3 mRNA |
CTD |
PMID:30245210 |
|
NCBI chr13:58,413,883...58,846,828
Ensembl chr13:58,413,883...58,846,770
|
|
G |
Cldn11 |
claudin 11 |
multiple interactions |
ISO |
[bisphenol A co-treated with Stigmasterol] results in increased expression of CLDN11 mRNA; NR1H4 gene mutant form inhibits the reaction [[bisphenol A co-treated with Stigmasterol] results in increased expression of CLDN11 mRNA] |
CTD |
PMID:30245210 |
|
NCBI chr 2:112,207,745...112,221,050
Ensembl chr 2:112,207,745...112,221,050
|
|
G |
Dnmt3l |
DNA methyltransferase 3 like |
multiple interactions |
ISO |
[bisphenol A co-treated with Stigmasterol] results in increased expression of DNMT3L mRNA; NR1H4 gene mutant form inhibits the reaction [[bisphenol A co-treated with Stigmasterol] results in increased expression of DNMT3L mRNA] |
CTD |
PMID:30245210 |
|
NCBI chr20:10,614,933...10,629,337
Ensembl chr20:10,614,934...10,629,516
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
[bisphenol A co-treated with Stigmasterol] results in increased expression of ESR1 mRNA; NR1H4 gene mutant form inhibits the reaction [[bisphenol A co-treated with Stigmasterol] results in increased expression of ESR1 mRNA] |
CTD |
PMID:30245210 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Fshr |
follicle stimulating hormone receptor |
multiple interactions |
ISO |
Stigmasterol inhibits the reaction [GW 4064 results in decreased expression of FSHR mRNA] |
CTD |
PMID:30245210 |
|
NCBI chr 6:5,198,825...5,406,785
Ensembl chr 6:5,198,825...5,406,785
|
|
G |
Gabarap |
GABA type A receptor-associated protein |
decreases expression |
ISO |
Stigmasterol results in decreased expression of GABARAP mRNA |
CTD |
PMID:30245210 |
|
NCBI chr10:54,714,777...54,718,099
Ensembl chr10:54,714,198...54,717,765
|
|
G |
Gfra1 |
GDNF family receptor alpha 1 |
multiple interactions |
ISO |
[bisphenol A co-treated with Stigmasterol] results in decreased expression of GFRA1 mRNA; NR1H4 gene mutant form inhibits the reaction [[bisphenol A co-treated with Stigmasterol] results in decreased expression of GFRA1 mRNA]; Stigmasterol inhibits the reaction [GW 4064 results in decreased expression of GFRA1 mRNA] |
CTD |
PMID:30245210 |
|
NCBI chr 1:257,315,682...257,552,004
Ensembl chr 1:257,321,742...257,551,473
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions increases expression |
ISO |
[Stigmasterol co-treated with KNG1 protein modified form] results in increased expression of HMGCR mRNA; [Stigmasterol co-treated with Oligomycins] results in decreased expression of HMGCR mRNA; [Stigmasterol co-treated with Rotenone] results in decreased expression of HMGCR mRNA Stigmasterol results in increased expression of HMGCR mRNA |
CTD |
PMID:23454145 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hoxa5 |
homeo box A5 |
multiple interactions |
ISO |
[NR1H4 gene mutant form affects the susceptibility to Stigmasterol] which results in decreased expression of HOXA5 mRNA |
CTD |
PMID:30245210 |
|
NCBI chr 4:81,302,341...81,306,234
Ensembl chr 4:81,302,353...81,306,234
|
|
G |
Ifi35 |
interferon-induced protein 35 |
decreases expression |
ISO |
Stigmasterol results in decreased expression of IFI35 mRNA |
CTD |
PMID:30245210 |
|
NCBI chr10:86,381,023...86,389,279
Ensembl chr10:86,381,010...86,389,952
|
|
G |
Il10 |
interleukin 10 |
increases secretion |
ISO |
Stigmasterol results in increased secretion of IL10 protein |
CTD |
PMID:23454145 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
Stigmasterol inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA] |
CTD |
PMID:23535395 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Kng1 |
kininogen 1 |
multiple interactions |
ISO |
[Stigmasterol co-treated with KNG1 protein modified form] results in decreased expression of ABCG5 mRNA; [Stigmasterol co-treated with KNG1 protein modified form] results in decreased expression of ACAT1 mRNA; [Stigmasterol co-treated with KNG1 protein modified form] results in increased expression of HMGCR mRNA; [Stigmasterol co-treated with KNG1 protein modified form] results in increased expression of NPC1L1 mRNA |
CTD |
PMID:23454145 |
|
NCBI chr11:77,812,757...77,835,555
Ensembl chr11:77,812,752...77,835,555
|
|
G |
Mybpc2 |
myosin binding protein C2 |
multiple interactions |
ISO |
[NR1H4 gene mutant form affects the susceptibility to Stigmasterol] which results in decreased expression of MYBPC2 mRNA |
CTD |
PMID:30245210 |
|
NCBI chr 1:94,994,121...95,017,584
Ensembl chr 1:94,994,104...95,017,584
|
|
G |
Nanog |
Nanog homeobox |
decreases expression multiple interactions |
ISO |
Stigmasterol results in decreased expression of NANOG mRNA [bisphenol A co-treated with Stigmasterol] results in decreased expression of NANOG mRNA; Stigmasterol inhibits the reaction [GW 4064 results in decreased expression of NANOG mRNA] |
CTD |
PMID:30245210 |
|
NCBI chr 4:155,943,737...155,951,116
Ensembl chr 4:155,943,737...155,951,116
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
Stigmasterol inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; Stigmasterol inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] |
CTD |
PMID:23535395 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Npc1l1 |
NPC1 like intracellular cholesterol transporter 1 |
multiple interactions |
ISO |
[Stigmasterol co-treated with KNG1 protein modified form] results in increased expression of NPC1L1 mRNA; [Stigmasterol co-treated with Rotenone] results in increased expression of NPC1L1 mRNA |
CTD |
PMID:23454145 |
|
NCBI chr14:81,071,448...81,091,113
Ensembl chr14:81,071,451...81,091,113
|
|
G |
Nr0b1 |
nuclear receptor subfamily 0, group B, member 1 |
multiple interactions decreases expression |
ISO |
[bisphenol A co-treated with Stigmasterol] results in increased expression of NR0B1 mRNA; GW 4064 promotes the reaction [Stigmasterol results in increased expression of NR0B1 mRNA]; NR1H4 gene mutant form inhibits the reaction [[bisphenol A co-treated with Stigmasterol] results in increased expression of NR0B1 mRNA]; NR1H4 gene mutant form inhibits the reaction [Stigmasterol results in decreased expression of NR0B1 mRNA]; Stigmasterol inhibits the reaction [GW 4064 results in decreased expression of NR0B1 mRNA] |
CTD |
PMID:30245210 |
|
NCBI chr X:50,756,886...50,761,014
Ensembl chr X:50,756,886...50,761,011
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
multiple interactions |
ISO |
Stigmasterol promotes the reaction [GW 4064 results in increased expression of NR0B2 mRNA] |
CTD |
PMID:30245210 |
|
NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions affects response to substance decreases expression |
ISO |
[bisphenol A co-treated with Stigmasterol] results in decreased expression of NR1H4 mRNA; [NR1H4 gene mutant form affects the susceptibility to Stigmasterol] which results in decreased expression of ANKRD1 mRNA; [NR1H4 gene mutant form affects the susceptibility to Stigmasterol] which results in decreased expression of BRINP3 mRNA; [NR1H4 gene mutant form affects the susceptibility to Stigmasterol] which results in decreased expression of HOXA5 mRNA; [NR1H4 gene mutant form affects the susceptibility to Stigmasterol] which results in decreased expression of MYBPC2 mRNA; NR1H4 gene mutant form inhibits the reaction [[bisphenol A co-treated with Stigmasterol] results in decreased expression of GFRA1 mRNA]; NR1H4 gene mutant form inhibits the reaction [[bisphenol A co-treated with Stigmasterol] results in decreased expression of ZBTB16 mRNA]; NR1H4 gene mutant form inhibits the reaction [[bisphenol A co-treated with Stigmasterol] results in increased expression of ABCB11 mRNA]; NR1H4 gene mutant form inhibits the reaction [[bisphenol A co-treated with Stigmasterol] results in increased expression of APOA1 mRNA]; NR1H4 gene mutant form inhibits the reaction [[bisphenol A co-treated with Stigmasterol] results in increased expression of CLDN11 mRNA]; NR1H4 gene mutant form inhibits the reaction [[bisphenol A co-treated with Stigmasterol] results in increased expression of DNMT3L mRNA]; NR1H4 gene mutant form inhibits the reaction [[bisphenol A co-treated with Stigmasterol] results in increased expression of ESR1 mRNA]; NR1H4 gene mutant form inhibits the reaction [[bisphenol A co-treated with Stigmasterol] results in increased expression of NR0B1 mRNA]; NR1H4 gene mutant form inhibits the reaction [Stigmasterol results in decreased expression of NR0B1 mRNA]; NR1H4 gene mutant form inhibits the reaction [Stigmasterol results in decreased expression of ZBTB16 mRNA] Stigmasterol results in decreased expression of NR1H4 mRNA |
CTD |
PMID:30245210 |
|
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
Stigmasterol inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; Stigmasterol inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein] |
CTD |
PMID:23535395 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rpl18a |
ribosomal protein L18A |
decreases expression |
ISO |
Stigmasterol results in decreased expression of RPL18A mRNA |
CTD |
PMID:30245210 |
|
NCBI chr16:18,542,555...18,544,578
Ensembl chr16:18,542,566...18,545,546
|
|
G |
Rpl31 |
ribosomal protein L31 |
decreases expression |
ISO |
Stigmasterol results in decreased expression of RPL31 mRNA |
CTD |
PMID:30245210 |
|
NCBI chr 9:41,647,397...41,651,441
Ensembl chr 9:41,647,426...41,662,129
|
|
G |
Rpl36 |
ribosomal protein L36 |
decreases expression |
ISO |
Stigmasterol results in decreased expression of RPL36 mRNA |
CTD |
PMID:30245210 |
|
NCBI chr 9:1,441,986...1,447,397
Ensembl chr 6:98,809,534...98,809,897
|
|
G |
Rpph1 |
ribonuclease P RNA component H1 |
decreases expression |
ISO |
Stigmasterol results in decreased expression of RPPH1 mRNA |
CTD |
PMID:30245210 |
|
NCBI chr15:24,033,679...24,033,935
Ensembl chr15:24,033,662...24,033,959
|
|
G |
Rps14 |
ribosomal protein S14 |
decreases expression |
ISO |
Stigmasterol results in decreased expression of RPS14 mRNA |
CTD |
PMID:30245210 |
|
NCBI chr18:54,227,854...54,232,638
Ensembl chr18:54,227,854...54,233,166
|
|
G |
Rps27 |
ribosomal protein S27 |
decreases expression |
ISO |
Stigmasterol results in decreased expression of RPS27 mRNA |
CTD |
PMID:30245210 |
|
NCBI chr 2:175,665,858...175,666,963
Ensembl chr 2:175,665,853...175,666,964
|
|
G |
Rps7 |
ribosomal protein S7 |
decreases expression |
ISO |
Stigmasterol results in decreased expression of RPS7 mRNA |
CTD |
PMID:30245210 |
|
NCBI chr 6:45,266,200...45,271,064
Ensembl chr 6:45,223,980...45,271,145
|
|
G |
Stra8 |
stimulated by retinoic acid 8 |
decreases expression multiple interactions |
ISO |
Stigmasterol results in decreased expression of STRA8 mRNA GW 4064 inhibits the reaction [Stigmasterol results in decreased expression of STRA8 mRNA]; Stigmasterol inhibits the reaction [GW 4064 results in decreased expression of STRA8 mRNA] |
CTD |
PMID:30245210 |
|
NCBI chr 4:63,601,443...63,624,777
Ensembl chr 4:63,601,604...63,624,771
|
|
G |
Tm2d3 |
TM2 domain containing 3 |
decreases expression |
ISO |
Stigmasterol results in decreased expression of TM2D3 mRNA |
CTD |
PMID:30245210 |
|
NCBI chr 1:119,267,194...119,277,094
Ensembl chr 1:119,264,576...119,277,099
|
|
G |
Tnf |
tumor necrosis factor |
increases secretion multiple interactions |
ISO |
Stigmasterol results in increased secretion of TNF protein Stigmasterol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA] |
CTD |
PMID:23454145 PMID:23535395 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Zbtb16 |
zinc finger and BTB domain containing 16 |
multiple interactions decreases expression |
ISO |
[bisphenol A co-treated with Stigmasterol] results in decreased expression of ZBTB16 mRNA; NR1H4 gene mutant form inhibits the reaction [[bisphenol A co-treated with Stigmasterol] results in decreased expression of ZBTB16 mRNA]; NR1H4 gene mutant form inhibits the reaction [Stigmasterol results in decreased expression of ZBTB16 mRNA]; Stigmasterol inhibits the reaction [GW 4064 results in decreased expression of ZBTB16 mRNA] |
CTD |
PMID:30245210 |
|
NCBI chr 8:48,989,376...49,177,011
Ensembl chr 8:48,994,566...49,177,011
|
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
increases metabolic processing |
ISO |
CYP27A1 protein results in increased metabolism of zymosterol |
CTD |
PMID:14622972 |
|
NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551
|
|
G |
Msmo1 |
methylsterol monooxygenase 1 |
decreases abundance |
ISO |
MSMO1 protein results in decreased abundance of zymosterol metabolite |
CTD |
PMID:23125191 |
|
NCBI chr16:24,980,680...24,997,927
Ensembl chr16:24,980,697...24,998,016
|
|